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Abstract
This study focuses on integrating and applying computational techniques for mod-
elling quantitative traits and complex diseases, such as hypertension and diabetes,
using the rat model system and translating the findings to humans. Complex dis-
ease traits are heritable, highly polygenic, and influenced by environmental factors.
Human studies, like Genome Wide Association Studies (GWAS), have identified
many genetic determinants underlying these traits but have provided little infor-
mation about the functional effects of these variants and mechanisms regulating
the disease. This study takes a systems-level approach for looking at the genetic
regulation of complex traits in the rat by analysing multiple phenotypes, genome-
wide genetic variation and gene expression data in multiple tissues. I integrated
these multi-modality datasets in the BXH/HXB rat Recombinant Inbred (RI)
lines, an established model of the human metabolic syndrome, to identify candi-
date genes, pathways and networks associated with complex disease phenotypes. I
evaluated methods for Expression Quantitative Trait Locus (eQTL) analysis and
used sparse Bayesian regression approaches to map eQTLs in the RI lines, delin-
eating a new, large eQTL data resource for the rat genetic community. I have
also developed and applied signal processing and time series analysis methods to
physiological traits to extract more detailed indices of blood pressure, and inte-
grated these with genetic, expression and eQTL data to inform on the regulation
of these traits. Then, using publicly available data, I used comparative genomics
approaches to elucidate a set of genes and pathways that can play a role in human
diseases. This study has provided a valuable resource for future work in the rat,
by means of new eQTLs in multiple tissues, and physiological time series pheno-
types and approaches. This has enabled an integrative analysis of these data to
give new insights into the regulation of complex traits in rats and humans.
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Chapter 1
Introduction
1.1 Complex diseases, metabolic syndrome and hypertension
Common, complex diseases are some of the major causes of mortality in the westernised world
[Brundtland, 2002, King and Rotter, 2002]. Cardiovascular diseases, metabolic syndrome
and cancer are examples of these diseases. They are not only affected by environmental and
developmental factors, but also by complex genetic regulation and their interactions [King
and Rotter, 2002, Wellcome Trust Case Control Consortium, 2007]. The genetic regulation
can be highly polygenic, with several genes affecting the disease state. Heritability is the
proportion of a phenotypic variation which can be described by genetic variation. Common
diseases often have heritabilities of over 50%, as in type II diabetes [Wellcome Trust Case
Control Consortium, 2007, Herder and Roden, 2011], but much of that heritability has yet to
be explained [Eichler et al., 2010, Makowsky et al., 2011, Vineis and Pearce, 2010, Manolio
et al., 2009].
There is some debate surrounding the heritability estimates of complex traits and the
differences between the estimates and the observed effect sizes of the identified genetic variants
associated with disease - so called ’missing heritability’. This ‘missing heritability’ may be, in
part, due to several factors, including an inflation of the estimates. The classical method for
estimating heritability is based on trait variances and covariances among related individuals
and is based on narrow-sense heritability [Zaitlen and Kraft, 2012]. These estimates, h2, only
take into account the additive effect and ignore the epistatic and dominance effects. Recent
work by Zuk et al. shows that some epistatic interactions can bias estimates, giving rise to
artificially inflated narrow-sense heritabilities [Zuk et al., 2012]. These heritability estimates
do show that the trait or disease is controlled by genetic factors, but they may not accurately
describe the effect size of the genetic factors on the phenotypic variation.
16
CHAPTER 1. INTRODUCTION 17
1.1.1 Metabolic syndrome and hypertension
Reaven, in 1988, described a cluster of complex traits which were precursors to diabetes and
cardiovascular diseases [Reaven, 1988]. ‘Syndrome X’ as it was termed, included dyslipi-
daemia, hyperglycaemia, and hypertension and it was suggested that insulin resistance was
the cause [Aldons J Lusis, 2008, Reaven, 1988]. Soon after, ‘syndrome X’ was changed to
‘metabolic syndrome’ as insulin resistance, though it does affect the most of the traits, was
determined not to be the underlying cause. In addition, visceral obesity was added to the
cluster of traits [Alberti et al., 2005, Aldons J Lusis, 2008, Reaven, 1993]. There are several
definitions of metabolic syndrome, but the working definition set forth by the World Heath
Organisation (WHO) in 1998 [Consultation, 1999] states that metabolic syndrome is one of
the following:
• impaired glucose tolerance
• impaired glucose
• diabetes mellitus
• insulin resistance
coupled with two or more of the following:
• raised arterial blood pressure (hypertension)
• dyslipidemia
• obesity
• microalbuminuria
There are other classifications of the syndrome [Huang, 2009] and even some debate over
whether or not this cluster of disease traits should be considered as a ‘syndrome’. Kahn et
al. recommends that these traits should be considered as clinically separate risk factors and
that treatment should follow each trait rather than the syndrome as a whole [Kahn et al.,
2005]. Similarly, Simmons et al. in a WHO report suggest that ‘metabolic syndrome’ may be
a useful term for educational and research areas, but is unsuitable for clinical diagnostics and
treatment [Simmons et al., 2010]. However, both Khan et al. and Simmonds et al. recommend
further research into the underlying genetics and molecular pathways of these traits. Each of
the traits in metabolic syndrome has been shown to be under genetic control in both human
and animal models, with heritability rates ranging from 20% for hypertension to over 70% for
dyslipidemia and obesity [King and Rotter, 2002, Aldons J Lusis, 2008]. However, genetic and
genomic studies have found the regulatory mechanisms to be more complex than originally
thought, with interactions between common variants of small effect size and rare variants
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affecting the disease [Aldons J Lusis, 2008, Schork et al., 2009]. Despite being related traits,
there appears to be little common genetic regulation of metabolic syndrome [Aldons J Lusis,
2008].
Essential hypertension, a component of metabolic syndrome, is a high ranking risk fac-
tor for cardiovascular diseases, which are the leading causes of death in the western world
[Brundtland, 2002, Chockalingam et al., 2006]. Kearney et al. estimates that approximately
26% of the worldwide population has hypertension and this could increase by 60% before the
year 2025 [Kearney et al., 2005]. Hypertension is characterised by elevated blood pressure
(BP) where individuals with BP measurements of 140/90 mmHg are classified as hypertensive
[Binder, 2007, Kearney et al., 2005]. Essential hypertension, or primary hypertension, occurs
when there is an elevation of BP without the presence of a known cause, such as renal failure
or a mendelian variant [Carretero and Oparil, 2000]. Heritability for essential hypertension
is estimated to be between 15 - 40% [Feinleib et al., 1977, Staessen et al., 2003, Delles et al.,
2010], but little is known about the functional genetic basis of the trait.
Like many common complex diseases, essential hypertension has been the focus of sev-
eral genetic studies including linkage and genome-wide association studies (GWAS). Link-
age or family studies have been successful in identifying the genetic determinants causing
the Mendelian forms of hypertension, such as Liddle’s syndrome and Gordon’s syndrome
[Warnock, 1998, Binder, 2007], but have found little regarding the more prevalent essential
hypertension. The genetic variants which have been identified are those in the hormonal reg-
ulation of blood pressure, including variants in the renin-angiotensin-aldosterone system and
in the vasopressin regulation of baroreflex sensitivity [Tiret et al., 1998, Bonnardeaux et al.,
1994, Giner et al., 2000, Berecek and Swords, 1990, Abboud et al., 1990].
Since 2007, several GWAS have investigated hypertension and BP variation, with limited
results [Newton-Cheh et al., 2009, Levy et al., 2009, Wellcome Trust Case Control Consortium,
2007, Adeyemo et al., 2009, Fox et al., 2011, Org et al., 2009, Cho et al., 2009, Lettre
et al., 2011, Padmanabhan et al., 2010, Sabatti et al., 2009, Hong et al., 2010, International
Consortium for Blood Pressure Genome-Wide Association Studies et al., 2011, Wain et al.,
2011]. GWAS utilise large groups of unrelated individuals to identify associations between
disease traits and common genetic variants. Those GWAS which have found significant and
replicated loci associated with hypertension used meta-analyses with large population sizes,
which are time consuming and expensive to phenotype and genotype [Newton-Cheh and
Hirschhorn, 2005, Levy et al., 2009, International Consortium for Blood Pressure Genome-
Wide Association Studies et al., 2011, Wain et al., 2011]. In order to dissect the genetic from
environmental factors and increase the power to identify disease-causing genes, rodent models
of hypertension have been developed.
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1.2 Rodents as a model of human diseases
1.2.1 Using Rat/Rodent models for human diseases
Rodents, particularly rats (Rattus norvegicus) and mice (Mus musculus), have been used as
models of human diseases for over 100 years. Clarence Cook Little and Helen Dean King
derived the first experimental inbred mouse and rat strains in 1909, respectively [Crow, 2002,
Festing and Fisher, 2000, Lindsey, 1979, Jacob, 1999]. Inbred animals are homozygous across
the genome and are genetically identical within a strain. Scientists have used both rodent
models extensively, with the mouse being favoured by geneticists and the rat by physiologists
[Jacob, 1999, Jacob and Kwitek, 2002, Aitman et al., 2008, Gill et al., 1989]. Specific rat and
mouse models have been developed to study hypertension and metabolic syndrome [Johns
et al., 1996, Sugiyama and Yagami, 2001, Rapp, 2000]. Hypertension is a complex trait
where environmental factors play a role in the development and progression of the disease.
This complexity adds difficulty when investigating hypertension in humans as variability in
diet and exercise can mask genetic effects. Animal models allow for a greater degree of
experimental control, which can alleviate some of these issues. The trade off, of course, is
that there is not a one-to-one correspondence between models and humans and the genetic
variants found in such models may be irrelevant to human hypertension.
From a phenotypic perspective, rats have generally been favoured as the model of hy-
pertension [Lerman et al., 2005]. Spontaneous hypertension occurs more often in rats than
mice, leading to development of several hypertensive inbred strains [Pinto, 1998]. In addi-
tion to the spontaneously hypertensive strains, there are several strains which developed high
blood pressure as a result of diet, including salt sensitivity. The review by Rapp provides an
overview of the most commonly used hypertensive rat strains [Rapp, 2000]. The larger size
of the rat makes it more amenable to in-depth and invasive phenotyping techniques [Jacob,
1999, Jacob and Kwitek, 2002, Aitman et al., 2008]. The limiting factor in rat studies was
the inability to create gene knock outs which had been available in mice for many years.
The mouse models of hypertension were driven by a candidate gene approach where potential
hypertension genes were either knocked out or knocked down. Often a combination of both
rat and mouse models were used in genetic studies of hypertension. According to the Mouse
Genome Informatics Database [Blake et al., 2011] and the Rat Genome Database [Twigger
et al., 2007], there are 66 mouse quantitative trait loci (QTL) ( see Chapter 1.5), and 256
rat QTL relating to hypertension and BP. However, recent technological advances now enable
one to create rat knockouts using zinc-finger nucleases [Geurts et al., 2009], and the genomes
of several rat strains have been or are being fully sequenced [Genome Therapeutics et al.,
2004, Atanur et al., 2010], paving the way for the field of rat genetics to expand.
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1.2.2 SHR/BN Recombinant Inbred (RI) lines
There have been several inbred rat strains which exhibit hypertensive properties, both with
and without external stimuli [Rapp, 2000]. The Spontaneously Hypertensive rat (SHR) was
developed in 1963 by Okamoto and Aoki [Okamoto and Aoki, 1963, Okamoto et al., 1973]
and exhibits elevated BP without any additional external factors, such as diet or exercise.
Okamoto and Aoki created the SHR strain by selectively breeding the Wistar Kyoto rat
until 100% of the offspring developed hypertension spontaneously. Since its development,
the SHR has been widely used as a model of hypertension and metabolic syndrome, as the
strain also exhibits insulin resistance, hypertriacylglycerolaemia and obesity [Aitman et al.,
1999, Collison et al., 2000, Aleixandre de Artiñano and Miguel Castro, 2009]. In addition
to hypertensive rat strains, there are normotensive inbred strains such as the Brown Norway
(BN). The Brown Norway was chosen by researchers to be the genome sequence reference
strain and the first draft sequence was completed in 2004 [Genome Therapeutics et al., 2004].
In 1989, Pravenec et al. derived a segregating rat population from the SHR/ola and
BN.lx/cub substrains to investigate hypertension, metabolic syndrome and cardiovascular
traits [Pravenec et al., 1989]. A panel of 29 recombinant inbred (RI) strains was created by
crossing BN with SHR to get an F1 population, then mating the F1 population to get an F2
population. The F2 population was matched into sib-sib pairs and subsequently mated until
each line was fully inbred (20+ generations), see Figure 1.1. The BXH/HXB RI panel is a
gender reciprocal cross, where both males from BN were mated with females from SHR and
females from SHR were mated with males from BN. RI panels have been used extensively in
plant systems, such as Arabidopsis thaliana and Zea mays [Koornneef et al., 2004, Burr et al.,
1988, Burr and Burr, 1991] as well as in Caenorhabditis elegans [Viñuela et al., 2010] and
Drosophila melanogaster [Ruden et al., 2009]. Generating RI panels in higher organisms, such
as rodents, have proven to be time consuming and expensive. There are several mouse RI
lines, including the BXD [Peirce et al., 2004] and the LXS RI panels [Williams et al., 2004].
At its creation in 1989, the BXH/HXB panel was the largest mammal RI panel, but in the
past few years, other large panels have been bred. In particular, the ‘collaborative cross’ aims
to have a mouse inbred panel consisting of 1,000 strains available for complex trait mapping
[Iraqi et al., 2008, Churchill et al., 2004].
The BXH/HXB RI panel has now been bred for 80+ generations and has provided the rat
genetics community with a valuable resource for genetic and genomic studies [Aitman et al.,
2008]. The BXH/HXB panel has been used to study several diseases and traits, including
hypertension [Pravenec et al., 1989, Pravenec et al., 2008a], type II diabetes mellitus [Aitman
et al., 1999], metabolic syndrome [Pravenec et al., 2004] and cardiac mass [Petretto et al.,
2008, Pravenec et al., 1995, McDermott-Roe et al., 2011]. Because the strains within a RI
panel are fully inbred, the data collected from them can be used as a cumulative resource for
genetic studies.
CHAPTER 1. INTRODUCTION 21
X
X
X XX X
XXXX
P1 P2
F1
F2
F3
F20
Figure 1.1: Recombinant Inbred Lines. This illustrates the sib-sib breeding pattern used in the
BXH/HXB RI lines. The two parental strains, here SHR and BN, are mated to get an F1 population.
The F1 population was then mated to produce an F2 population. The F2 population was matched
brother-sister and mated until fully inbred (20+ generations) (adapted from [Broman, 2005]).
1.3 Measuring physiological variation in BP
To investigate the genetic basis for complex diseases, the disease status or disease trait must
be measured across a population. Disease phenotypes can either be discrete, case/control
classifications or they can be measured quantitatively [Newton-Cheh and Hirschhorn, 2005].
For some diseases, the discrete classification accurately describes the trait and can provide
a direct association between the disease and the underlying genetic cause. These are often
identified disease states (i.e., cancer versus normal) rather than risk factors or quantitative
traits [Newton-Cheh and Hirschhorn, 2005]. For other traits and diseases, quantitative traits
may provide a better measure for genetic studies due to a vague definition of a disease state
or inaccurate measurements[Newton-Cheh and Hirschhorn, 2005, Timberlake et al., 2001].
Hypertension, for example, is defined by BP measurements which reach a given threshold of
140/90 mmHg. While this is a clinically useful definition, those individuals who have BP
measurements just under the threshold may not be normotensive and thus not representative
of a control state [Pravenec et al., 2008a].
1.3.1 BP and hypertension phenotypes
The methods and technology for BP phenotyping can vary depending on the genetic system
being used. In humans, BP phenotypes are often based upon a single measurement made
during a visit to the physicians. This measurement can determine whether or not a subject
is classified or diagnosed as hypertensive. For some case-control genetic studies, hypertension
is classified as a binary phenotype as it is feasible for large scale studies [Wellcome Trust
Case Control Consortium, 2007, Adeyemo et al., 2009, Org et al., 2009, Lettre et al., 2011,
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Padmanabhan et al., 2010, Hong et al., 2010].
In other studies, single BP measurements are taken from individuals within a popu-
lation and used as a quantitative trait [Levy et al., 2009, International Consortium for
Blood Pressure Genome-Wide Association Studies et al., 2011, Wain et al., 2011, Fox et al.,
2011, Adeyemo et al., 2009, Org et al., 2009, Cho et al., 2009, Sabatti et al., 2009, Hong
et al., 2010, Newton-Cheh et al., 2009, Levy et al., 2007]. Systolic, diastolic, mean arterial
and pulse pressure measurements can be used to investigate hypertension and BP regulation
[Levy et al., 2009, International Consortium for Blood Pressure Genome-Wide Association
Studies et al., 2011, Wain et al., 2011, Fox et al., 2011, Adeyemo et al., 2009, Org et al.,
2009, Cho et al., 2009, Sabatti et al., 2009, Hong et al., 2010, Newton-Cheh et al., 2009, Levy
et al., 2007]. However, as Parati et al. describes, singular clinical BP measurements do not
fully capture the physiologically relevant variability in BP and that singular measurements
can be affected by stress [Parati and Valentini, 2007]. In 2005, Pickering et al. proposed
recommendations for ambulatory BP measurements collected over multiple cardiac cycles as
a time series [Pickering et al., 2005]. While time series BP measurements have been used to
assess differences in heart rate variability [Parati et al., 1995], respiratory rates [Bracic and
Stefanovska, 1998] and baroreflex sensitivity [Gallet et al., 2011, Keissar et al., 2010] between
populations, they have rarely been used in studies to identify genetic variants underlying BP
regulation [Pickering et al., 2005, Kurtz et al., 2005].
In rat models of hypertension, singular or average BP measurements have been commonly
used. BP in rat was first measured using a tail cuff on both conscious or unconscious animals
[Krege et al., 1995, Van Vliet et al., 2000]. While useful in assessing systolic blood pres-
sure (SBP), tail cuff measurements do not provide accurate diastolic blood pressure (DBP)
readings nor are they refined enough to measure subtle changes in pressure over a small num-
ber of cycles [Kurtz et al., 2005]. As the technology advanced, the phenotyping methods
moved to continuous BP measurements, which utilise either fluid catheters or implanted aor-
tic transducers. BP can be measured over minutes, hours or days and can be high frequency
or low frequency depending on the physiological trait of interest. Of the two methods, ra-
diotelemetry, via implanted transducers, provides the greater accuracy as the transducers,
unlike catheters, do not need to be directly connected to an external device. Once a trans-
ducer has been implanted, the animal can be fully ambulatory and measurements can be
made while they are conscious or unconscious [Kurtz et al., 2005].
1.3.2 Time series blood pressure methods
BP measured continuously over a period of time can inform on different physiological features:
recording over minutes can capture information about heart rate and respiratory rate whereas
recording over days can capture features relevant to circadian rhythm including dipper and
non-dipper patterns [Basset et al., 2004, Kuo and Yang, 2005, Parati et al., 1990]. One
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can use signal processing techniques to extract trends from the time series; spectral and
wavelet analyses are two such techniques that have been commonly used for the analysis of
physiological time series.
Fast Fourier transform (FFT) and autoregressive techniques have been used for many
years to investigate cardiovascular properties from time series data. Sayers, in 1973, began to
look at the periodic components in heart rate variability using FFT methods with others soon
to follow [Sayers, 1973, Akselrod et al., 1981, Parati et al., 1990, Di Rienzo et al., 1989, Parati
et al., 1995]. Spectral analyses extract periodic features out of a time series, but rely on the
series being stationary and de-trended, where the mean and variance must not vary over time
and location [Bloomfield, 2004].
Because spectral methods rely on stationarity, they often miss or exclude information
about transient, large scale events within the time series [Burgess et al., 2003, Keissar et al.,
2010]. In 1946, Gabor developed time-frequency wavelet methods to analyse time series in
both domains and there have been several wavelet methods developed around this concept
since [Gabor, 1946]. Wavelets have been used to non-invasively assess physiological features
such as baroreflex sensitivity, which is an important feedback mechanism for BP regulation
[Keissar et al., 2010, Gallet et al., 2011]. The commonly used waveform for BP and blood
flow dynamics has been the complex Morlet waveform [Kashihara et al., 2008, Keissar et al.,
2010, Gallet et al., 2011] developed by Morlet in 1983. The Morlet wavelet transform adjusts
for high and low frequency events in the time series.
These wavelet and spectral techniques have been used to investigate the physiology of BP,
and to some extent, the sympathetic and parasympathetic nervous system, but these time
series traits have been used in only a few genetic studies [Kurtz et al., 2005]
1.4 Genetic variation
Across a population, whether natural or derived, there are genetic variations throughout the
genome which gives rise to inter-individual genetic differences. Genetic variations can present
in several forms, including single nucleotide polymorphisms (SNP), insertions and deletions
(indels), copy number variations (CNV) and microsatellites. These variations can be identified
by genetic markers; the two most commonly used markers in linkage and association studies
are microsatellites and SNPs.
1.4.1 Microsatellite markers
Microsatellites are short repetitive DNA sequences which can differ in length between two
alleles. One can amplify the microsatellite via a polymerase chain reaction (PCR) and run
out the results on an electrophoresis gel to determine the alleles of a given individual [Jirout
et al., 2003]. With the sequences given below, the PCR product for (a) would be bigger than
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that of (b). When run out on a gel, the product from (b) would travel further down the gel
and separate from the product from (a), allowing one to determine which alleles were present
in a given individual. Microsatellites can now be identified using multiplex-PCR techniques
or next generation sequencing techniques [Guichoux et al., 2011].
(a) ...AACCACACACACACACACTGA...
(b) ...AACCACACACAC............CTGA...
1.4.2 SNP markers
SNPs are single differences in a sequence of DNA, (see below), where a single nucleotide
differs between two alleles. SNPs are identified via genome sequencing, starting with Sanger
sequencing and progressing through whole genome shotgun (WGS) sequencing, next gen-
eration sequencing (NGS) and now third generation sequencing [STAR Consortium et al.,
2008, Atanur et al., 2010].
(a) ...AACTCTGA...
(b) ...AACCCTGA...
Once genomic sequences are generated from a particular strain, they are compared to
a reference strain to identify SNPs; for the laboratory rat, the BN is the reference strain
[Genome Therapeutics et al., 2004]. After SNPs have been identified between strains, specific
genome assays can be created to genotype a population. If microsatellites or SNPs are chosen
across the genome, they form a genetic map and strain distribution patterns (SDP) which can
be used for linkage and association studies. A genetic map shows the location of the markers
across the genome in genetic distance (centiMorgan(cM)) but the physical locations (mega
basepair (Mb)) of a marker can also be reported. Some methods for linkage and association
studies rely on genetic distances and others on the physical distance [Broman et al., 2003].
In the BXH/HXB strains the rats are homozygous, and, at a particular genetic marker, they
carry either two SHR alleles or two BN alleles. In an F2 population between SHR and BN,
for example, a rat could be homozygous SHR, homozygous BN or heterozygous with one
allele of each. Sometimes there are missing genotypes within a SDP, but there are several
computational methods available for inferring or imputing the missing values [Broman et al.,
2003, Scheet and Stephens, 2006].
Genotyping imputation methods use the surrounding genetic markers as well as the link-
age disequilibrium (LD) and recombination rates to infer the missing genotypes as well as
untyped SNPs. LD is the non-random association of alleles at different loci and these LD
patterns can be exploited to fill in missing information. Several techniques have been used for
imputation, including Hidden Markov Models (HMM) (fastPhase, IMPUTE, Beagle) [Scheet
and Stephens, 2006, Marchini et al., 2007, Browning and Browning, 2007], Markov chains
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(MaCH) [Li et al., 2010] and Expectation-Maximisation (EM) (PLINK) algorithms [Purcell
et al., 2007]. There have been several reviews of and comparisons between these common
methods [Pei et al., 2008, Nothnagel et al., 2008, Biernacka et al., 2009, Marchini and Howie,
2010]. Marchini et al. is a comprehensive review of these methodologies which also discusses
some of the following issues surrounding the use of imputed genotypes. The different LD pat-
terns, and, as an extension, the different ethnic and genetic composition of the populations
can effect the false positive/negative association rates. As the minor allele frequency (MAF)
decreases for an allele, the harder it is to correctly impute, which can mask the effect of
rare variants. For any imputation method, the imputed genotypes, whether they are missing
genotypes or un-typed genotypes, will have associated error rates.
1.5 Genetic and Quantitative Trait Locus (QTL) analysis
1.5.1 Genetic Linkage and Linkage Disequilibrium Analysis
Genetic linkage occurs when two loci reside on the same chromosome and are inherited to-
gether more than 50% of the time. The closer the two loci are in the genome, both in terms
of genetic distance (cM) and physical distance (bp), the greater the likelihood that the two
loci will be co-inherited. The known genetic linkage between two loci can be used to estimate
the relative distance between them in the genome and, if the position of one of the loci is
known, the position of the other can be estimated from that relative distance. This relative
distance can be exploited to map loci containing disease genes from known genetic markers
across the genome. Linkage analysis is performed with family pedigrees to study a disease,
and the ability to detect functional variants relies on the family pedigrees and availability of
affected families as well as the disease penetrance [Lander and Schork, 1994]. Large families
with parents, multiple siblings and cousins, both affect and unaffected, present the pedigrees
with the greatest power, but often these families are not available. However, the effect size
of the locus is the main limiting factor in the analysis; the genotype risk ratios associated
with a disease allele may be the best predictor of whether or not a linkage study will be
effective [Risch and Merikangas, 1996, Terwilliger and Göring, 2009]. Even if a locus has a
large effect size, the actual genomic region may be too large for the effective identification of
a functional variant. However, this was the standard method for many years, and the genetic
determinants underlying many Mendelian traits, such as cystic fibrosis [Iannuzzi and Collins,
1990] and Huntington’s disease [Group, 1993] were identified.
Linkage disequilibrium is the non-random association of alleles within a population. Like
linkage analysis, LD analysis aims to estimate the relative genetic distance between two loci
and use that information to identify genomic regions associated with disease. LD analysis
utilises the patterns of LD and haplotypes in the affected and unaffected members of the
population to identify loci containing functional variants [Terwilliger and Göring, 2009, Risch
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and Merikangas, 1996]. Regions of the genome which are identical by descent, and shared by
the affected members of the population more often than expected, can indicate the location of
potential disease causing variants. Like linkage analysis, LD analysis is dependent on several
factors including the frequency of transmission between generations, and the penetrance of
the disease. Linkage disequilibrium mapping was often used in tandem with linkage mapping
to help narrow the genetic regions of interest and identify functional variants. The large loci
identified in linkage analysis can be narrowed with LD mapping. Linkage and LD analyses
have been shown to work well for Mendelian traits, but have had limited success with complex,
polygenic diseases.
1.5.2 Quantitative Trait Locus (QTL) analysis
In the more general case, QTL analysis is based upon the same premise as linkage analysis,
and can be applied to different genetic systems. A phenotype of interest is measured in
a population, either an experimental cross (RI panels, for example) or a family, and the
population is genotyped across a region of interest or the entire genome. Variation in a
phenotype is associated with a region or locus in the genome [Lander and Botstein, 1989, Haley
and Knott, 1992]. Theoretically, there is a functional genetic variant underlying the locus,
or QTL, which causes the phenotypic variation across the population [Lander and Botstein,
1989, Haley and Knott, 1992]. Model systems are frequently used for QTL studies because
large segregating animal populations allow for greater experimental control and can increase
the power to identify QTLs. However, QTLs are often large genomic regions and finding the
causal gene within the QTL can be difficult [Glazier and Nadeau, 2002]. QTL studies can
be coupled with gene expression or functional data to aid in locating the functional variant
[Jansen, 2001, Doss et al., 2005].
1.5.3 Genome-Wide Association Studies (GWAS)
Within the past five years, GWAS became feasible at a relatively low cost [Wellcome Trust
Case Control Consortium, 2007]. Similar to linkage studies and QTL analysis, GWAS takes a
disease phenotype or trait and looks for an association to SNPs in the genome [Hardy, 2009].
GWAS, compared to traditional linkage studies, are more powerful at detecting common
variants, with relatively small effect sizes, by looking at large population cohorts. The ease and
affordability of genotyping technologies, coupled with large clinical cohorts, now allows for a
large scale analysis of common diseases in humans [Wellcome Trust Case Control Consortium,
2007]. Human GWAS are greatly aided by the Human HapMap project, which maps common
alleles across populations of Europeans, Africans, Japanese and Chinese [Consortium, 2003].
However, the associations that are identified by GWAS are not necessarily the functional
variants. The SNPs may be in genes which are in linkage disequilibrium with the true variant
or the SNPs may be outside coding regions [Hirschhorn and Daly, 2005, Stranger et al., 2011].
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With GWAS, standard multiple testing corrections, such as the Bonferroni correction, are too
constrictive and may not be appropriate [Ziegler et al., 2008].
In the first large GWAS, the WTCCC proposed using both frequentist and Bayesian
approaches to address the issues of false positives [Wellcome Trust Case Control Consortium,
2007]. They subscribe to the notion that the significance levels should not be based on the
number of tests performed but recognise that small p-values are needed for a reasonable
threshold. The authors also considered the power of the study with the prior expectations of
association and estimated the significant p-values to be on the order of 10−7. The WTCCC
reported p-values from both trend tests and genotype tests as well as the analogous Bayes
factors. The Bayes factor is a Bayesian measure which indicates the strength of evidence
for association and can inform on the power of the study [Wellcome Trust Case Control
Consortium, 2007, Ziegler et al., 2008]. The Bayes factor is the ratio of the marginal likelihood
of the two models being compared. The significance estimates can vary according to the
individual parameters of a specific study but, for most studies, genome-wide significance is
estimated or assumed to be 10−8. This stringent p-value threshold reduces the number of
type I errors, or false positives, at the expense of type II errors, or false negatives. Significant
associations need to be replicated in more than one population and additional functional
studies often need to be done in order to validate the biological role of these associations.
There have been over 1,100 GWAS performed to date, most of which have been published
since 2009, and encompass over 500 traits and diseases [Hindorff and Sethupathy, 2009]. For
some traits, GWAS has found significant and reproducible associations, with functional data
to support the associations. Klein et al. published one of the first GWAS to find a functional
variant when studying age-related macular degeneration [Klein et al., 2005]. Other complex
diseases and traits have not been so amenable to association studies and have not provided the
results that were initially envisioned. For example, there have been several GWAS focusing on
hypertension and BP variation [Adeyemo et al., 2009, Fox et al., 2011, Org et al., 2009, Cho
et al., 2009, Lettre et al., 2011, Padmanabhan et al., 2010, Sabatti et al., 2009, Hong et al.,
2010, International Consortium for Blood Pressure Genome-Wide Association Studies et al.,
2011, Wain et al., 2011], yet only four of them have found reproducible associations which
reach genome-wide significance [Newton-Cheh et al., 2009, Levy et al., 2009, Wain et al.,
2011, International Consortium for Blood Pressure Genome-Wide Association Studies et al.,
2011]. Table 1.1 provides a list of the reproducible associations which reached genome-wide
significance, p < 10−8, in each of the of the four studies. These four studies are meta-analyses
of GWAS results, whereby several studies are grouped together to increase the power to detect
significant and reproducible associations.
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Author Phenotype* SNP Gene(s) Reported**
International Consortium SBP/DBP/HTN rs1173771 NPR3-C5orf23
for Blood Pressure
International Consortium SBP/DBP rs11953630 EBF1
for Blood Pressure
International Consortium DBP rs13082711 SLC4A7
for Blood Pressure
International Consortium SBP/DBP rs13107325 SLC39A8
for Blood Pressure
International Consortium DBP rs13139571 GUCY1A3-GUCY1B3
for Blood Pressure
International Consortium SBP/DBP rs1327235 JAG1
for Blood Pressure
International Consortium SBP rs176087661742 GOSR2
for Blood Pressure
International Consortium SBP/DBP/HTN rs1799945 HFE
for Blood Pressure
International Consortium SBP/DBP rs2521501 FURIN-FES
for Blood Pressure
International Consortium SBP/DBP rs2932538 MOV10
for Blood Pressure
International Consortium SBP/DBP rs419076 MECOM
for Blood Pressure
International Consortium SBP/DBP/HTN rs4373814 CACNB2(5_)
for Blood Pressure
International Consortium SBP/DBP/HTN rs6015450 GNAS-EDN3
for Blood Pressure
International Consortium SBP/DBP/HTN rs633185 FLJ32810-TMEM133
for Blood Pressure
International Consortium SBP/DBP rs7129220 ADM
for Blood Pressure
International Consortium SBP/DBP/HTN rs805303 BAT2-BAT5
for Blood Pressure
International Consortium SBP/HTN rs932764 PLCE1
for Blood Pressure
Wain et al. PP rs11222084 ADAMTS8
Wain et al. PP rs17477177 PIK3CG
Wain et al. PP rs2071518 NOV
Wain et al. MBP rs2782980 ADRB1
Wain et al. MBP rs319690 MAP4
Wain et al. PP rs871606 CHIC2
Levy et al. SBP rs1004467 CYP17A1
Levy et al. DBP rs11014166 CACNB2
Levy et al. DBP rs2384550 TBX3/TBX5
Levy et al. DBP/HTN rs2681472 ATP2B1
Levy et al. SBP rs2681492 ATP2B1
Levy et al. SBP/DBP rs3184504 SH2B3
Levy et al. SBP rs381815 PLEKHA7
Levy et al. DBP rs6495122 CSK/ULK3
Levy et al. DBP rs9815354 ULK4
Newton-Cheh et al. SBP rs11191548 c10orf26 CYP17A1 c10orf32
AS3MT CNNM2 NT5C2
Newton-Cheh et al. SBP rs12946454 PLCD3 ACBD4 HEXIM1
HEXIM2 FMNL1
Newton-Cheh et al. DBP rs1378942 CYP1A1 CYP1A2 CSK
LMAN1L CPLX3 ARID3b
Newton-Cheh et al. DBP rs1530440 c10orf107 TMEM26 RTKN2
RHOBTB1 ARID5B
Newton-Cheh et al. DBP rs16948048 ZNF652 PHB
Newton-Cheh et al. DBP rs16998073 PRDM8 FGF5 C4orf22
Newton-Cheh et al. SBP rs17367504 MTHFR CLCN6 NPPA
NPPB AGTRAP
Newton-Cheh et al. DBP rs653178 SH2B3 ATXN2
*SBP - Systolic Blood Pressure; DBP - Diastolic Blood Pressure; HTN - Hypertension; MBP - Mean Blood Pressure, PP - Pulse Pressure
**Genes (or loci) reported in the publication for each association
Table 1.1: List of published reproducible GWAS results reaching genome wide significance p < 10−8
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There are several established statistical methods for meta-analyses which can be applied
to GWAS data [Tseng et al., 2012], but complications arise in preparing the genotype and
phenotype for the analysis. The populations in the meta-analyses are not from a single cohort,
but from several independent studies which may lead to differences in the genotyping, phe-
notyping and even the basic underlying genetic structure across the cohorts. The genotyping
in each GWAS may have been performed on the same platform, but often these individual
studies use different platforms where there may less than a 20% overlap between the SNPs
[Begum et al., 2012]. There are several imputation methods which aim to provide a com-
mon genetic map across the studies [Marchini and Howie, 2010]. The imputed genotypes will
have error levels and confidence intervals associated with them that may not always be taken
into consideration. Depending on the coverage of the different platforms, different regions in
the genome may have different levels of false positive and false negative rates [Begum et al.,
2012]. The underlying genetic structure can also effect the genotype imputations and even
the quality control methods as different ethnic populations have different LD patterns and
MAF. Similarly, the differences in phenotyping procedures between studies can effect the error
rates in meta-analyses. The different studies can have varying proportions of case to control
subjects, which can effect the genotype imputations [Begum et al., 2012].
1.6 Gene expression variation
Gene expression can be measured by quantifying messenger RNA (mRNA) abundances. These
mRNA or transcript abundances can be used to identify up-regulated and down-regulated
genes or identify genetic variations which may cause the differences in gene expression. Ex-
pression levels for individual genes can be quantified using quantitative-PCR techniques, but
to assess expression genome-wide, microarray technologies are commonly used [VanGuilder
et al., 2008, Woo et al., 2004]. Oligonucleotide microarrays are commercially available for
several species, including rats and humans. There are several other types of microarrays, in-
cluding spotted and complimentary DNA (cDNA) which can be customised to assess specific
genes, but the arrays are often highly variable [Woo et al., 2004]. Oligonucleotide microar-
rays are available across several platforms with a different number of probes available for
each genome-wide analysis. The Rat Affymetrix GeneChip arrays RAE 230 A and RAE 230
2 were used in this work to assess genome-wide expression in the RI strains across multiple
tissues. Sequencing technologies now allow for gene expression variations to be assessed using
RNA-seq methods. mRNA transcripts are sequenced and simplistically, the abundances are
quantified by the number of times an individual sequence is present [Hawkins et al., 2010].
There are a number of effects that need to be taken into consideration when analysing
microarray gene expression data. The gene expression levels can exhibit batch effects due the
chips being processed on different days as well as background variation across an individual
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chip. There are normalisation techniques to correct for these effects so that the expression can
be compared within and between chips. For Affymetrix microarray chips, there are several
commonly used methods including the Microarray Suite (MAS) 5.0 provided by Affymetrix,
the robust multichip average (RMA) method, LOESS-based methods and the GC robust mul-
tichip average (GC-RMA). The MAS 5 methodology uses probe pair matching to normalise
data (Affymetrix) whereas RMA uses quantile-quantile adjustments [Irizarry et al., 2003].
GC-RMA utilises the RMA method with an additional step that uses probe sequences to cal-
culate affinity measures. LOESS based methods use local regression for normalisation. The
probe sequences can also introduce non-biological variation into the analysis. Some probes
may cover repetitive sequences and thus map back to several locations in the genome. These
probes are not informative as the differences in expression could arise from a number of lo-
cations in the genome. Variants in the probe binding region can give rise to spurious effects.
SNPs located in the probe binding regions can cause differences in the hybridisation of probes
which can appear as differential expression in later analyses [Benovoy et al., 2008, Alberts
et al., 2007].
In addition to normalisation techniques, basic standards have been developed to ensure
the comparability and reproducibility of microarray experiments across laboratories. The
Minimum Information About a Microarray Experiment (MAIME) is a guideline for providing
information alongside microarray experiments [Brazma et al., 2001]. There are six criteria for
a dataset to be MIAME compliant:
1. overall experimental design
2. array design
3. sample preparation and labeling
4. hybridisation procedures
5. measurements
6. normalisation controls
There are two main repositories for gene expression data - the Gene Expression Omnibus
(GEO) database held at the NCBI [Barrett et al., 2011] and the ArrayExpress database held
at the EBI [Parkinson et al., 2011]. Both of these databases require that the submitted data
be MIAME compliant.
1.7 Expression Quantitative Trait Locus (eQTL) analysis
Gene expression can be used as an intermediary molecular level phenotype between genetic
and phenotypic variation. Mapping expression traits to the genome can inform on the genetic
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regulation of gene expression variation, which can be referred to as expression quantitative
trait locus (eQTL) analysis or ‘genetical genomics’ [Jansen, 2001, Doss et al., 2005]. eQTL
studies have been performed in several organisms, ranging from yeast [Storey et al., 2005,
Ambroset et al., 2011], and maize [Holloway et al., 2011] to mice [Derry et al., 2010, Davis
et al., 2012], rats [Hubner et al., 2005, Petretto et al., 2010] and humans [Dixon et al.,
2007, Cookson et al., 2009, Rotival et al., 2011, Fairfax et al., 2012]. eQTL analysis can provide
more information about the genetic regulation underlying gene expression and complex traits
because one knows the location of the transcripts in the genome. If a transcript maps back
to the original location of the probe, it is termed cis-regulated; if it maps elsewhere in the
genome, it is termed trans-regulated (Figure 1.2) [Jansen, 2001, Doss et al., 2005]. However,
Petretto et al. have shown that some transcripts can be under polygenic control and some
can have both cis and trans regulated control points [Petretto et al., 2010].
Chromosome 1 
Chromosome 5 
Figure 1.2: Cis and Trans eQTL: This represents the genetic control of both cis and trans eQTL.
Cis eQTLs are represented on the left, where the transcript is associated to a local region in the
genome, suggesting local regulation. Trans eQTLs are represented on the right, where the transcript
is associated with a distant region.
The genomic regions designating cis and trans eQTLs vary by genetic model and, while
these definitions are good a indication of local versus distant regulation, they are not absolute.
eQTLs which map to a location on a different chromosome can assigned as trans with high
confidence, but for those which map to the same chromosome, there will be some ambiguity.
Cis eQTLs indicate that the gene expression is regulated by a variant within the gene sequence
itself, including non-coding elements such as promoters and UTRs, but there will be the case
where a variant close to the gene is actually regulating the gene expression, not the gene itself.
No matter what the definition of cis and trans eQTLs are, there will always be some eQTL
that will inadvertently be wrongly classified.
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1.7.1 Cis eQTLs
In principle, a cis eQTL points to a gene whose expression is regulated by a local genetic
variant that segregates within the mapping population [Doss et al., 2005]. Depending on the
genetic system used, one can adjust the criteria to classify a cis-acting eQTL. Here, in the
BXH/HXB rat RI panel, those eQTLs which map to within 10 Mb either side of the probe
location are defined as cis acting [Hubner et al., 2005]. Others have used 100 kilo basepair
(Kb) [Cookson et al., 2009], 1 Mb [Breitling et al., 2008], 5 Mb [Morley et al., 2004], or 20 Mb
[Derry et al., 2010] regions to define cis or trans. The recombination rate, marker density, and
the length of LD can be used to determine the appropriate region for cis eQTL as previously
shown [Hubner et al., 2005]. Hubner et al. designated cis eQTLs in the BXH/HXB RI panel
to be those which mapped to within 10Mb either side of the probe location. They took into
consideration differences in recombination rates, long range regulation and the inexactness
in the linkage peaks as well as the desire not to exclude positional candidates. To find the
optimal cis and trans windows, they simulated a range of windows across the genome. The
region of 20Mb (10Mb either side of the probe) proved to be the optimal choice in terms
of total number of cis eQTLs and the percent variation in the number of cis eQTLs. The
average identical-by-descent region in the RI panel is ∼ 5−6 Mb, so the 10Mb region slightly
biases the analysis towards detecting cis eQTL [Hubner et al., 2005]. In concordance with
this previous work, the cis eQTLs in this work are defined as those eQTLs which map to
within 10Mb either side of the probe location.
Genes with cis regulated transcripts are often considered to be candidate genes for complex
diseases or traits, especially when the eQTL co-localises with a physiological QTL [Hubner
et al., 2005]. Morrissey et al. identified and validated ‘3C’ candidate genes where ‘3C’
stands for cis regulated, co-localising and correlated [Morrissey et al., 2011]. These are cis
regulated genes whose transcripts map back to the same location as a physiological QTL and
whose transcripts are correlated with that same physiological trait. These ‘3C’ genes have
been identified as candidate genes in other rat studies of cardiovascular traits including Ogn
(cardiac mass), CD36 (blood pressure) and EndoG (cardiac hypertrophy) [Petretto et al.,
2008, Pravenec et al., 2008a, McDermott-Roe et al., 2011]. Because the strain differences in
gene expression are reflected in the phenotypic levels, the cis regulation of these ‘3C’ genes
indicate that the gene itself, or a variant nearby, regulates the gene expression and phenotypic
levels. As QTLs can be large genomic regions, the additional information provided by the
eQTLs can narrow these regions and prioritise functional variants affecting gene expression.
1.7.2 Trans eQTLs
Trans eQTLs map to a different location in the genome from that of the transcribed gene,
suggesting a distant regulatory mechanism of the gene expression. Some have hypothesised
that trans eQTLs map to locations of regulatory elements such as transcription factors or
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microRNAs and for some studies this holds true [Yvert et al., 2003]. However, studies in
yeast have shown trans eQTLs mapping to locations of the genome which are void of obvious
regulatory elements [Yvert et al., 2003]. Expression data in the rat suggest that there are more
trans eQTLs than cis eQTLs genome-wide, but most trans eQTLs have weaker associations
[Petretto et al., 2006b, Petretto et al., 2006a].
1.7.2.1 Trans eQTL clusters
Groups of trans eQTLs can map to the same location in the genome and are often referred to
as clusters, ‘hot spots’ [Breitling et al., 2008] or ‘trans eQTL bands’ [Wu et al., 2008]. These
clusters can represent genes which are co-expressed or play a role in the same functional
pathway. It has been suggested that the missing heritability in GWAS can be found in trans
regulated genes as the large scale association studies do not find these effects [Fehrmann et al.,
2011]. Several studies have shown the effects of trans clusters on complex traits and disease
associations, indicating that they may be responsible for undetected genetic regulation.
Heinig et al. identified a trans cluster in the rat which was enriched for immune response
genes and regulates type I diabetes risk in humans [Heinig et al., 2010]. The trans cluster
was initially detected in the rat and replicated across four tissues (adrenal gland, heart, liver
and adipose) and was conserved in human monocytes. By integrating eQTLs and transcrip-
tion factor binding sites, they identified interferon regulatory transcription factor Irf7, which
mapped in trans to a locus, as the transcription factor which modulates the cluster. From
there, they identified a putative ‘master regulator’ gene underlying the trans cluster locus,
Epstein - Barr virus induced gene 2 (Ebi2 ), which regulated Irf7 and the cluster [Heinig et al.,
2010]. In another study which integrated transcription factor binding sites and eQTLs, Small
et al. identified functional variants near the cis regulated, maternally expressed transcription
factor trans KLF14 which were associated with metabolic syndrome traits [Small et al., 2011].
They tested genome wide gene expression in adipose for associations with the KLF14 locus
and found an enrichment for trans eQTLs. The associations were further strengthened by
transcription factor binding site analysis and by a GWAS meta analysis of the cluster.
Other studies have also looked at trans clusters genome-wide and utilised functional en-
richment data to inform on and prioritise trans clusters. Wu et al. identified 1,659 trans
clusters or ‘trans eQTL bands’ in the adipose tissue of a mouse recombinant inbred line.
They investigated potential ‘master regulators’ as well, but instead of focusing on regulatory
mechanisms, like transcription factors, they looked at the functional enrichment of the cluster
and the annotation of the genes at the locus. They performed functional enrichment anal-
ysis on each of their clusters and found 367 clusters to be significantly enriched for Kyoto
Encyclopaedia of Genes and Genomes (KEGG) pathways and Gene Ontology (GO) terms.
The cluster with one of the strongest enrichments was found to contain genes relating to the
KEGG pathway, ‘Oxidative Phosphorylation’ (mmu00190), and have a putative ‘master reg-
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ulator’, cyclin H (CCNH ), at the trans locus. As the technology and subsequent methodology
improves, one will be able to fully investigate the effect that these trans regulated eQTLs and
clusters have on complex diseases.
1.8 Quantitative Trait Transcript (QTT) analysis
Quantitative trait transcript (QTT) analysis investigates the relationship between gene ex-
pression variation and physiological phenotypes by correlation analysis [Passador-Gurgel
et al., 2007, Petretto et al., 2008, Morrissey et al., 2011]. QTT analysis has been performed
on gene expression genome-wide [Passador-Gurgel et al., 2007] as well as the subset of genes
under cis regulation [Petretto et al., 2008, Morrissey et al., 2011]. Gene expression that
significantly correlates with a physiological phenotype can suggest a potential functional re-
lationship between the gene and the phenotype. As mentioned above, the ‘3C’ genes are
strong candidate genes for a given trait due to the gene expression traits correlation and
co-localisation with the physiological phenotype [Morrissey et al., 2011]. The correlation be-
tween the phenotypes and the gene expression as well as the co-localisation of the eQTL and
pQTL suggests a relationship between the gene and the phenotype. The cis-regulation of the
‘3C’ genes indicates that the gene is under local regulation by the gene itself. It is the combi-
nation of these factors which makes the ‘3C’ genes strong candidate genes. This does indicate
a simplistic view where a variant in the gene causes differences in the gene’s expression, which
then manifests into a difference in the phenotype. Obviously, this is not always the case as the
underlying genetics is complex and the designation of cis eQTLs such that another variant
near to the gene could be regulating it. However, when faced with large regions associated
with a disease risk, these ‘3C’ genes are strong candidates for initial investigations into the
causal variants.
1.9 Functional enrichment analysis
High-throughput genetic and genomic technologies now allow one to investigate large sets of
genes statistically associated with a trait or disease. Functional data and analyses can be
used to suggest which of those are biologically relevant to the disease or trait being studied.
They can provide information about gene lists such as gene-gene interactions, protein-protein
interactions, presence in molecular pathways, cellular function and cellular location [Khatri
and Drăghici, 2005, Curtis and Oresic, 2005, Huang et al., 2008]. Many genetics and genomics
studies have used functional analyses to further validate or inform on genes of interest.
For example, Wu el al. used functional enrichment to show the biological relevance of
trans eQTL bands and to prioritise one for further validation. They were able to identify a
trans eQTL band which was enriched for oxidative phosphorylation using functional data from
the Gene Ontology database, KEGG pathways and the Ingenuity Pathways Knowledge Base
CHAPTER 1. INTRODUCTION 35
(ING) [Wu et al., 2008]. In addition, they were able to locate a putative ‘master regulator’
for their trans eQTL band by incorporating functional data. Heinig et al. utilised GO term
enrichment to inform on a trans regulated network which was enriched for immune response
genes [Heinig et al., 2010]. The network, as mentioned above, was associated with type I
diabetes risk in humans. Rotival et al. also investigated the functional relationship of eQTLs
by looking at the enrichment of GO terms [Rotival et al., 2011]. They identified co-expressed
modules in human monocytes which were enriched for immune response and low level cellular
metabolic processes [Rotival et al., 2011].
There are several different publicly available applications and tools for the functional
annotation of large gene lists [Khatri and Drăghici, 2005, Curtis and Oresic, 2005, Huang
et al., 2009]. One of these applications, used in this thesis, is the Database for Annotation,
Visualization and Integrated Discovery (DAVID). DAVID has multiple functionalities includ-
ing gene functional classification and functional annotation clustering and uses information
from multiple sources including GO Biological Process, GO Molecular Function, GO Cellular
Component, KEGG Pathways, BioCarta Pathways, Swiss-Prot Keywords, BBID Pathways,
SMART Domains, NIH Genetic Association DB, UniProt Sequence Features, COG/KOG
Ontology, NCBI OMIM, InterPro Domains, and PIR Super-Family Names [Dennis Jr et al.,
2003, Huang et al., 2007]. Two of the main functional groups GO and the KEGG pathways
were used here to look for functional enrichment.
The GO database provides an ontology for terms relating to genes and their products.
There are three classifications of ontologies
• Cellular component
• Biological process
• Molecular function
which are species independent [Ashburner et al., 2000]. The three ontologies are related to
each other by directed acyclic graphs with each term in a defined relationship with other
terms in the same domain and occasionally other terms in domains as well [Ashburner et al.,
2000]. By looking for an enrichment within these categories, one can begin to dissect the
biological meaning of a specific gene list.
KEGG pathway database contains manually curated molecular pathways relating to [Kane-
hisa, 2004],
• Metabolism
• Genetic information processing
• Environmental information processing
• Cellular processes
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• Human disease
and can represent differences in pathways between species [Kanehisa, 2004]. Similar to GO
terms, an enrichment in one or more KEGG pathways can inform on the biological meaning
and relevance of a gene set to a given trait or disease. Occasionally, a grouping of statistically
significant genes can happen artificially and cannot be representative of a biological function.
For example, co-expressed genes can result from the proximity of the microarray probes on
a slide [Kluger et al., 2003]. Functional enrichment can help determine which significant
associations are biologically relevant and are not due to artefacts in the data.
1.10 Overall Aims
The work following aims to address limitations in current genetic and genomic studies of BP
variation and hypertension by performing a systems-wide genetic analysis of BP regulation in
the BXH/HXB rat recombinant inbred lines. I aim to address these limitations by means of
new genetic mapping techniques, novel BP phenotypes and an integrated multi-tissue analysis
in rat. The rat has been used as a model for hypertension, specifically the SHR and SHR
derived strains, and using a model provides access to tissues and BP measurements that
are not feasible in humans. The results derived from the integrated analysis in the rat will
then be compared with the results from human genome-wide association studies to identify
genetic variants associated with BP regulation in both species. This work takes advantage of
genome-wide gene expression and genetic maps previously measured in the BXH/HXB panel
along with the new BP phenotypes from the radiotelemetric measurements.
• Identify optimal eQTL mapping methods for genome-wide analyses
Expression levels can aid in the investigation of hypertension by acting as an intermediate
phenotype between genetic variation and BP variation. eQTLs can inform on the genetic
regulation of the gene, and can indicate local (cis acting) or distal regulation (trans acting)
or, for polygenic traits, a combination of the two. By applying the optimal eQTL mapping
method to the gene expression data, I aim to identify expression traits with moderate to
small genetic effect sizes in addition to expression traits with large effect sizes. These weakly
regulated genes are often highly polygeneic or trans regulated and are not likely to reach
genome-wide significance in human GWAS.
Chapter 3 presents a comparative analysis of eQTL mapping methods, using subset of
the gene expression data from the BXH/HXB in the analysis. Different methods for single
phenotype mapping will be compared and will include QTL Reaper [Wang et al., 2003], the
Sequential Search Method [Storey et al., 2005] and the Sparse Bayesian Regression method
[Petretto et al., 2010]. The multiple phenotype mapping methods compared will include
GFLASSO [Kim et al., 2009], the Mixture-over-Markers method [Kendziorski et al., 2006],
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Hotelling’s T 2 test [Hotelling, 1931] and the Sparse Bayesian Multiple Regression method
[Petretto et al., 2010]. I will use the results from this comparative analysis to inform a
genome-wide, multi-tissue analysis of expression in primary and secondary tissues relevant to
hypertension.
• Derive novel BP phenotypes from radiotelemetric time series measurements
Since BP measurements in human GWAS are limited, the aim is to derive novel BP and
HR phenotypes from radiotelemetric time series measurements to capture dynamic features
of BP. These novel phenotypes may have different genetic control points from the standard
phenotypes. Signal processing techniques will be applied to extract cyclical and dynamic
indices of BP and heart rate. Transformations using fast Fourier and wavelet methods will
be implemented to derive dynamic phenotypes. In addition, standard indices of BP will also
be extracted from the time series.
• Integrate genetic, genomic and phenotypic information in the rat
Any novel phenotypes derived will be incorporated to provide an integrated analysis of BP,
gene expression and genetic variation of the BXH/HXB rat RI panel. By performing genome-
wide eQTL mapping in multiple tissues, I aim to identify gene expression traits which are
under both strong and weak genetic effects. Previous eQTL studies and GWAS typically
only identify variants with strong phenotypic effects; these variants tend to be predominantly
under cis regulation. Trans-regulated eQTLs, however, can cluster and show patterns of both
common and co-regulation. Within the eQTLs, I am to identify trans eQTL clusters across
the genome in each of the seven tissues and identify putative ‘master regulators’ associated
with these clusters. These clusters and potential ‘master regulators’ will be used to investigate
potential genetic regulatory mechanisms associated with BP regulation.
I aim to investigate genetic effects in both primary and secondary tissues relevant for
BP regulation by performing the eQTL mapping in multiple tissues and integrating those
expression levels with any BP phenotypes. Because hypertension is a component of metabolic
syndrome and is linked to obesity and lipid traits, investigating gene expression traits from
primary tissues relevant to other metabolic traits may identify genetic determinants which
would have otherwise been missed. The secondary tissues may also show responsive as well
as causal changes in gene expression and highlight downstream effects that these variations
may have within these secondary tissues.
The functional annotation of the genes of interest can inform on the downstream molec-
ular function. The functional annotation of ‘3C’ genes and putative ‘master regulators’ can
strengthen their positions as candidate genes and as potential points of common regulation.
Functional enrichment analyses on lists of genes, such as cis eQTLs, can provide information
on shared functional pathways and molecular function. A significant enrichment within a
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group of genes can also indicate novel molecular disease mechanisms, both in the develop-
ment and in the responses to the disease progression.
• Translate findings on BP variation in rat to human hypertension
Here, I aim to identify genetic variants of smaller effect sizes for human GWAS hits by incor-
porating results from the BXH/HXB RI panel. The low number of genes identified through
GWAS that reach genome-wide significance may indicate that the genetic variants underlying
BP variation and hypertension may be of small effect sizes. The threshold for genome-wide
significance is conservative to restrict the number of false positives at the expense of potential
true positives of smaller effect sizes. I will derive a set of GWAS results using a relaxed
threshold, which may increase the number of those true positives at the expense of a higher
false positive rate. I will look for an enrichment of these genes associated with hypertension
in humans in several subsets of genes associated with BP regulation in the rat model. The
enrichment may inform on the genetic architecture which is conserved across species with
respect to hypertension. Cis regulated genes, including Cd36, have been associated with
hypertension in both rats and humans but trans regulated and non-eQTL (NE) genes have
not been studied to the same extent. By considering cis and trans regulated genes as well
as non-eQTL genes, I aim to investigate the relationship between the trans eQTLs and NE
genes and those genes associated with hypertension in humans. Additionally, the comparison
will result in a list of genes with an association to hypertension and BP regulation shared by
humans and rats.
• Provide resources to rat genetics community
I aim to provide a resource for further studies involving the BXH/HXB RI panel. Because the
RI panel is a cumulative resource, any new spectral and wavelet phenotypes could be used in
additional hypertension studies or with additional metabolic syndrome traits. Additionally,
the eQTLs that will be derived in this study are not specific to hypertension or BP regulation
and thus, could be used for any further genetic studies in the BXH/HXB panel.
Chapter 2
Rat and Human Datasets
2.1 Introduction
Essential hypertension is a risk factor for cardiovascular diseases, and thus has been the
focus for many human genome-wide association studies (GWAS) [Johnson and O’Donnell,
2009, Wellcome Trust Case Control Consortium, 2007, Adeyemo et al., 2009, Fox et al.,
2011, Org et al., 2009, Cho et al., 2009, Lettre et al., 2011, Padmanabhan et al., 2010, Sabatti
et al., 2009, International Consortium for Blood Pressure Genome-Wide Association Studies
et al., 2011, Newton-Cheh et al., 2009, Wain et al., 2011, Hong et al., 2010]. However, only four
of these studies have found reproducible loci and those studies have only done so at the expense
of large cohort sizes (60,000 - 200,000) [Newton-Cheh et al., 2009, International Consortium
for Blood Pressure Genome-Wide Association Studies et al., 2011, Wain et al., 2011, Levy
et al., 2009]. Human studies have limited experimental control with restrictions on the types
of tissues available and the blood pressure (BP) measuring techniques [Pickering et al., 2005].
By using a model system for hypertension, one can investigate more tissues, phenotypes and
exert greater experimental control. Rats have been a model for human diseases for over 100
years [Aitman et al., 2008, Lindsey, 1979], and have been used to investigate several human
diseases, including immune and cardiovascular diseases [Jacob, 1999]. Rats provide an ideal
model system for essential hypertension due to their size, physiology and maintenance [Aitman
et al., 2008].
The Spontaneously Hypertensive rat (SHR) was bred specifically for high blood pres-
sure and was crossed with the normotensive Brown Norway (BN) to study hypertension and
metabolic syndrome [Okamoto and Aoki, 1963, Okamoto et al., 1973, Pravenec et al., 1989].
According to the Rat Genome Database (RGD), there are twenty blood pressure and hyper-
tension quantitative trait loci (QTL) associated with the SHR and five which are associated
with the BXH/HXB recombinant inbred (RI) strains [Twigger et al., 2007]. Despite the
difficulty in identifying the causal variants underlying a QTL, several genes associated with
hypertension and metabolism have been identified in the SHR, including the CD36 molecule
39
CHAPTER 2. RAT AND HUMAN DATASETS 40
(thrombospondin receptor) CD36 [Pravenec et al., 2008a] and the sterol regulatory element
binding transcription factor 1 Srebf1 [Pravenec et al., 2008b]. The SHR’s predisposition for
spontaneous hypertension and the resources available make the SHR and the BXH/HXB RI
panel an ideal rat model for human essential hypertension.
The BXH/HXB RI lines were used here as a model for hypertension and metabolic syn-
drome. In this system, there is genome-wide gene expression, assessed by Affymetrix Microar-
ray technology, time series blood pressure measured radiotelemetrically and genome-wide ge-
netic variation in the form of microsatellites and single nucleotide polymorphisms (SNPs).
These rat datasets used in this thesis were either previously generated by the Physiological
Genomics and Medicine Group and collaborators or collected from publicly available sources.
In addition, publicly available results from human hypertension GWAS studies were used to
investigate the relationship between the results found in the rat and those in human hyper-
tension. This chapter describes these previously generated datasets which will be used in the
remaining chapters.
2.2 BXH/HXB RI panel
X
X
X XX X
XXXX
P1 P2
F1
F2
F3
F20
Figure 2.1: Recombinant Inbred Lines. This illustrates the sib-sib breeding pattern used in the
BXH/HXB RI lines. The two parental strains, here SHR and BN, are mated to get an F1 population.
The F1 population was then mated to produce an F2 population. The F2 population was matched
brother-sister and mated until fully inbred (20+ generations) (adapted from [Broman, 2005]).
The BXH/HXB RI panel is a gender reciprocal panel of recombinant inbred lines derived
from the SHR and the BN. Figure 2.1 shows the breeding strategy for creating a sib-sib
RI panel. There are 29 strains within the panel where each of the rats within a strain are
genetically identical. Out of the 29 strains, there are 10 BXH, which are female SHR by
male BN, and 19 HXB, which are female BN by male SHR. The RI strains become fully
inbred after approximately 20 generations of inbreeding. Currently, the BXH/HXB panel
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have been bred for more than 80 generations and are kept at the Czech Academy of Sciences
and Centre for Applied Genomics in Prague, Czech Republic. Over 200 phenotypes have
been measured in the RI panel and are publicly available from the GeneNetwork database
(http://www.genenetwork.org).
The RI panel can act as a cumulative resource because the animals within a strain are
genetically identical. This gives great flexibility to perform temporal, cumulative and repeated
experiments within this model. The genotypic, genomic, and phenotypic data used here takes
advantage of this property; the genotyping, phenotyping and gene expression measurements
were taken from different populations of the RI panel. This cumulative nature, however, does
not guarantee that the phenotypic and genotypic measurements were taken from rats of the
same age. The gene expression profiles and BP measurements were taken at two different
ages from the RI panel, 6 weeks and 42 weeks, respectively. The different time points may
introduce noise in the later analyses. An additional study where the BP and gene expression
measurements were taken from the same animals, at the same time point, may provide better
results in terms of the relationship between the gene expression and BP levels.
In the following work, the measurements taken were from multiple male rats within each
strain. Using only males reduces the complexity of the genetic, genomic, and phenotypic
analyses but at the expense of identifying gender specific differences in hypertension. There
are known gender differences in the development and progression of hypertension, both in
humans and rats [Reckelhoff, 2001, Maris et al., 2005], so the work presented here is limited
by the availability of data from female rats. To further expand on this work, a complementary
or integrated analysis with data from female BXH/HXB rats from the strains would provide
information on the gender differences in BP and HR in the rat and may inform on the human
GWAS results.
2.2.1 Microsatellite and single nucleotide polymorphism (SNP) panels
Genetic variations, or differences in DNA sequences, are vital to understanding the genetic
regulation of complex diseases and traits. Simplistically, functional variants in DNA se-
quences, such as SNPs, insertions/deletions (indels), and copy number variations (CNV), can
effect gene and protein expression levels, and consequently, be the underlying cause for a
disease state. To determine the association between these variants and a given disease or
trait, one needs a way to assess the genetic variation in a segregating population. Within the
BXH/HXB genetic system, there are two sources of genetic variations, or markers, available
for this study - microsatellites and SNPs.
Microsatellites are short repetitive sequences located throughout the genome which vary
in length between two alleles (see Chapter 1.4). The BXH/HXB RI lines have been genotyped
for 770 microsatellite markers located throughout the genome by Prof. Michal Pravenec and
colleagues (Czech Academy of Sciences and Centre for Applied Genomics). The microsatellites
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were evaluated with either polymerase chain reactions (PCR) or Southern blotting techniques
as described in Pravenec et al. and Jirout et al. [Pravenec et al., 1996, Jirout et al., 2003].
SNPs are DNA variations where a single nucleotide differs between strains. The RI lines
were genotyped for over 13,000 SNPs by the STAR Consortium, where those SNPs form
1,200 unique strain distribution patterns (SDP) (see Chapter 1.4) [STAR Consortium et al.,
2008, Pravenec and Kurtz, 2010]. The SNPs were evaluated using genome shotgun sequencing
techniques coupled with the Affymetrix Targeted Genotyping protocol as described by the
STAR Consortium [STAR Consortium et al., 2008]. Within both the microsatellite and SNP
panels, there were missing values across the RI strains. One can use information from the
flanking markers to infer or interpolate the missing value. The missing values for both the
microsatellites and SNPs were imputed using fastPHASE, which uses a hidden Markov model
to impute genotypes based on haplotype blocks [Scheet and Stephens, 2006]. Figure 2.2
shows (a) the genetic map of the microsatellite markers across chromosomes and (b) the
extent of missing values across the microsatellite panel. Similarly, Figure 2.3 shows (a) the
genetic map for the SNP markers and (b) the extent of missing values across the SNP panel.
Approximately 0.56% of the genotypes in microsatellite panel were missing and 1.67% of the
markers in the SNP panel were missing. For both panels, only the autosomes were used.
2.2.2 Gene expression from BXH/HXB RI lines
Gene expression can be used as an intermediary phenotype between genetic variation and
phenotypic variation as well as inform on regulatory pathways and networks. Gene expres-
sion in multiple tissues can provide information into primary and secondary regulation of
hypertension. Here, genome-wide gene expression profiles from adrenal gland (ADR), adi-
pose (FAT), and kidney (KID) were measured using the Affymetrix RAE 230 A expression
chips, with 15,923 probes located across the genome. Expression from aorta (AORTA), liver
(LIVER), left ventricle (LV) and skeletal muscle (SKM) was measured using the Affymetrix
RAE 230 2 expression chips, which have 31,099 located probes across the genome. The 15,923
probes on the RAE230 A chip are also contained within the RAE 230 2 chip so there is a
set of 15,923 probes assessed across all tissues. The RAE 203 A chip contains probes derived
from the refSeq database and probe set sequences that are related to those on the GeneChip
Rat Genome U34A Array. The RAE 230 2 chip contains the probes from RAE 203 A plus
probes from expressed sequence tag (EST) clusters (http://www.affymetrix.com). Gene ex-
pression in all tissues was evaluated within each strain. There were four biological replicates
per strain, all male and the tissues were extracted at six weeks of age. The expression levels
from ADR, FAT, KID and LV were first used to investigate heritability and tissue specificity
of expression traits [Petretto et al., 2006a]. The original tissues were chosen to represent
metabolic syndrome traits, and particularly hypertension as this RI panel is a model system
for both.
CHAPTER 2. RAT AND HUMAN DATASETS 43
250
200
150
100
50
0
Chromosome
Lo
ca
tio
n 
(c
M
)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Genetic map
Lo
ca
%o
n	  
(M
b)
	  
Chromosome	  
(a) Microsatellite Genetic Map
100 200 300 400 500 600 700
5
10
15
20
25
Markers
In
di
vi
du
al
s
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20
Missing genotypesChromosome	  
Markers	  
In
di
vi
du
al
s	  
(b) Microsatellite Missing Values
Figure 2.2: 770 microsatellites across the genome. (a) describes the distribution of the microsatellite
markers across the genome by chromosome. (b) shows the missing genotypes by samples across the
genome. Approximately 0.56% of the genotypes were missing across the RI panel.
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(b) SNP Missing Values
Figure 2.3: 1,404 SNPs across the genome. (a) describes the distribution of the SNP markers across
the genome by chromosome. (b) shows the missing genotypes by samples across the genome. Approx-
imately 1.67% of the genotypes were missing across the RI panel.
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The additional tissues were selected for similar reasons and have been used in several studies,
including those looking at blood pressure [Pravenec et al., 2008a], LV mass [Petretto et al.,
2008], and inflammatory response [Heinig et al., 2010].
Gene expression from each tissue was normalised using the robust multi-array averaging
(RMA) method [Irizarry et al., 2003], where background corrections are performed followed
by quantile normalisation and summarisation [Bolstad et al., 2003]. Outliers within a strain
were removed using the Nalimov test as described previously [Hubner et al., 2005, Petretto
et al., 2006a, Petretto et al., 2008], where the test uses standard deviations to determine
outlying values [Burke, 2001]. Expression values were averaged across the replicates to reduce
the within strain variability and increase heritability [Petretto et al., 2006a, Belknap, 1998].
These gene expression profiles were generated by the Physiological Genomics and Medicine
Group with Prof. Stuart Cook (MRC Clinical Science Centre) and Prof. Norbert Hubner
(Max-Delbruck-Center for Molecular Medicine).
2.2.3 Radiotelemetric blood pressure
To improve BP phenotyping, BP was measured over a time period of 30 minutes using in-
dwelling aortic transducers by Prof. Michal Pravenec and colleagues (Czech Academy of
Sciences and Centre for Applied Genomics). The transducers allow the animals to be am-
bulatory and unrestricted, which provides more accurate measurements than other methods
[Kurtz et al., 2005]. The aorta indwelling transducers were implanted in the femoral artery
at 8 weeks of age and the measurements were taken between 40 and 42 weeks of age. The BP
measurements were taken once the rats reached adulthood and displayed differences in BP.
The laboratory rats reach sexual maturity between 10 and 12 weeks of age and the life span
ranges between two and three years. The time difference between implantation allowed for
the rats to acclimate to the transducers. Blood pressure measurements from these animals
were also used for another study where the BP was measured day and night over the course
of a week. These measurements were used in Petretto et al. [Petretto et al., 2008] to dissect
the regulation of left ventricular mass (LVM). The continuous time series measurements used
here were taken after those used in Petretto et al.
175 animals were used; there were between two and eleven animals per strain and all
were male. The rats were placed four at a time on radio-receivers connected to a microcom-
puter running the Dataquest Software Package (Data Sciences International), as previously
described [Churchill et al., 1997, Petretto et al., 2008]. BP was measured at 500 Hz over the
course of 30 minutes between 9 am and 12 pm, resulting in 900,000 measurements per animal.
Figure 2.4 shows an example of the blood pressure data with Figure 2.4a giving an overall
view, Figure 2.4b giving a subset of the measurement equal to two seconds and Figure 2.4c
giving an example of the time series with outliers present.
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(c) Radiotelemetric Blood Pressure Outliers
Figure 2.4: Radiotelemetric Blood Pressure: BP was measured in 175 animals across the BXH/HXB
RI lines at 500 Hz for 30 minutes. (a) gives the measurements taken from one animal over the course
of 30 minutes. (b) gives a subset of 1,000 BP measurements taken from one animal, representing
0.11% of the measurements for that animal. (c) gives the measurements taken from one animal over
the course of 30 minutes for an animal exhibiting outliers within the series.
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2.3 Human Genome-Wide Association Studies (GWAS)
To translate findings from the rat model system to humans, publicly available results from
human GWAS were used. Johnson and O’Donnell [Johnson and O’Donnell, 2009] compiled
the results from 118 GWAS studies published until 2009. They reported SNPs that were
nominally significant based upon
1. the SNP had an identifiable ID or verifiable genomic position
2. a statistical p-value for association was reported
3. the p-value was less than or equal to 0.001 (allowing for rounding) if the association
was from a raw, unadjusted scan
4. the p-value was less than or equal to 0.05 if the association was derived from replication,
fine mapping or re-sequencing efforts, or if it was identified as belonging to a locus or
region that was specifically identified as an a priori candidate by the authors
The relaxed threshold allows for an even representation from the studies which pub-
lished genome-wide results and from those which published only genes which reached genome-
wide significance as well as incorporating common variants of small effect size [Johnson and
O’Donnell, 2009]. There will be a greater number of false positives with a relaxed thresh-
old, but for this study, the inclusion of common genetic variants of small effects, detected
with low significance by GWAS studies, was desired. The results from their database were
filtered to include only those which had phenotypes relevant to hypertension (hypertension,
blood pressure, systolic blood press, diastolic blood pressure). The database included results
from five hypertension studies [Wellcome Trust Case Control Consortium, 2007, Kato et al.,
2008, Diabetes Genetics Initiative of Broad Institute of Harvard and MIT et al., 2007, Newton-
Cheh et al., 2009, Levy et al., 2009]. With the same criteria that Johnson and O’Donnell
utilised, the list was manually expanded to include ten other GWAS published from 2009
to 2011 [Adeyemo et al., 2009, Fox et al., 2011, Org et al., 2009, Cho et al., 2009, Lettre
et al., 2011, Padmanabhan et al., 2010, Sabatti et al., 2009, Hong et al., 2010, International
Consortium for Blood Pressure Genome-Wide Association Studies et al., 2011, Wain et al.,
2011].
Utilising dbSNP and Ensembl’s biomart tool, a gene was assigned to a SNP if that SNP
was located between the 5’ and 3’ UTRs of the gene. There were 4,145 human genes associated
with hypertension by the above criteria. The rat orthologs of these hypertension associated
genes were identified using biomart, resulting in a set of 2,292 rat orthologs. Table B10 in
Appendix B contains the full listing of human GWAS genes as well as the rat orthologs.
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Rat
Genome-wide gene expression in 7 tissues (15,000-30,000 probes)
Genome-wide microsatellites (770)
Genome-wide SNPs (1,400)
Radiotelemetric BP (∼ 900, 000 BP measurements)
Human
GWAS data (p < 0.001 un-replicated; p < 0.05 replicated)
Table 2.1: Brief summary of rat and human data used in this thesis
2.4 Discussion
The datasets above were used in this work to investigate the genetic regulatory mechanisms
of essential hypertension in a rat model and compare these results with human hypertension
GWAS results. The BXH/HXB RI lines provide a large and extensive dataset which allows for
a system-wide analysis of blood pressure regulation. Genome-wide gene expression in multiple
tissues allows for the investigation into primary tissues which directly regulate blood pressure,
either locally or globally (ADR, AORTA, KID, LV), [Cowley, 2006, Lanfranchi, 2002, Pravenec
et al., 2008a], as well as secondary tissues (FAT, LIVER, SKM) associated with hypertension.
While blood pressure regulation does not originate in SKM, LIVER and/or FAT, these tissues
have been shown to be associated with different aspects of metabolic syndrome [Jornayvaz
et al., 2010, Watanabe et al., 2008, Després et al., 2008], suggesting that there may be a
physiological connection between these tissues and hypertension.
The radiotelemetric blood pressure measurements in the BXH/HXB RI strains can be
used to capture variations and fluctuations that conventional measurements may miss by
using signal processing methods [Parati et al., 1995, Di Rienzo et al., 1989, Bracic and Ste-
fanovska, 1998]. The model system gives one access to invasive blood pressure monitoring
techniques that are not available in human studies and allows for an in-depth analysis of
refined phenotypes. In addition to standard or conventional blood pressure phenotypes, one
can use the signal processing to extract phenotypes which can inform on the cyclical and
dynamic nature. Because these measurements are all from the same model system, they can
be integrated together to provide a system-wide view of blood pressure regulation and used
to inform on human hypertension GWAS results.
The relaxed GWAS threshold highlights approximately 20% of the estimated 20,000 hu-
man protein coding genes as associated with hypertension. This identifies a substantial por-
tion of the genome which can be a result of the lower threshold level and the underlying
genetic structure. The FDR associated with the relaxed p-value is approximately 25%, which
leaves close to 3,000 true associations. The assignment of GWAS SNPs to genes, however, was
a simplistic approach. This approach was used due to the volume of data and the complex
nature of identifying true causal variants from GWAS SNPs. The gene in which the GWAS
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SNP resides is not necessarily the causal gene for the trait because the causal SNP may not
be on the genotype array but be in LD with the GWAS SNP. The LD patterns and confi-
dence intervals surrounding the GWAS SNP vary by the population and genotyping array
used within a study. Finding a causal variant from a GWAS SNP is often a second study
in itself and few variants have been found at the genome-wide significance level; validating
the associations at a relaxed threshold is far beyond the scope of this work. This simplistic
approach will affect the later analyses due to genes being falsely linked to hypertension within
the human studies. However, if a gene shows an association with BP variation in the rat and
an association with hypertension in humans, there is a stronger case for that gene to be truly
associated with hypertension. The following chapters utilise the radiotelemetric blood pres-
sure, gene expression and genetic variation to investigate the underlying genetic regulation of
hypertension in the RI strains and translate the finding to humans.
Chapter 3
Comparative expression
quantitative trait locus (eQTL)
analysis
3.1 Introduction
Gene expression, measured by the abundances of RNA transcripts in a tissue, represents a
quantitative trait which can inform on the intermediary relationship between genetic and
phenotypic variation. Using high throughput technologies like oligonucleotide microarrays
and RNA-seq, one can measure gene expression genome-wide. Oligonucleotide microarrays
capture gene expression across the genome, within a specific tissue, by using probes, which are
sequences consisting of approximately 25 nucleotides. Each probe corresponds to a different
location in the genome and most locations are within coding regions [Lockhart et al., 1996].
These gene expression abundances can be used to investigate the genes which are differentially
expressed between diseases states, derive an enrichment for a subset of genes in particular
tissue types, or to investigate the underlying genetic regulation of gene expression. This
chapter focuses on the latter - investigating the genetic determinants of gene expression.
With genome-wide gene expression and genetic variation, one can map gene expression to
the genome by a process called expression quantitative trait locus (eQTL) analysis or more
generally, ‘genetical genomics’ [Jansen, 2001]. Gene expression which maps to the genome
(eQTLs) can be categorised as cis or trans acting [Doss et al., 2005, Jansen, 2001]. Cis acting
eQTLs are expression traits which map back to the location of the probe whereas trans
acting eQTLs are expression traits which map to regions elsewhere in the genome. While
cis acting eQTLs suggest that the expression is being regulated by the gene itself, there are
additional factors which can cause a cis acting eQTL. The locality of a cis eQTL depends on
the genetic system being used. Here, a cis eQTL is designated as an eQTL which maps within
50
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10 megabases (Mb) either side of the probe location. Given that designation, there may be
eQTLs which are regulated in trans by a variant within that cis eQTL region. Additionally,
single nucleotide polymorphisms (SNPs) within the probe binding regions can affect the probe
binding affinity, creating artificial differences in gene expression levels [Alberts et al., 2007].
Regardless, eQTLS can provide valuable information about the mechanisms underlying the
regulation of expression (see Figure 1.2) and, when combined with physiological data, can
help disentangle the genetic basis of complex traits.
There have been several studies which have incorporated gene expression levels measured
in multiple tissues within the same genetic system. However, the expression is often analysed
within each individual tissue and then the transcripts are compared across tissues. As Petretto
et al. have shown, the heritability and the false discovery rate (FDR) associated with the
detection of eQTLs can vary from tissue to tissue [Petretto et al., 2006a]. This may cause
discrepancies in the lists of significant associations between the tissues and result in expression
traits being erroneously excluded [Petretto et al., 2010]. Cis regulated transcripts have been
shown to exhibit strong inter and intra tissue effects. Recent studies into the underlying
regulatory mechanisms of cis eQTLs have shown that up to 70% of cis regulated transcripts
in humans may show associations across multiple tissues, yet loci which are associated with
both physiological phenotypes and cis regulated expression are more likely to be tissue specific
[Fu et al., 2012]. Trans regulated transcripts, including trans clusters or ‘hot spots’ have been
shown to be predominantly tissue specific, however, that may be due to the lack of power
in eQTL methods to detect trans regulated transcripts rather than being a function of the
underlying biology [Hubner et al., 2005, van Nas et al., 2010, Petretto et al., 2006a].
With the ability to measure expression genome-wide (and in multiple tissues), one can
gain insight into co-expression and co-regulation patterns, as well as the polygenic control of
clusters of genes. With genome-wide expression, the large p, small n problem arises, where
the number of gene expression traits, p, is often far larger than the number of observations, n
[Johnstone and Titterington, 2009]. In addition, with genomic data, not only is there a com-
paratively large number of traits (responses), p, but a large number of markers (predictors),
q, in the order of thousands in the BXH/HXB rat system. With this situation, the power to
detect eQTLs diminishes and correcting for multiple testing can become constrictive.
This chapter discusses the results from a comparative eQTL analysis using gene expression
from the BXH/HXB recombinant inbred (RI) panel. Two types of eQTL mapping methods
will be compared - single response and multiple response. The single response methods
compared here are QTL Reaper [Wang et al., 2003], the Sequential Search Method (SSM)
[Storey et al., 2005] and the Sparse Bayesian Regression (SBR) method [Petretto et al., 2010].
The multiple response methods include Hotelling’s T 2 test [Hotelling, 1931], the Mixture-over-
Markers (MOM) method [Kendziorski et al., 2006], graph guided fused lasso (GFLASSO)
[Kim et al., 2009] and the Sparse Bayesian Multiple Regression (SBMR) method [Petretto
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et al., 2010].
3.2 Methods
3.2.1 BXH/HXB RI gene expression
For the following comparison of eQTL methods, a subset of the gene expression dataset
described in Chapter 2.2.2 was used to evaluate the eQTL mapping methods. 2,000 of the
highest varying transcripts across the adrenal gland (ADR), adipose (FAT), kidney (KID),
and left ventricle (LV) tissues were chosen in order to evaluate the methods with transcripts
under complex genetic control. Portions of the following analysis were published in Petretto
et al. and the 2,000 transcripts were chosen in accordance with the other analyses presented
in the publication [Petretto et al., 2010].
3.2.2 Review of genetic mapping methods
The eQTL mapping methods, both single and multiple response methods, were chosen as
a representation of the commonly used methods available. The single response methods
analysed were QTL Reaper, SSM and SBR. Both QTL Reaper and SSM have been used
to map genome-wide eQTLs in several genetic systems [Chesler et al., 2005, Gilad et al.,
2008, Storey et al., 2005]; QTL Reaper was previously used to map genome-wide eQTLs
in the BXH/HXB RI panel [Hubner et al., 2005]. QTL Reaper is a batch implementation
of the standard Haley-Knott regression method for QTL mapping; Haley-Knott regression
calculates a test statistic in a trait by marker fashion. SSM is an extension of the trait
by marker approach to sequentially investigate multiple genetic control points as well as
epigenetic interactions. In this analysis, only the additive effect of multiple loci was considered
rather than the full epistatic interaction. SBR was proposed more recently and has been used
mainly in the BXH/HXB RI panel. SBR differs from both QTL Reaper and SSM in several
ways. Instead of testing every marker - transcript pair, SBR searches for the set of markers;
it is a model based algorithm rather than a hypothesis test based algorithm. In SSM, the
selection of multiple genetic control points is restricted when used with a relatively small
sample size, whereas SBR can assess models with several genetic control points, albeit with
less power, in comparable sample sizes. QTL Reaper does not consider multiple genetic
control points.
The multiple response methods were chosen to represent the available approaches to mul-
tiple response eQTL mapping: regularised regression, Bayesian variable selection and a finite
mixture model algorithm. The multivariate extension of the Students t-test, Hotelling’s T 2
test, was also used as a standard. Regularised regression and variable selection methods en-
compass two commonly used statistical families for addressing sparse regression and the large
p, small n paradigm. Both Lasso regression and Bayesian variable selection methods have
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been proposed for eQTL mapping methods [Hoggart et al., 2008, Zhang et al., 2008], including
those designed for multiple responses [Kim et al., 2009, Banerjee et al., 2008]. GFLASSO is a
regularised Lasso regression with an additional fusion penalty. Lasso regression combines the
minimisation of the sum of squared errors with a L1 penalty to introduce a bound on sum of
the absolute values of the regression coefficients. In GFLASSO, an additional fusion penalty
is included to share information across correlated expression traits. The results from the
Lasso, and by extension GFLASSO, regression have good predictability qualities but are not
always easily interpretable. SBMR is a fully multivariate Bayesian regression which utilises
a Bayesian variable selection scheme to identify the best model of predictors. The Bayesian
framework provides an improved interpretability and allows for an incorporation of uncer-
tainty within the model. SBMR varies from other previously proposed Bayesian methods
by a novel Bayesian variable selection algorithm, the evolutionary Stochastic Search (ESS)
method. The MOM algorithm was one of the first multiple response methods proposed for
eQTL analysis. MOM assumes that the expression traits are not independent and addresses
that assumption by fitting a finite mixture model to the data.
Each method was run on the subset of 2,000 expression traits in each of the four tissues,
either individually or as a multiple response. The methods were compared at the same FDR
threshold; the FDR controls the type I errors, or false positives, in the case of multiple testing.
A FDR indicates the proportion of false positives expected within a number of significant test
statistics. Although there are differences in the methodologies, each method aims to detect
significant associations between the expression traits and genomic loci. The aim is to keep
the results from the methods as comparable as possible by restricting the multiple testing
methods to only FDR estimations, rather than a combination of FDR, family-wise error rates
and other multiple testing corrections. Admittedly, there are differences across the methods
in the way that the FDR is calculated, but, apart from the MOM algorithm, the FDR was
estimated with a null model estimated from permutations (either p-values or Bayes factors).
3.2.2.1 Single response
In single response eQTL analysis, gene expression traits are considered individually, ignoring
the correlation structure between the expression traits across tissues. Some single response
methods may include multiple predictors, while others may only consider a single predictor at
a time. In this analysis, the results from the Sequential Search Method [Storey et al., 2005],
the sparse Bayesian regression method [Petretto et al., 2010] and QTL Reaper [Wang et al.,
2003] were compared as single response methods. Here, n is the number of observations and
p is the number of genetic markers (predictors).
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QTL Reaper QTL Reaper is an implementation of Haley-Knott regression [Wang et al.,
2003]
H0 : y = m+ 
H1 : y = m+ βX + 
(3.1)
where y is the n× 1 vector of gene expression, m is the intercept,  is the normal error term,
 ∼ Nn(0, σ2In), β is the p× 1 vector of regression coefficients and X is the n× p matrix of
predictors. The significance of the eQTL is estimated by a likelihood ratio statistic
likelihood ratio test = n logc
(
RSSH0
RSSH1
)
(3.2)
where RSSH0 is the residual sum of squares for the null model, RSSH1 is the residual sum
of squares for the alternative model and n is the number of observations [Haley and Knott,
1992]. The likelihood ratio statistic was used in the original Haley-Knott regression method for
QTL mapping [Haley and Knott, 1992] and QTL Reaper is an extension of that methodology.
The likelihood ratio statistic is analogous to the logarithm of odds (LOD) score proposed by
Lander and Botstein [Lander and Botstein, 1989]. Genome-wide significance was determined
by permutation tests [Churchill and Doerge, 1994] and the corresponding FDR levels were
derived using the q-values method [Petretto et al., 2006a, Storey, 2002]. The q-values method
uses the distribution of p-values and the null distribution estimated from permutations to
control the false discovery rate. Q-values are the FDR equivalent of p-values and the method
reports a q-value for each p-value.
SSM The two-stage SSM proposed by Storey et al. maps the most significant eQTL for
each gene expression trait, and then sequentially identifies an additional eQTL conditional
on the first eQTL [Storey et al., 2005]. Compared to an exhaustive 2-D search through all
of the possible pairwise combinations, this stepwise procedure reduces the computational
time required and decreases the number of statistical tests needed. The 2-eQTLs model is
calculated from
H0 : y = m+ 
H1 : y = m+ βjXj + 
H2 : y = m+ βjXj + βj′Xj′ + βjXj × βj′Xj′ + 
(3.3)
y is the n × 1 vector of gene expression, m is the intercept,  is the normal error term,
 ∼ Nn(0, σ2In), βj and βj′ are the p× 1 vectors of regression coefficients and Xj and Xj′ are
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the jth and j′th columns of the n× p matrix of predictors with j, j′ = 1, ..., p, j 6= j‘.
Here, SSM has been adapted to make it comparable with the SBR and QTL Reaper
analyses. The sequential method for locating the two loci remained the same, but the epistatic
interaction between the βjXj and βj′Xj′ , (i.e., βjXj × βj′Xj′), is not considered. The model
given below is then directly comparable to the additive models which does not consider
epistatic interactions between eQTLs. The modified SSM is now
H0 : y = m+ 
H1 : y = m+ βjXj + 
H2 : y = m+ βjXj + βj′Xj′ + 
(3.4)
The significance is determined by an improvement in the goodness of fit between models.
A least squares model was calculated at each locus which compares the goodness of fit for
the model of no linkage, H0, to the model that one locus is linked, H1. The second locus is
similarly identified with a least squares model on the first locus and each additional locus.
The goodness of fit for both the first and second locus was quantified using an F-statistic.
The null distributions for both the first and second locus were derived sequentially by
permutations. To estimate the null distribution for the first locus, the gene expression was
randomised and the maximal F-statistic was calculated for each transcript. For the second
locus, the gene expression was permuted within each segregant group defined by the first locus.
The F-statistics were calculated for five permutations for both the first and second locus, and
then pooled together. This results in 10,000 permuted values for the null distribution in
each of the sequential steps. The F-statistics can be pooled together due to the statistic
being asymptotically pivotal. The F-statistics from the null distribution and the observed
data were used for a non-parametric estimation of the probabilities of locus-specific linkage,
represented by,
Pr(first locus is linked|Data)× Pr(second locus is linked|first locus is linked, Data) (3.5)
The FDR associated with the locus-specific probabilities was calculated by q-values, described
in the previous section. A gene expression trait was deemed to be a false positive if either
the first or the second locus was a false positive.
SBR The SBR method is a Bayesian linear regression model proposed by Petretto et al.
and is the single response version of the SBMR model (see Multiple Phenotype Mapping) [Pe-
tretto et al., 2010]. A sparse variable selection method is used for detecting the combination
CHAPTER 3. COMPARATIVE EQTL ANALYSIS 56
of predictors that explain variation in phenotypes due to the high number of markers com-
pared to observations, and one can select the number of possible markers associated with the
traits. SBR uses a Bayesian variable selection (BVS) approach which differs from previous
BVS implementations in three ways. The model formulation i.) integrates out instead of
updates the regression coefficients at each sweep of the algorithm, ii.) performs moves in
the model space comprised of only selection indicators, iii.) utilises an evolutionary Monte
Carlo algorithm to search multi-modal space with parallel chains set to different temperatures
[Bottolo, 2010]. For this analysis, four chains were used with 110,000 iterations and a 10,000
iteration burn-in.
For the single response model, the linear model is
y ∼ Nn(Xβ, σ2), (3.6)
where y is the n× 1 vector of gene expression, β is the p× 1 vector of regression coefficients
and σ2 is the variance of the error term. To create sparsity in the model, a latent binary
vector γ is introduced where γ is of p× 1 dimensions. γ is then a vector of 0s and 1s, where,
given j = 1, ..., p, γj = 1, if Xj , the jth column of X, is used as a predictor for y, otherwise
γj = 0. Thus, the regression coefficient associated with γj is set to 0. Equation 3.6 then
becomes
y ∼ Nn(Xγβγ , σ2), (3.7)
where Xγ is the original matrix X minus the columns that do not contain predictors for
y. Each model visited is recorded and ranked according to the posterior model probability,
p(γn|yn) where γn = (γn1, ..., γnj , ..., γnp). γn is the latent vector which gives the best com-
bination of predictors for yn. The best model visited, γbn is the model which contains the
combination of predictors that best explains the variability in y. In addition, the marginal
posterior probability of inclusion (PPI) for each predictor is returned, pnj = p(γnj |γn!j) where
γn!j represents all predictors but the jth. The marginal PPI indicates the strength of associ-
ation between the jth predictor and the nth phenotype, conditioned on all other predictors.
With in a Bayesian framework, uncertainty about the parameters is introduced be spec-
ifying prior distributions over the unknowns. Here, the prior densities for regression coeffi-
cients and the error variance, once conditioned on γ, are given by β|γ ∼ Np(0, σ2Hγ) and
σ2 ∼ InvGam(aσ, bσ), respectively. Hγ is a variance-covariance matrix which controls the
correlation structure between the predictors (pγ) and Np(·, ·) is the p-variate normal distri-
bution. Hγ is modelled with a g-prior setup where Hγ = τ(XTγ Xγ)−1 where τ represents
the relative amount of information provided by the prior with regards to the sample. This
tuning parameter, τ is not a fixed value, but is specified by the data by means of a modi-
fied Jeffery’s prior. The exchange priors on the predictors are given by γj ∼ Bernoulli(w)
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and includes a prior on the model size pγ = 1τγ is proportional to a Binomial distribution,
γ|w ∼ Binomial(p, w). With w integrated out, γ is distributed as a β-Binomial with hy-
perparameters aw and bw. The hyper parameters are calculated by the algorithm from two
inputs, the expected model size and the expected standard deviation of the model. Here the
expected model size, E(pγ), was set to 5 and the expected standard deviation, V (pγ) was set
to 9, which heavily penalises models with over twelve genetic control points.
For each of the best models visited, the Bayes factor is calculated with respect to the
null model and the Jeffery’s scale of evidence is used to determine the relative strength of
each model. Permutation tests are used to determine which Jeffery’s scale level corresponded
to different FDR levels. In principle, permutations break the association between the gene
expression and genotypes, so for the permuted tests, the null model should be the best model.
However, associations will arise out of the permuted data by chance, giving a false-positive
model as the best model. Briefly, the permutation tests were performed in four steps:
1. Simulate the null model by randomly re-ordering the observations
2. Run SBR on each tissue with the re-ordered observations
3. Calculate the Bayes factor against the null model
4. For a given FDR level, select the Jeffreys’ scale level above which the best model visited
is irrevocably different from the null model
At a given Jefferys’ scale level, the number of false positives declared in the re-ordered
dataset is compared to the number of gene expression traits declared different from the null
in the original dataset. The Jeffery’s scale cutoff is then scaled so that the ratio of the
number of false positives in the re-ordered dataset to the number of gene expression traits
declared different in the original dataset is less than 5%. This allows the Jeffery’s scale to
be calibrated to a 5% FDR level which is then reasonably comparable to the other methods
analysed. Because the FDR is calculated differently in SBR than in QTL Reaper or SSM,
there may be differences in results which are due to the FDR methodology rather than the
eQTL methods.
The performance of SBR and the underlying ESS methods were originally tested by simu-
lation studies, including datasets based on 775 SNPs from HapMap and a real dataset with up
to 10,000 predictors. Generally, a stationary distribution is achieved by the end of the burn
in with a high probability of inclusion for the simulated effects. Additional work concerning
the convergence of the method was done by Bottolo and Richardson [Bottolo, 2010] in the
same dataset. By visually inspecting the trace of the proposal, they deemed convergence to
not be an issue because the trace’s standard deviation stabilises quickly and remains within
the bounded conditions (See Figure 3 of Bottolo and Richardson).
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3.2.2.2 Multiple response
To compare multiple phenotype mapping approaches, Hotelling’s T 2 test, MOM, GFLASSO
and SBMR methods were performed on all tissues, where the same transcript in four tissues
was considered as a multiple response of the same measurement and the results were compared
at a 5% FDR level. Here, n is the number of observations, p is the number of markers
(predictors) and q is the number of gene expression traits (responses).
Hotelling’s T 2 test Hotelling’s T 2-test is the multivariate extension of the Students t-test,
where multiple gene expression traits can be analysed as a multiple response to the same
measurement [Hotelling, 1931] following
t2 = nxny
nx + ny
(x¯− y¯)′W−1(x¯− y¯) (3.8)
where x1, ...xnx ∼ Np(µ, V ) and y1, ...yny ∼ Np(µ, V ) are the independent samples, with
equal means, µ, and variances, V of the gene expression by genotype. W is the covariance
matrix and nx and ny are the number of observations, by genotype, respectively. The FDR
is calculated using the q-values method [Storey, 2003].
MOM The Mixture over Markers (MOM) approach, proposed by Kendziorski et al. is
driven by the notion that the probability of a gene expression trait mapping to a specific
marker should not be calculated without considering the probability that it may map to
another marker [Kendziorski et al., 2006]. The algorithm uses information across both the
markers and gene expression traits to estimate the marginal probability associated with each
marker as a genetic control point.
If y is a gene expression trait that maps to any marker j with probability pj and maps to
any other marker with probability p0, then
Py(y) = p0f0(y) +
p∑
j=1
pjfj(y) (3.9)
gives the marginal distribution where f0 and fmand are the distribution of the data, y, if the
trait maps to nowhere or to a marker m, respectively. MOM fits a finite mixture model with
the number of components determined by the number of markers. MOM accounts for the pos-
sibility that there are different variances within clusters of gene expression traits. Clusters of
gene expression traits were determined by K-means, where the number of clusters was derived
from the Bayes Information Criterion (BIC). The mixing parameters and hyper parameters of
the parametric distributions were estimated by an iterative Expectation-Maximisation (EM)
approach which uses the clusters of gene expression traits. With the parameter estimations,
the posterior probabilities of a gene expression trait mapping nowhere or to any of the p
CHAPTER 3. COMPARATIVE EQTL ANALYSIS 59
locations are derived using Bayes’ rule. The significance threshold for controlling the poste-
rior expected FDR at α · 100% is based on the posterior probability. The threshold is set at
the smallest posterior probability for which the average of the larger posterior probabilities
is greater than 1 − α. A transcript is then called as differentially expressed if the posterior
probability of no differential expression is below that threshold.
GFLASSO The GFLASSO method is based upon a Lasso regression, where sparsity has
been introduced to reduce the instabilities from the large number of genetic control points
[Tibshirani, 1996, Kim et al., 2009]. Lasso regression methods are typically used for inde-
pendent phenotypes, whereas GFLASSO, proposed by [Kim et al., 2009], is used to identify
genetic control points for multiple correlated gene expression traits. The lasso regression
follows
yq = Xβq + q (3.10)
where yq is the gene expression from a n× q matrix Y . X is the n× p matrix of markers, βq
is the p × 1 vector of regression coefficients and q is the normal error term. The matrix of
regression coefficients B, where B = β1...βq can be estimated following
ˆBlasso = argmin
∑
q
(yq −Xβq)T (˙yq −Xβq) + λ
∑
qj
|βqj | (3.11)
where λ is the regularisation parameter controlling the sparsity. GFLASSO takes into consid-
eration the correlation structure of the gene expression traits in matrix Y by using a relevance
network, such as a correlation network, where the edges are significant correlations between
two gene expression traits. GFLASSO can use the weighted or unweighted relevance network;
for this analysis, the unweighted version was used where B was estimated following
ˆBGC = argmin
∑
q
(yq −Xβq)T (˙yq −Xβq) + λ
∑
q
∑
j
|βjq|+ ρ
∑
(m,l)∈E
∑
j
|βjm − sign(rml)βjl|
(3.12)
where m and l are two correlated traits and (m, l) represents the edge between the two
in the relevance network. λ and ρ are regularisation parameters and ρ∑(m,l)∈E∑j |βjm −
sign(rml)βjl| is the fusion penalty. Combining the lasso and fusion penalty (equation 3.12)
reduces the number of non-zero regression coefficients and flattens non-zero coefficients across
highly correlated traits.
Before the analysis, each gene expression trait is mean centred and the variance was scaled
to one. Here, for a gene expression trait to be called an eQTL, there must be a non-zero effect
in each of the four tissues at the same marker. Alternatively, there could be a looser definition
of an eQTL; a transcript could be called an eQTL if there is a non-zero effect in at least one of
CHAPTER 3. COMPARATIVE EQTL ANALYSIS 60
the four tissues. The stricter definition of an eQTL was used here. Petretto et al. performed
simulation studies on GFLASSO and found that both the loose and strict definitions of an
eQTL were underpowered compared to other multiple response methods [Petretto et al., 2010].
SBMR SBMR is a fully multivariate Bayesian multiple linear regression model [Petretto
et al., 2010]. A sparse method for detecting the combination of associations that explain
variation in gene expression traits is used due to the high number of markers compared to
observations. For the multiple response, the linear model is
Y −XB ∼ N(In,Σ), (3.13)
where Y is the n x q matrix of gene expression values, X is the n x p matrix of genetic
markers, B is the p x q matrix of regression coefficients and Σ is the q x q phenotype correlation
matrix. In the same fashion as SBR, sparsity is introduced into the model with a latent
binary vector γ, where γ is of p x 1 dimensions. γ is then a vector of 0s and 1s, where, given
j = 1, ..., p, γj = 1, if Xj , the jth column of X, is used as a predictor for Y , otherwise γj = 0.
In the multivariate case, the 1 x q vector of regression coefficients associated with γj is set to
0. Equation 3.13 then becomes,
Y −XγBγ ∼ N(In,Σ), (3.14)
where Xγ is the original matrix X minus the columns that do not contain predictors for Y .
As with SBR, each model visited is recorded and ranked according to the posterior model
probability, p(γqn|Yqn) where γqn = (γqn1, ..., γqnj , ..., γqnp). γqn is the latent vector which
gives the best combination of predictors for Yqn. Again, the best model visited, γbqn is the
model which contains the combination of predictors that best explains the variability in Y .
For SBMR, the marginal PPI for each predictor is returned, pqnj = p(γqnj |γqn!j) where γqn!j
represents all predictors but the jth. The marginal posterior probability of inclusion PPI
indicates the strength of association between the jth predictor and the nth phenotype in the
qth response, conditional on all other predictors.
In a similar manner to SBR, uncertainty about the parameters in the SBMR model is
introduced be specifying prior distributions over the unknowns. For SBMR the prior density
for the regression coefficients conditioned on γ is B|γ,Σ ∼ N(Hγ ,Σ), and the correlation
structure between the q dimensions of B is given by the variance-covariance matrix of Y . The
prior density of Σ is given by Σ ∼ IW (δ,Q) with IW (·, ·) as the inverse Wishart distribution
with δ = 3 and Q = kIq. Setting δ = 3 allows for the first moment of the inverse Wishart
distribution to exist. As for SBR, Hγ is a variance-covariance matrix which controls the
correlation structure between the predictors (pγ) where Hγ is modelled with a g-prior setup;
Hγ = τ(XTγ Xγ)−1. τ represents the relative amount of information provided by the prior with
regards to the sample and is not a fixed value, but is specified by the data by means of a mod-
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ified Jeffery’s prior. The exchange priors on the predictors are given by γj ∼ Bernoulli(w)
and includes a prior on the model size pγ = 1τγ is proportional to a Binomial distribution,
γ|w ∼ Binomial(p, w). With w integrated out, γ is distributed as a β-Binomial with hy-
perparameters aw and bw. The hyper parameters are calculated by the algorithm from two
inputs, the expected model size and the expected standard deviation of the model. Here the
expected model size, E(pγ), was set to 5 and the expected standard deviation, V (pγ) was set
to 9, which heavily penalises models with over twelve genetic control points.
For each of the best models visited, the Bayes factor is calculated with respect to the null
model and the Jeffery’s scale of evidence is used to determine the relative strength of each
model. Permutation tests are used to determine which Jeffery’s scale level corresponded to
different FDR levels. In principle, permutations break the association between phenotypes
and genotypes, so for the permuted tests, the null model should be the best model. However,
associations will arise out of the permuted data by chance, giving a false-positive model as
the best model. Briefly, the permutation tests were performed in four steps:
1. Simulate the null model by randomly re-ordering the observations
2. Run SBMR on across the tissues with the re-ordered observations
3. Calculate the Bayes factor against the null model
4. For a given FDR level, select the Jeffreys’ scale level above which the best model visited
is irrevocably different from the null model
At a given Jefferys’ scale level, the number of false positives declared in the re-ordered
dataset is compared to the number of transcripts declared different from the null in the
original dataset. The Jeffery’s scale cutoff is then scaled so that the ratio of the number of
false positives in the re-ordered dataset to the number of transcripts declared different in the
original dataset is less than 5%. This allows the Jeffery’s scale to be calibrated to a 5% FDR
level which is then comparable to the other methods analysed.
The issue of convergence is more complicated for SBMR than for SBR. Expression in each
tissue may be associated to different group of covariates yet share others, mainly trans and cis
effects, respectively. For the 2,000 expression traits, the number of times SBMR visited the
top model was recorded. For 557 transcript ( 28%), SBMR reached the top model less than 25
times in each of the two halves of the iterations. These transcripts were rerun with 510,000
iterations with a 10,000 burn-in to fully explore the posterior probability. With a greater
number of iterations, only seven transcripts reached the top model less than 25 times in each
of the two halves of the iterations. The traces of these transcripts were then visually inspected
to check that SBMR reached the top model at evenly spread intervals which reassured that
the method detected a good combination of markers [Petretto et al., 2010, Bottolo, 2010].
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3.3 Results
3.3.1 Single Response eQTL analysis
3.3.1.1 SSM
At a 5% FDR level, SSM found 11.7% to 16.6% of the 2,000 transcripts to be under genetic
control across the four tissues. 8.2% to 10.5% of those transcripts were under cis-regulation,
2.1% to 4.6% were under trans-regulation and 1.3% to 2.4% were unknown (due to probes
mapping to multiple locations), summarised in Table 3.1. SSM did not find any transcripts
to be under polygenic control due to power limitations. With a population size of 29 (the
BXH/HXB RI lines), SSM does not have enough power to identify any significant eQTL inter-
actions; the method is limited by the Wilcox rank-sum test at the secondary locus [Langley,
2008].
3.3.1.2 QTL Reaper
At a 5% FDR level, QTL Reaper found 7.8% to 9.3% of the 2,000 transcripts to be under ge-
netic control over the four tissues. 6.2% to 7.5% of those transcripts were under cis-regulation,
0.8% to 1.2% were under trans-regulation and 1.1% to 1.5% were unknown (Table 3.1). QTL
Reaper is not implemented to detect polygenic control.
3.3.1.3 SBR
At a 5% FDR level, SBR found 17.5% to 19.6% of the 2,000 transcripts to be under genetic
control over the four tissues. 10.4% to 12.5% of those transcripts were under cis-regulation,
4.2% to 5.8% were under trans-regulation and 2.1% to 2.9% were unknown (Table 3.1). SBR
was able to detect polygenic control in each of the tissues with 2.4% to 2.7% of all transcripts
being under the regulation of two or more genetic control points (Table 3.2).
3.3.1.4 Comparison between SSM, QTL Reaper, SBR
Figure 3.1 shows the overlap in the identified eQTLs for the three methods in the four tissues
analysed. The black bars represent the number of transcripts found in common across the
three methods, per tissue, and the blue, grey and white bars represent the transcripts found
individually by SBR, SSM and QTL Reaper, respectively. SSM found a similar number of
transcripts to SBR and both found an ∼ 2-fold increase over QTL Reaper. 88% to 98% of the
transcripts identified by QTL Reaper were also found by SSM and SBR, indicating SSM and
SBR had more power to identify associations in traits of weaker associations. Table 3.1 shows
the number of transcripts found to be under genetic control by method, tissue and cis/trans
regulation.
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Figure 3.1: Number of significant transcripts found in common between SBR (FDR <5%),
SSM (FDR < 5%), and QTL Reaper (PGW= 0.001, FDR < 5%). Transcripts were considered
to be in common if one locus in the ‘best model’ matched one locus found by SSM and QTL
Reaper after removing redundant eQTLs.
Across tissues and methods, the highest proportion, 72% to 78%, of transcripts under
genetic control were under cis-regulation, with a lesser proportion under trans-regulation
(8% to 33%). SBR found a higher percentage (22% to 33% across tissues) of trans-regulated
transcripts than either SSM (16% to 28%) or QTL Reaper (8% to 15%), suggesting that SBR
has more power to identify transcripts with lower heritabilities than SSM, and SSM has more
power than QTL Reaper. SBR was the only method to detect transcripts under polygenic
control; QTL Reaper does not search for polygenic control and SSM cannot efficiently handle
a population size of 29 as the power of the method is limited by the Wilcox rank-sum test
[Langley, 2008]. Table 3.2 gives the breakdown of genetic control in each tissue found by SBR
at a 5% FDR threshold. SBR was able to find 12% to 15% of all transcripts to be under
polygenic control (eQTL ≥ 2) despite the relatively large number of phenotypes and small
population size.
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Tissue eQTL QTL Reaper SSM SBR Overlap*
(FDR < 5%) (FDR < 5%) (FDR<5%)
ADR cis 125 (6.25%) 164 (8.20%) 223 (11.15%) 112 (5.60%)
trans 25 (1.25%) 43 (2.15%) 86 (4.30%) 23 (1.15%)
unknown 22 (1.10%) 27 (1.35%) 42 (2.10%) 21 (1.05%)
total 172 (8.6%) 234 (11.7%) 351 (17.55%) 156 (7.80%)
FAT cis 134 (6.70%) 207 (10.35%) 208 (10.40%) 132 (6.60%)
trans 17 (0.85%) 93 (4.65%) 116 (5.8%) 17 (0.85%)
unknown 20 (1.00%) 33 (1.65%) 42 (2.10%) 20 (1.00%)
total 171 (8.55%) 333 (16.65%) 366 (18.30%) 169 (8.45%)
LV cis 151 (7.55%) 211 (10.55%) 250 (12.50%) 139 (6.95%)
trans 16 (0.80%) 55 (2.75%) 85 (4.25%) 15 (0.75%)
unknown 30 (1.50%) 49 (2.45%) 58 (2.90%) 30 (1.50%)
total 197 (9.85%) 315 (15.75%) 393 (19.65%) 184 (9.20%)
KID cis 142 (7.10%) 179 (8.95%) 243 (12.15%) 126 (6.3%)
trans 24 (1.20%) 42 (2.10%) 79 (3.95%) 19 (0.95%)
unknown 24 (1.20%) 34 (1.70%) 51 (2.55%) 22 (1.10%)
total 190 (9.50%) 255 (12.75%) 373 (18.65%) 167 (8.35%)
*Overlap between all three methods.
Each method was considered at a 5% FDR level which corresponded to a PGW = 0.001 [Petretto et al., 2006a].
Percentages were calculated with respect to the full 2,000 transcripts.
Table 3.1: Comparison between QTL Reaper, SSM and SBR
Tissue no eQTL∗ 1 eQTL 2 eQTLs∗∗ ≥ 3 eQTLs
SBR in FAT 1,634 (81.7%) 311 (15.5%) 44 (2.2%) 11 (0.6%)
SBR in KID 1,627 (81.3%) 323 (16.2%) 38 (1.9%) 12 (0.6%)
SBR in ADR 1,649 (82.4%) 301 (15.1%) 40 (2.0%) 10 (0.5%)
SBR in LV 1,607 (80.3%) 345 (17.2%) 39 (2.0%) 9 (0.5%)
∗Transcripts classified under no eQTL had the null model as the best model, or did not reach
significance (FDR < 5%) .
∗∗ Polygenic models (≥ 2 eQTL) consist of two or more distinct loci located ≥ 10cM apart.
Table 3.2: Monogenic and polygenic control in SBR by tissue (FDR < 5%)
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3.3.2 Multiple response eQTL analysis
3.3.2.1 Hotelling’s T 2 test
Hotelling’s T 2 test found 459 transcripts to be under genetic control, with 369 (80%) tran-
scripts under cis-regulation, 68 (15%) under trans-regulation and 22 (5%) unknown. Cis-
regulated transcripts were defined to be those which mapped to at least one cis-eQTL or a
cis-eQTL plus other trans-eQTL(s) Trans-regulated transcripts were those which mapped to
one or more trans-eQTL(s). 62 transcripts were found to be under polygenic control where
≥ 2 control points were identified.
3.3.2.2 MOM
As MOM estimates the parameters of a finite mixture model using all the phenotypes, it could
not handle the situation where there were far fewer transcripts in tissues (i.e., 4 responses)
than markers (770); the method expects that the number of phenotypes is equal to or greater
than the number of markers. It was not apparent from the Kendziorski et al. publication
that the number of responses should be on the same order as the number of markers. This
requirement was only established post analysis and after personal communications with the
authors.
3.3.2.3 GFLASSO
GFLASSO detected 201 of transcripts to be under genetic control with 87 (43%) as cis-
regulated, 111 (55%) as trans regulated and 3 (1%) as unknown. 59 (29%) of transcripts
were found to be under polygenic control where ≥ 2 control points were identified, whereas
the rest, 142 (71%) were found to be under monogenic control. 34 transcripts mapped to ten
or more predictors (up to 39) and, as an example Figure 3.2 shows the betas for one these
transcripts; the betas are noisy with no real defined set of predictors. This is indicative of the
method failing to identify the correct predictors for these traits and so the transcripts which
have 10 or more genetic control points were deemed to not be under genetic control.
3.3.2.4 SBMR
SBMR identified 531 transcripts to be under genetic control, 368 (69%) with under cis-
regulation, 137 (26%) under trans-regulation and 26 (5%) unknown. 256 of the transcripts
were found to be under polygenic control, where ≥ 2 genetic control points were identified.
3.3.2.5 Comparison of multiple response methods
Out of the three multiple response methods, SBMR found the greatest number of transcripts
(531) followed by Hotelling’s T 2 (459) and then GFLASSO (201), see Table 3.3. SBMR and
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Figure 3.2: An example of the betas from a transcript with 39 genetic control points identified
by GFLASSO. The betas across the genome show the noise in GFLASSO and indicate that
the method has failed to identify the correct predictors for the given transcript.
Hotelling’s T 2 test found the same number of transcripts to be under cis-regulation (368 and
369) with GFLASSO finding substantially less (87). SBMR outperformed both Hotelling’s
T 2 test and GFLASSO in identifying trans-regulated transcripts, 137 versus 68 and 111,
respectively. Table 3.3 gives the total number of transcripts for each method by cis or trans
regulation.
Hotelling’s T 2 GFLASSO SBMR
cis 369 (80%) 87 (43%) 368 (69%)
trans 68 (15%) 111 (56%) 137 (26%)
undefined 22 (5%) 3 (1%) 26 (5%)
total 459 201 531
1For each transcript identified, it is cis if there is at least one cis-eQTL, or one cis-eQTL and other
trans-eQTL(s).
2 For each transcript identified, it is trans if it mapped to at least one trans-eQTL.
*Percentages are calculated with respect to the total number of transcripts identified within each analysis.
Table 3.3: Total number of eQTLs for Hotelling’s T 2, GFLASSO, SBMR
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Figure 3.3 shows the overlap of transcripts for the three methods with Figure 3.3a giving
the total overlap of all three methods. Figure 3.3(b-e) gives the proportion of transcripts
in common (left bars) between the methods and those found uniquely (right bars) by each
method. Figure 3.3b gives the overlap of transcripts between SBMR and Hotelling’s T 2 test.
Figure 3.3c gives the overlap of transcripts between SBMR and GFLASSO. Figure 3.3d gives
the overlap between Hotelling’s T 2 test and GFLASSO. The final panel, Figure 3.3e gives the
overlap between all three methods.
SBMR identified more transcripts under genetic control (531) than the other two methods
(459 and 201) as well as identifying more trans regulated transcripts and transcripts under
polygenic control. While Hotelling’s T 2 identified fewer transcripts than SBMR, a large
proportion (81%) of those that it did identify were also found by SBMR, especially with
regard to transcripts under polygenic control (98%). This suggests Hotelling’s T 2 test is under
powered, compared to SBMR, for identifying transcripts with smaller effect sizes. GFLASSO
identified fewer transcripts than either SBMR or Hotelling’s T 2 test with a smaller proportion
of those identified found to be in common with SBMR (54%) and Hotelling’s T 2 test (46%)
than the proportion of those found by SBMR and Hotelling’s T 2 alone. GFLASSO is also
under powered, but the lack of concordance with SBMR and Hotelling’s T 2 test suggests that
those it did identify may not be true eQTLs. This is further supported by the transcripts
GFLASSO identified which had between 10 and 39 genetic control points and unstable betas.
Analysis no eQTL∗ 1 eQTL 2 eQTLs∗∗ ≥ 3 eQTLs
Hotelling’s T 2 1,541 (77%) 397 (19.9%) 62 (3.1%) -
GFLASSO 1,799 (90%) 142 (7.1%) 32 (1.6%) 27 (1.3%)
SBMR in all tissues 1,472 (73.6%) 273 (13.6%) 93 (4.7%) 162 (8.1%)
∗Transcripts classified under no eQTL had the null model as the best model, or did not reach
significance (FDR < 5%) .
∗∗ Polygenic models (≥ 2 eQTL) consist of two or more distinct loci located ≥ 10cM apart.
Table 3.4: Monogenic and polygenic control by method (FDR < 5%)
SBMR and Hotelling’s T 2 test found a higher proportion of transcripts to be under genetic
control than any of the single response methods in any individual tissue, whereas GFLASSO
found the smallest number of transcripts under genetic control (see Table 3.4). In addition,
SBMR identified more transcripts under polygenic control than Hotelling’s T 2 test, GFLASSO
and any of the single response methods. SBMR and Hotelling’s T 2 test identified more cis
regulated transcripts than GFLASSO or any of the single response methods, but only SBMR
identified a higher number of trans regulated transcripts.
SBMR outperformed all methods in terms of number of transcripts identified, the propor-
tion of trans-regulated transcripts and the number of transcripts under polygenic control, see
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(c) Comparison between SBMR and GFLASSO
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(d) Comparison between HOT and GFLASSO
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(e) Comparison between all three methods
Figure 3.3: For the 2,000 transcripts, here is the number of those transcripts identified in common between
the multiple response methods. (a) gives the overlap in number of transcripts between all three methods. (b-e)
gives the number of transcripts in common between methods and those found uniquely by a given method.
The portion in white represents the number of transcripts identified to be under monogenic control and the
black represents the number of transcripts identified to be under polygenic control. (b) gives the comparison
between SBMR and Hotelling’s T 2 test, (c) gives the comparison between SBMR and GFLASSO, (d) gives the
comparison between Hotelling’s T 2 test and GFLASSO and (e) gives the comparison for all three methods.
CHAPTER 3. COMPARATIVE EQTL ANALYSIS 69
Table 3.4 and Figure 3.3. Because SBMR is multivariate in both predictors (markers) and
in responses (phenotypes), it has more power to identify weaker trans-associations and more
complex genetic control structures than the other methods examined in the analysis.
3.4 Discussion
In this analysis, single and multiple phenotype mapping methods were compared using gene
expression traits from four tissues. The single phenotype mapping methods analysed included
QTL Reaper, SSM and SBR. QTL Reaper is a standard regression method which looks for
associations marker-by-marker for each phenotype analysed. QTL Reaper found the fewest
number of transcripts under genetic control out of all the methods, both single and multiple
response. For those transcripts that QTL Reaper did identify, few were found uniquely by the
method; 92.2% of cis regulated transcripts and 90.2% of trans regulated transcripts identified
by QTL Reaper were also identified by SSM and SBR (see Table 3.1). In addition, SSM
and SBR found > 2 fold more trans regulated transcripts than QTL Reaper, see Table 3.1,
suggesting that QTL Reaper is only able to identify transcripts with strong effects which are
predominantly cis regulated [Petretto et al., 2006a].
SSM identified more transcripts than QTL Reaper but fewer than SBR. SSM can identify
transcripts under polygenic control, as shown by Storey et al. [Storey et al., 2005], but here,
there are power constraints due to the population size of the BXH/HXB RI strains. Storey et
al. utilised a yeast population with 112 segregants, which was a large enough population for
the method to have enough power to detect a secondary locus [Storey et al., 2005]. SSM works
by identifying an eQTL with the strongest association with the phenotype and then identifying
a second locus conditional on the first. Both eQTLs are identified using a Wilcox rank-sum
test; as previously shown, the Wilcox rank-sum test is not able to accurately calculate p-
values for populations smaller than 25 [Langley, 2008]. Thus, there is enough power in the
Wilcox-rank sum test to identify the first QTL in a population of 29, but, as the second QTL
is conditional on the first, there is not enough power to identify the second locus [Langley,
2008].
Given that QTL Reaper does not identify polygenic control and that the population size of
29 is limiting for SSM, SBR was the only single response method to identify polygenic control
in the four tissues. In addition, SBR outperformed SSM and QTL Reaper with respect to
identifying trans-regulated transcripts and to a lesser extent, cis regulated transcripts. Trans-
regulated transcripts have lower heritabilities than cis-regulated transcripts [Petretto et al.,
2006a] and are harder to detect as often are the secondary loci associated with a polygenic
model. SBR is fully multivariate in predictors (markers) which increases to power to detect
associations by using information contained in the whole set of markers rather than singular
markers. Despite attempting to make the results from all methods as comparable as possible,
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it may be that some of the differences between the methods may be due the FDR calculations.
SBR (and SBMR) utilise a different method for thresholding the FDR from the other methods
compared.
In multiple phenotype mapping, expression levels of the same transcripts in four tissues
were considered to be a multiple response of the same measurement; information from each
tissue is combined to increase the power of detecting significant associations. Multiple pheno-
type mapping methods include MOM, the Hotelling’s T 2 test, GFLASSO and SBMR. MOM,
GFLASSO and Hotelling’s T 2 are multivariate in response, but univariate in predictors while
SBMR is fully multivariate. MOM was not able to detect any transcripts in this analysis, due
to the number of responses (4) being far fewer than the number of predictors (770). However,
in other circumstances, MOM is able to use information across phenotypes. Bottolo et al.
showed that MOM was able to identify regulatory ‘hot-spots’ in a situation where the number
of responses was on the order of predictors [Bottolo et al., 2011b].
When compared to SBMR and Hotelling’s T 2 test, GFLASSO found the fewest number
of associations (201) and a low proportion of those were found to be in common with SBMR
and Hotelling’s T 2. Here, GFLASSO was used with the default settings provided by the
authors and the input network structure between the phenotypes was based on the Pearson
correlation. Petretto et al. has shown by extensive simulation studies that GFLASSO does
not have as much power as either SBMR or Hotelling’s T 2 test to detect trans regulated
transcripts or those transcripts under polygenic control [Petretto et al., 2010]. The results
given here, and supported by the simulation studies in Petretto et al. [Petretto et al., 2010],
suggest that GFLASSO may be improved upon by optimising the input parameters and by
utilising a different network structure. A Gaussian graphical model (GGM) or a relevance
network based on mutual information may give better results for GFLASSO, as they may
better portray the covariance structure between the phenotypes.
Both SBMR and Hotelling’s T 2 test outperformed the single mapping methods and
GFLASSO by identifying more transcripts under polygenic control. SBMR and Hotelling’s
T 2 test identified the same number of cis regulated transcripts, but SBMR identified more
trans regulated transcripts (see Table 3.3). Both methods identified transcripts under poly-
genic control, see Table 3.4, but almost all (Figure 3.3) of the transcripts found to be under
polygenic control by Hotelling’s T 2 test were also found by SBMR, and SBMR found many of
those transcripts to have more genetic control points. SBMR utilises the covariance structure
between the transcripts in different tissues as well as information across markers to fit the
best model, which contains the markers that best explain the variation in the trait rather
then testing individual markers for associations. The evidence for each marker and amount
of variation in the phenotype that each marker explains can be extracted from the model.
By utilising multivariate methods, which draw information about gene expression from
multiple tissues, one can investigate the weaker trans regulation and the more complex poly-
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genic regulation which can effect expression traits. The missing heritability associated with
many common, complex diseases may be explained by these polygenic and trans acting effects
as standard analyses, such as quantitative trait locus (QTL) and GWAS, are not able to de-
tect them. Incorporating information about the tissue specificity of regulation, especially in
disease tissues and in relation to systemic effects, may provide insight into the gene regulation
of common, complex diseases. Both systemic effects identified by SBMR and tissue specific
effects identified by SBR are important in understanding the regulation of gene expression and
the relationship between gene expression variation and phenotypic variation. Until recently,
the eQTL mapping methods were only available for single tissue analysis but now, for mod-
els that have gene expression in more than one tissues, the systemic effects can be assessed
in conjunction with these tissue specific effects. The results of this comparative analysis of
eQTL mapping methods suggest to use SBR to detect tissues specific effects or SBMR to
detect systemic effects to map genome-wide eQTLs in the rat and integrate these with blood
pressure (BP) variation and human genome-wide association studies (GWAS) data.
Chapter 4
Extracting features from
physiological time series
4.1 Introduction
Hypertension is characterised or diagnosed by an elevation in blood pressure (BP) and is a
heritable risk factor for heart disease (see Chapter 1.1). Because of its prevalence and disease
risk, hypertension has been the focus of many genetic studies, from linkage and quantitative
trait locus (QTL) studies to large human genome-wide association studies (GWAS) [Fung
et al., 2011, Doris, 2002, Pravenec and Kurtz, 2007, Delles et al., 2010, Rapp, 2000, Timber-
lake et al., 2001, Johnson and O’Donnell, 2009]. Linkage studies have identified functional
variants affecting Mendelian forms of hypertension [Warnock, 1998, Binder, 2007], but human
GWAS have found few common variants with marginal effects truly associated with essential
hypertension [Rafiq et al., 2010, Franceschini et al., 2011].
There have been several hypotheses as to why these GWAS have not produced results
with one being inadequate phenotyping. Human GWAS have either classified hypertension
as a discrete, case/control trait or used quantitative BP measurements [Pickering et al., 2005,
Kurtz et al., 2005]. The case/control classification does not accurately portray hypertension.
Hypertension has been defined in humans to be an average BP of ≥140/90 mmHg [Binder,
2007, Kearney et al., 2005]. However, as Whelton et al. describes, a third of high BP induced
cardiovascular diseases are in individuals who are not classified as hypertensive, but have
BP between the optimal 120/80 mmHg and the hypertensive 140/90 mmHg [Whelton, 2004].
Each increase in BP above 120/80 mmHg increases the risk of cardiovascular disease, and
so classifying those subjects as normotensive may cause uninformative phenotypes [Whelton,
1994].
In other human studies, BP measurements are used as a quantitative trait and animal
studies almost exclusively use BP as a quantitative trait for genetic analysis [Pickering et al.,
2005, Kurtz et al., 2005]. Hypertensive ranges are harder to define in animals than humans.
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Analysing these measurements retains information about the physiological variations in BP
which are lost in a case/control hypertension classification. However, inaccuracies in mea-
suring techniques can mask true BP estimates. For example, there is a well documented
phenomenon, called ‘white coat syndrome’, where BP becomes elevated due to a clinical envi-
ronment [Anjum et al., 2009, Parati et al., 2009]. In clinically diagnosing hypertension, there
have been recommendations for using ‘at home ambulatory’ measurements over those taken
during an office visit to reduce these effects. These at home methods record BP over a period
of time, often 24 hours, to reduce the clinical artefacts and to give insight into nocturnal
BP variations. Whilst these methods have been used clinically to inform on the patient’s
condition, they have yet to be utilised for genetic studies.
BP regulation is a part of the dynamic sympathetic and parasympathetic nervous system
and functions on cyclical as well as feedback loops [Bracic and Stefanovska, 1998, Cowley,
2006, Julius and Majahalme, 2000, Kurtz et al., 2005]. Many of the genetic variants associated
with hypertension regulate BP through hormonal control and the sympathetic nervous sys-
tem. The renin-angiotensin-aldosterone system has been well studied with the Angiotensin
Converter Enzyme (ACE) gene being the target of anti-hypertensive drugs [Giner et al.,
2000, Harrap et al., 1993, Rieder et al., 1999]. The role of the adducin family, vasopressin
and the interactions with the renin-angiotensin system have also been studied [Bianchi et al.,
2005, Lanzani et al., 2005, Pedrinelli et al., 2006, Berecek, 1986, Abboud et al., 1990]. The
hormonal regulation controls sodium and fluid levels as well as vascular tone and is mainly reg-
ulated through tubules in the kidneys [Bianchi et al., 2005, Berecek and Swords, 1990, Brooks
and Osborn, 1995]. Despite the known effect on hypertension, these long range hormonal con-
trols will not be explicitly considered here as the BP measurements were taken over the short
time period of 30 minutes.
It has been suggested that fluctuations around the mean BP measurements are as im-
portant as the mean averages themselves in evaluating cardiovascular function [Parati et al.,
1996, Parati et al., 1990, Parati et al., 1995, Bracic and Stefanovska, 1998]. These dy-
namic changes in BP represent physiological features like baroreflex sensitivity [Gallet et al.,
2011, Keissar et al., 2010] and circadian rhythms [Basset et al., 2004, Kuo and Yang, 2005].
Information about these physiological features can be extracted from time series BP using
signal processing techniques. Measuring BP over different time periods can be used to assess
different physiological features; measurements taken over the course of 24 hours can inform
on circadian rhythms [Parati et al., 1996] and Dipper status [Basset et al., 2004], whereas
measurements taken over the course of minutes can inform on heart rate [Bracic and Ste-
fanovska, 1998, Parati et al., 1995] and respiratory rate [Bracic and Stefanovska, 1998]. Two
commonly used techniques for analysing cardiovascular data have been spectral and wavelet
methods.
There have been several studies which use spectral analyses to investigate the differences
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in cyclical features of BP in both human and rat [Parati et al., 1996, Parati et al., 1990, Parati
et al., 1995, Di Rienzo et al., 1989, Persson et al., 2001, Persson, 1997]. These studies, while
informative about the underlying physiology between disease states, have not focused on the
underlying genetic basis. Spectral analysis, often performed with a fast Fourier transform
(FFT), takes discrete time series measurements and transforms the series from the time
domain to the frequency domain [Stoica and Moses, 1997, Bloomfield, 2004]. By looking
at the series in the frequency domain, periodic features display as sharp peaks which can
be quantified and analysed. The FFT relies on the series being stationary, de-trended and
within the Nyquist frequency in order to prevent ailiasing and artificial peaks [Stoica and
Moses, 1997, Bloomfield, 2004]. Local variations in the series, however, will not be captured
by spectral analysis.
Wavelet analysis, on the other hand, transforms a time series from the time domain to
the time and frequency domain, allowing for more information to be retained about the series
[Morlet et al., 1982a, Morlet et al., 1982b]. The time domain retains information about high
frequency components and the frequency domain retains information about low frequency
components [Morlet et al., 1982a, Morlet et al., 1982b]. In addition, non-cyclical variations
in a time series can be captured by wavelet analysis [Burgess et al., 2003] and the series
is not required to be stationary [Morlet et al., 1982a, Morlet et al., 1982b]. Similarly to
spectral analyses, there have been studies in both rats and humans which have looked at
wavelet indices of BP and the differences in physiology, but have not investigated the genetic
underpinnings of these traits [Bracic and Stefanovska, 1998, Kashihara et al., 2008, Keissar
et al., 2010, Gallet et al., 2011, Burgess et al., 2003, Pola et al., 1996, Morlet et al., 1982a].
A commonly used wavelet for analysing BP regulation has been the complex Morlet wavelet,
which is a Gaussian function modified by a sine wave, as it achieves time-frequency localisation
[Morlet et al., 1982a, Morlet et al., 1982b].
This chapter focuses on the analysis of radiotelemetric BP measurements in the BXH/HXB
recombinant inbred (RI) panel. Standard, spectral and wavelet phenotypes were derived from
the BP time series described in Chapter 2.2.3. Before either standard, spectral or wavelet
analyses were performed, the time series data was processed to remove outliers and technical
artefacts present in the series. The spectral analysis was performed using an FFT, providing
indices relating to the frequency, amplitude and power associated with heart rate (HR), while
the wavelet analysis was performed using the Morlet wavelet, giving indices related to the
waveform amplitude and wave frequency in the HR range. These measurements will inform
on the short range regulation of blood pressure, but not the long term hormonal regulation.
Standard analysis was also performed on the series and phenotypes relating to BP, pulse
pressure (PP) and HR were derived. The results of these analyses will be used in the following
chapter.
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4.2 Methods
The BP time series measurements described in Chapter 2.2.3 were use in the following anal-
yses. The time series BP was measured across the BXH/HXB RI strains (n=175) by Prof.
Michal Pravenec and colleagues at the Czech Academy of Sciences and Centre for Applied
Genomics.
4.2.1 Technical outlier removal
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Figure 4.1: Radiotelemetric Blood Pressure: BP was measured in the BXH/HXB RI strains at 500 Hz
for 30 minutes. (a) gives the measurements taken from one animal over the course of 30 minutes. (b)
shows the time series after measurements outside of the transducer range were removed (c) gives time
series after the measurements greater that 3 standard deviations from the minimum and maximum
means were removed.
Several of the individual time series contain technical artefacts from the transducers and it
is important that these are removal from the series. Figure 4.1a shows an instance of a techni-
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cal outlier. The transducers used are calibrated for BP measurements between 0 mmHg and
300 mmHg and therefore, any measurements outside of this range were deemed unreliable and
removed prior to subsequent analysis (Data Sciences International, http://www.datasci.com/).
Figure 4.1a illustrates a time series after the removal of outliers. To remove further technical
artefacts, like the one shown in Figure 4.1b, the minimum and maximum peak values were
calculated using a window of seven measurements, where peaks determined if a point was
greater than the three before and after. A range of seven measurements was used to ensure
that all of the true peaks detected remained in the analysis and that the large artefacts in
the series were not treated as true maximum peaks. Standard deviations were calculated
from these values and those measurements which fell outside of three standard deviations of
the mean minimum and maximum were treated as outliers. This range is relaxed to include
the peaks in the BP which are physiological and to remove the large artefacts. Figure 4.1c
shows the same time series after the artefacts have been removed. Some technical artefacts
will still remain within each series, but given the large number of measurements in each time
series these remaining artefacts will have minimal effects on the downstream analysis. Fig-
ure 4.2 presents an overview of the technical outlier removal and phenotype extraction for
the standard, wavelet and spectral methods. These initial time series processing steps are
given in white, and the standard, wavelet and spectral methods are in yellow, purple and red,
respectively.
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Removed BP < 0 and BP > 300
Determined min and max peaks
based on 7 measurements
Calculated σ from min and max
removed BP > 3σ
Calculated SBP, DBP,
MBP, HR, PP, PDIST
Applied 1D digital filter
Sampled by a factor of 10
Removed outliers within a strain
using a Grubbs test
Applied Morlet wavelet
De-meaned and de-trended
Calculated WAVE and WFREQ
Periodogram with
Hamming window
Removed outliers within a strain
using a Grubbs test
Calculated SPEC,
POWER and FREQ
Removed outliers within a strain
using a Grubbs test
Figure 4.2: Overview of phenotype extraction: The initial data cleaning and outlier removal are represented
by the white boxes. The standard steps in calculating the standard phenotypes are represented in yellow,
the steps in calculating the wavelet phenotypes are represented in purple and the steps in calculating the
spectral phenotypes are represented in red. The phenotypes resulting from the standard, wavelet and spectral
phenotypes are presented as strain means.
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4.2.2 Standard BP phenotypes
The following standard phenotypes were derived from each of the 175 time series and then
those which came from the same strains were averaged together to form strain means. As
mentioned in Chapter 2.2.3, there were unequal numbers of animals within each strain. The
unequal number of animals will create unequal variance associated with the strain means and
this will need to be taken into consideration in further analyses.
• Diastolic Blood Pressure (DBP, mmHg) - DBP was considered to be the minimum peak
measurement at the HR frequency. The local minimum peak values were calculated
using a window of seven measurements, where peaks determined if a point was less than
the three before and three after.
• Heart Rate (HR, beats/second) - After the maximum peaks were calculated as previ-
ously described, the number of peaks found was then divided by the time to obtain a
measurement of beats per second.
• Mean Blood Pressure (MBP, mmHg) - A total mean BP was calculated by averaging
all measurements together within each animal.
• Peak-toPeak Distance (PDIST, seconds) - After the maximum peaks were calculated as
previously described, the distance between each consecutive peak was calculated and
then all distances were averaged over the time series.
• Pulse Pressure (PP, mmHg) - After calculating the minimum and maximum peak val-
ues, PP was calculated by averaging the difference between consecutive minimum and
maximum values.
• Systolic Blood Pressure (SBP, mmHg) - SBP was considered to be the maximum peak
measurement at the HR frequency. The local maximum peak values were calculated
using a window of seven measurements, where peaks determined if a point was greater
than the three before and three after.
4.2.3 Spectral analysis of BP
Each of the time series was first sampled by a factor of ten so that the frequency of measure-
ments was reduced from 500 to 50, to reduce the computational time needed for the spectral
analyses. As the highest anticipated physiological frequency is due to the HR, this falls within
the Nyquist frequency; it is important for the time series to be within this frequency in order
to prevent aliasing [Bloomfield, 2004]. The spectral analyses derive cyclical aspects of the
time series, and are not focused on the maximum and minimum peaks within the time series.
Thinning the time series, as long as it remains within the Nyquist frequency, will have limited
effects on the transformed data.
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To calculate the spectral power of a time series, the series must be strictly stationary
where the joint probability distribution of the series remains constant when shifted in time
or space [Bloomfield, 2004]. However, few measured time series are strictly stationary over
the entire course of the series and so, to obtain an accurate estimate of the spectral power,
the time series must be at least weakly stationary, i.e.,
1. E(Xt) is constant
2. E(XtXu) depends only on t− u
where X is the time series. The Kwiatkowski-Phillips-Schmidt-Shin (KPSS) [Kwiatkowski
et al., 1992] test was used to determine the trend and level stationarity of each time series. In
the time series for each of the 175 rats analysed, the null hypothesis was rejected and so a lag
plot was used as a rough guide to determine the order of the differencing. Figure 4.3 shows a
time series plotted against lagged versions of itself for lags of one to nine. A difference of lag
one falls closer to the diagonal than the rest, suggesting it may be the best fit. There were
similar results for each series, so the lag 1 differencing was applied to each series to correct
for the non-stationarity. Correcting for non-stationarity prevents the maximum spectral peak
from being distorted to zero [Basset et al., 2004, Bloomfield, 2004]. The KPSS test was
applied again and the spectral peaks were visually checked after the application of the FFT
to ensure the series was stationary and that the maximum peak was not distorted.
The smoothed periodogram, for each series was calculated using a FFT [Stoica and Moses,
1997, Oppenheim and Schafer, 1989]. The FFT takes a time series, Xt and transforms it from
the time domain into the frequency domain S(ejω); by doing so one can decompose the signal
into periodic components which can have physiological relevance. Each series was de-meaned
and de-trended and a periodogram with a Hamming Window, following equation 4.1 was
used,
S(ejω) = 12pi
|
N∑
n=1
xnwne
−jω|2
||w||2 (4.1)
where x1...xN is the time series sequence, w1...wN is the Hamming window and −jω is the
frequency in radians per sample. The Hamming window was used to reduce spectral leakage,
specifically from the side lobes attached to the main peaks, creating a smoother periodogram
[Harris, 1978]. As cosine tapers are also commonly used in cardiovascular time series analyses
[Parati et al., 1990, Di Rienzo et al., 1989], an FFT was performed on each time series using
a 10% cosine taper but there were no discernible differences between the results of the two
methods. In equation 4.1, S(ejω) is the spectral power density of the original sequence and
has units of power per radians per sample. The three spectral phenotypes derived from this
analysis are listed below.
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Figure 4.3: Example lag plot showing with lags 1 - 9 from a time series of one rat. The plot in the
top left corner represents the time series after a differencing of one was applied and the bottom right
shows the time series after a differencing of lag 9. Visual comparing the lag plots show the that the
differencing of one fell closest to the diagonal, signalling it was the best fit. The differencing of lag one
was applied to the time series and the resulting stationarity was assessed with a KPSS test.
• Maximum Spectra (SPEC, ∝mmHg) - The highest peak in S(ejω) was identified, with
respect to frequency, and SPEC was defined to be the height of that peak.
• Maximum Frequency (FREQ, Hz) - FREQ was defined as the frequency corresponding
to the maximum spectra.
• Total Power (POWER, ∝mmHg2) - POWER was calculated by integrating over the
95% confidence interval around the maximum spectral peak.
4.2.4 Wavelet analysis
Wavelet analysis transforms a time series from the time domain to the frequency domain,
allowing for a better resolution of both high and low frequency components. Wavelet analyses
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can also capture non-stationary features, which may have physiological relevance [Bracic and
Stefanovska, 1998]. The time series was filtered using a 1-D digital filter with a coefficient
vector equal to [1/4, 1/4, 1/4, 1/4] to reduce the trend in the series. Then a Morlet wavelet
was applied, following the continuous wavelet transform,
f˜(s, t) =
∫ ∞
−∞
Ψ¯s,t(u)f(u)du (4.2)
where f(u) is the signal, f˜(s, t) is the transform of the signal and Ψs,t is a family of basis
functions. Ψs,t can be determined by scaling a wave function; in this case, a scaling vector of
[0.5, 0.5, 512] was used with a Morlet wave function, given by
ψ(u) = (pifb)−1/2e−i2pifcue
−u2
fb (4.3)
where u is the original time series, fb is the bandwidth parameter, fc is the centre frequency
[Teolis, 1998] and ψ(u) are the wavelet coefficients. The local maximum of the wavelet
coefficients was calculated within the HR range (4-8 Hz).
• Wave Amplitude (WAVE, ∝mmHg) - WAVE was defined as the local maximum peak
within the HR range of 4-8 Hz.
• Wave Frequency (WFREQ, Hz ) - WFREQ is the frequency (between 4-8 Hz) that
corresponds to the local maximum.
For all phenotypes - standard, spectral and wavelet, outlying means within a strain were
identified and removed using a Grubbs test [Grubbs, 1950] which identified outliers based
upon the mean and variances of the measurements.
4.2.5 Partial correlation analysis
A Gaussian graphical model (GGM) was created of the eleven phenotypes to assess the partial
correlation structure between the standard, spectral and wavelet phenotypes. The GGM
was calculated in R [Ihaka, 1996] using the GeneNet package [Opgen-Rhein and Strimmer,
2007]. Partial correlations are the correlations which are left after the effects of all the other
variables have been regressed away. The GGMs are networks where the partial correlations
are calculated pairwise for each variable (in this case, each BP phenotype). The formulas used
by Opgen-Rhein and Strimmer to calculate the partial correlations are given in equations 4.4.
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variances : var(Xn) = σnn = σ2n
partial variances : var(Xn|X!n) = σ˜nn = σ˜2n = ω−1nn
covariances : cov(Xn, Xm) = σnm
correlation : corr(Xn, Xm) = ρn,m = σn,m(σnn, σmm)−1/2
partial correlation : corr(Xn, Xm|X!n,!m) = ρ˜nm = −ωnm(ωnnωmm)−1/2
(4.4)
Xn and Xm are the covariates, which are random variables with variances var(Y ), var(Xn)
and covariance cov(Y,Xn). Indices n and m go from 1 to p, where p is the number of
covariates. In the graphical model, the phenotypes are represented by nodes and the edges
between the nodes are significant partial correlations. Whist not fully utilised in this instance,
the GeneNet package incorporates a shrinkage approach to estimating the covariance matrix.
Permutations coupled with q-values are used to locally determine the false discovery rate
(FDR) of a given edge and here an FDR <10% is deemed significant.
4.3 Results
A summary description of the standard, spectral and wavelet analyses is presented below.
Table 4.1 gives the name, abbreviation and type of analysis for each of the eleven derived
phenotypes.
Name Abbrev. Type
Diastolic Blood Pressure DBP Standard
Heart Rate HR Standard
Mean Blood Pressure MBP Standard
Peak-to-Peak Distance PDIST Standard
Pulse Pressure PP Standard
Systolic Blood Pressure SBP Standard
Maximum Frequency FREQ Spectral
Total Power POWER Spectral
Maximum Spectra SPEC Spectral
Wave Amplitude WAVE Wavelet
Wave Frequency WFREQ Wavelet
Table 4.1: BP and HR phenotypes: Names, abbreviations and type.
The RI strains emulate a natural population for each of the phenotypes; Figure 4.4 gives
the distribution of SBP measurements across the strains. Each box represents the range
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from the first quartile to the third quartile with the median indicated by the black line.
The whiskers extend to the farthest measurement within 1.5 times the interquartile range.
Measurements which fall outside of that range are indicated by a circle and the strains are
arranged by the strain means. Graphs for each of the other ten phenotypes can be found in
Appendix A, Figure A.1.
As expected, the Spontaneously Hypertensive rat (SHR) has one of the higher systolic
BP measurements by strain and the Brown Norway (BN) has one of the lower, with the RI
strains distributed between the two. The other phenotypes exhibit similar features, however,
for some of the phenotypes (HR, PDIST, WAVE) the separation between SHR and BN is not
as prominent as the other phenotypes, but the distribution throughout the RI panel is still
continuous (See Appendix A).
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Figure 4.4: The range of SBP across the strains. The boxes stretch from the first to the third quartile
and the black lines represent the median. The whiskers of the plots extend to the farthest data point
within 1.5 times the interquartile range. The strains are ordered from lowest to highest by mean and
the strain means for BN and SHR are highlighted by the red boxes.
Table 4.2 gives the quartiles for the strain means in each of the phenotypes. The standard
phenotypes fall within the previously published ranges [Twigger et al., 2007, Rapp, 2000].
As SHR and BN differ in hypertensive measures, the phenotypes derived from the time
series should reflect those differences. Out of the eleven phenotypes, eight had a significant
(p < 0.01, Wilcox-rank sum test) difference between SHR and BN (see Figure 4.5). The other
three phenotypes - HR, PDIST and WAVE, did not show a significant difference between
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SBP DBP MBP PDIST PP HR SPEC FREQ POWER WFREQ WAVE
Min. 87.26 59.03 68.44 0.16 22.16 276.5 0.10 4.41 28.66 4.34 0.08
1st Qu. 105.00 76.17 86.23 0.19 29.91 287.6 0.14 4.66 54.20 4.73 0.20
Median 112.92 80.55 91.44 0.20 32.82 298.5 0.17 4.79 67.03 4.88 0.25
Mean 111.75 78.64 89.54 0.20 32.54 301.2 0.19 4.88 70.52 4.88 0.28
3rd Qu. 119.19 83.73 95.37 0.21 34.80 311.9 0.23 5.07 85.55 4.99 0.37
Max. 142.93 94.63 108.61 0.22 40.49 352.4 0.44 5.50 133.18 5.84 0.49
Table 4.2: Conventional, Spectral and Wavelet Phenotypes: the minimum, maximum, mean, median
and quartiles for each of the phenotypes derived from the time series. The standard phenotypes are:
DBP, MBP, PDIST, HR, PP, SBP. The spectral phenotypes are: FREQ, POWER, SPEC. The wavelet
phenotypes are WAVE, WFREQ.
SHR and BN. However, despite there being no significant difference between SHR and BN,
the phenotypes show a continuous distribution across the RI strains (see Appendix A).
The physiological relevance of the standard phenotypes is well understood and the pheno-
types have been used previously in genetic studies [Fung et al., 2011, Delles et al., 2010, Har-
rison et al., 2008]. The spectral and wavelet phenotypes are not as well characterised, and
so a partial correlation analysis was used to cluster the phenotypes and identify groups of
related phenotypes. Figure 4.6 shows the phenotypes clustered by a GGM at a 10% FDR
level. The eleven phenotypes clustered into four groups which suggest physiological relevance.
SBP, DBP and MBP group together and are all related to blood pressure; PP, POWER and
SPEC group together and are all related to pulse pressure. HR, FREQ, PDIST, WFREQ
group together and are related to heart rate and WAVE groups on its own. While the cluster
of blood pressure phenotypes shows that SBP, DBP and MBP are all correlated, the cluster of
heart rate phenotypes and pulse pressure phenotypes do no share that characteristic. Within
the heart rate cluster. HR, WFREQ and PDIST are all correlated to each other while FREQ
is only correlated with HR. In the pulse pressure cluster, PP and SPEC are both correlated
with POWER, but not each other. This suggests that while the phenotypes are related to
each other, they capture different aspects of blood pressure, heart rate and pulse pressure,
with WAVE on its own.
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Figure 4.5: The means and quartiles are represented by box plots for each phenotype in BN and
SHR: (a) DBP mmHg, (b) HR beats/min, (c) MBP mmHg, (d) PDIST sec, (e) PP mmHg, (f) SBP
mmHg, (g) FREQ Hz, (h) POWER ∝mmHg2, (i) SPEC ∝ mmHg, (j) WFREQ Hz, and (k) WAVE
∝ mmHg. The Wilcox-rank sum test was used to determine significant differences between SHR and
BN for each phenotype and the respective p-values are give in each graph.
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Figure 4.6: The eleven phenotypes were clustered by partial correlations using GGMs (FDR< 10%).
They clustered according to physiological relevance where the phenotypes relative to BP (SBP - sys-
tolic blood pressure; DBP - diastolic blood pressure; MBP - mean blood pressure) grouped together,
those relating to PP (PP - pulse pressure, POWER - total power, SPEC - maximum spectra) grouped
together, those relating to HR (HR - heart rate; PDIST - peak to peak distance; FREQ - maximum
frequency; WFREQ - wave frequency) grouped together and WAVE (wave amplitude) did not clus-
ter with any of the other phenotypes. The standard phenotypes are given in yellow, the spectral
phenotypes are given in red and the wavelet phenotypes are given in purple.
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4.4 Discussion
In addition to standard BP indices, spectral and wavelet analyses can provide greater insight
to the variability of BP and HR. Here, a FFT and a Morlet wavelet have been used to further
explore physiological phenotypes from time series. BP in 175 animals from the BXH/HXB RI
strains was measured over the time course of 30 minutes using indwelling aortic transducers.
This time period is physiologically relevant for pulse pressure and heart rate variability [Bracic
and Stefanovska, 1998, Parati et al., 1995] and, with measurements taken at 500 Hz, the time
series provide a large BP resource.
As Figure 2.4 and Figure 4.1 shows, there is inherent noise and variability within each of
the BP time series. A number of outlier and filtering techniques were employed to reduce this
noise within the BP signal but, as Figure 4.4 and Appendix A show, there is still within-strain
variability. Large within-strain, i.e., environmental variation and noise can mask the genetic
variation [Petretto et al., 2006a, Belknap, 1998].
The standard BP and HR indices vary across the rat inbred strains, with several hyper-
tensive and normotensive strains. The previously published indices fall into the following
ranges:
Phenotype Min. Max.
DBP (mmHg) 80.3 180.9
HR (beats/min) 167.9 744.7
MBP (mmHg) 50.43 241
PP (mmHg) 43.3 69.6
SBP (mmHg) 91 250.5
Table 4.3: The minimum and maximum values of the published standard BP and HR phenotypes
in the rat. These ranges presented here are from measurements in male rats. The data is available
from the PhenoMiner Database tool on the Rat Genome Database (RGD) ([Twigger et al., 2007],
PhenoMiner, Rat Genome Database Web Site, Medical College of Wisconsin, Milwaukee, Wisconsin.
World Wide Web (URL: http://rgd.mcw.edu/). September 2012.)
As the parental strains, SHR and BN, are hypertensive and normotensive, respectively, they
exhibit differences in many of the cardiovascular traits including blood pressure and heart rate
[Rapp, 2000, Twigger et al., 2007]. Several BP and HR phenotypes from BN, SHR and their
substrains are available from the PhenoMiner Database tool on the Rat Genome Database
(RGD) ([Twigger et al., 2007], PhenoMiner, Rat Genome Database Web Site, Medical Col-
lege of Wisconsin, Milwaukee, Wisconsin. World Wide Web (URL: http://rgd.mcw.edu/).
September 2012.). Under normal conditions, SHR and the SHR substrains have SBP aver-
ages ranging from 113 to 141 mmHg for BN and the BN substrains and 154 to 232 mmHg for
SHR and the SHR substrains with similar difference seen for DBP and MBP. Heart rate mea-
surements were also higher in SHR than in BN where HR measurements ranged from 264.7
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to 443 beats per minute for BN and substrains and 379.6 to 511 for SHR and substrains. For
comparison with the work here, the published BP and HR measurements were those taken
in male rats. These differences between SHR and BN should be reflected in the standard,
spectral and wavelet phenotypes phenotypes derived from the time series. Figure 4.5, show
significant differences between DBP, MBP, PP, SBP, SPEC, FREQ, POWER, and WFREQ.
For HR, PDIST, and WAVE, SHR and BN fall closer together in the range of strain means,
but the rest of the RI strains are widespread (Supplemental Figure A.1).
In addition, the phenotypes derived from the time series should be continuous across
the RI lines and emulate the variability observed in a natural population. As Figure 4.4
and Figure A.1 show, the standard, spectral and wavelet phenotypes are continuous and
variable across the population, with BN and SHR separating out in the population. Table 4.2
contains the mean value and quartiles for each of the phenotypes. The values and ranges
observed for the standard phenotypes are in accordance with previously published values
[Rapp, 2000, Twigger et al., 2007].
The partial correlations between the phenotypes show the physiological relevance for the
spectral and wavelet phenotypes. Each cluster represents a physiological feature with one
pertaining to blood pressure (SBP, DBP, MBP), one to pulse pressure (PP, POWER, SPEC),
one to heart rate (HR, PDIST, FREQ, WFREQ) and with WAVE separating out. SBP, DBP
and MBP are all correlated with each other, suggesting they are highly related and may have
common genetic control. The structures of the other clusters show that POWER and HR
are at the centre whereas others are only correlated with one or two other phenotypes. The
correlation structure for the pulse pressure cluster and the heart rate cluster suggest that
while these phenotypes are related, they capture different aspects of BP variation and may
point to separate determinants of genetic control.
These new phenotypes should inform on different aspects of BP regulation and may allow
for the identification of the genetic variants underlying BP variations and hypertension. Spec-
tral and wavelet methods have been used to characterise BP variations for clinical purposes
[Pickering and Shimbo, 2006, Parati and Valentini, 2007, Parati et al., 2009], but have yet to
fully be utilised for genetic studies. By investigating BP measurements in a model system,
which allows for a more accurate BP measuring technique, one can assess these spectral and
wavelet indices and improve on human BP phenotyping. In the next chapter, the phenotypes
derived here will be integrated with genetic and gene expression variation to further inform
on the genetic control of hypertension in the rat.
Chapter 5
Integrating gene expression, blood
pressure, and genetic variation in
the rat
5.1 Introduction
As technology advances, the focus for many complex disease studies has shifted from iden-
tifying singular candidate genes to analysing complex gene networks and pathways [Sieberts
and Schadt, 2007]. The integrated analysis of genetic, gene expression and physiological vari-
ation can provide insight into the regulation of complex diseases and traits. By integrating
each level of variation across the genome, one can begin to elucidate the molecular path-
ways of disease. Moving forward from ‘genetical genomics’, which combines genetic and gene
expression variation, studies have incorporated physiological variation and, in some cases,
additional intermediary phenotypes [Schadt, 2009]. These ‘integrative genomics’ approaches
have been used in both humans and animal models of disease. For instance, Schadt et al.
used genetic variation in a mouse population combined with gene expression in the liver and
obesity phenotypes to identify three novel obesity susceptibility genes [Schadt et al., 2005].
Similarly, in 2008, Schadt et al. profiled gene expression traits in human liver to look for
disease associations and identified RPS26 as the genetic variant underlying a type I diabetes
locus [Schadt et al., 2008]. In a study of metabolic and cardiovascular traits, Derry et al.,
utilised gene expression from adipose, kidney and liver in a mouse F2 population to identify
trans expression quantitative trait loci (eQTL) modules which were shown to affect metabolic
disease risk [Derry et al., 2010]. Rotival et al. used expression from human monocytes and
integrated it with genetic variation to inform on trans regulated modules which showed strong
associations with metabolic disease traits [Rotival et al., 2011].
While these ‘integrative genomics’ studies highlight the advantages of incorporating gene
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expression variation with both genetic and phenotypic variation, they do have their limita-
tions. In both the 2005 Schadt et al. study and the 2010 Derry et al. study, the authors
attempt to identify the causal gene for several metabolic syndrome traits in a mouse pop-
ulation. Despite the complex genetic architecture underlying these traits, the method by
which they aim to detect causal genes is overly simplistic. They only consider the relation-
ship between a gene, its expression and the phenotype of interest, and ignore any potential
interaction terms. Schadt et al. 2008 identifies the SNPs associated with eQTLs as ‘func-
tionally validated eSNPs’. This seems to be an overly broad term as the functionality is
based only on whether the SNPs were associated with eQTLs with no additional functional
evidence given. Further functional studies based around the results presented in these papers
are likely to show relationships which are far more complex than the simplistic ones reported.
Additionally, all of the studies above focus on one species, while combining species together
may provide additional evidence for the relationship between a gene and the phenotype of
interest.
Several ‘integrative genomics’ studies have been published using the BXH/HXB recom-
binant inbred (RI) panel. Petretto et al. identified osteoglycin (Ogn) as a major genetic
determinant of left ventricular mass (LVM) by integrating genome-wide genetic variation
with gene expression in the heart and physiological phenotypes relating to LVM. In addition,
they used gene expression in heart and LVM phenotypes in humans to strengthen the evi-
dence for the role of Ogn in the genetic regulation of LVM [Petretto et al., 2008]. Heinig et al.
integrated genetic and gene expression variation, with transcription factor binding site data
to deduce a trans regulated network which was associated with an increased type 1 diabetes
risk in humans [Heinig et al., 2010].
This chapter presents a large-scale integrative analysis of blood pressure (BP) regulation
in the BXH/HXB RI strains, with genome-wide gene expression in seven tissues, genome-
wide genetic variation and novel BP phenotypes derived from radiotelemetric time series
BP measurements. These data types have been integrated to inform on hypertension in a
rat model and these findings in the rat have been compared with publicly available human
genome-wide associations (GWAS) results to shed light on the genetic regulation of BP and
hypertension in humans.
5.2 Methods
5.2.1 QTL mapping
The eleven phenotypes described in Chapter 4.3 (systolic blood pressure (SBP), diastolic blood
pressure (DBP), mean blood pressure (MBP), heart rate (HR), pulse pressure (PP), peak-
to-peak distance (PDIST), maximum frequency (FREQ), maximum spectra (SPEC), total
power (POWER), wave frequency (WFREQ), wave amplitude (WAVE)) were mapped to the
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genome via quantitate trait locus (QTL) analysis using the single nucleotide polymorphism
(SNP) panel described in Chapter 2.2.1. The QTL mapping was performed in R [Ihaka,
1996] using the imputation method in R/qtl [Sen, 2001, Broman et al., 2003]. The imputation
method is based on an independent sample Monte Carlo method, where the mapping is
separated into two parts: the genetic model and the linkage model. The genetic model
relates the genotype to the phenotype and the linkage model determines the location of the
locus (loci) in the genome. Both are conditional on the unobserved genotypes [Sen, 2001].
Separating the mapping into two parts allows for pseudomarkers to be calculated and imputed
across the genome, and provides the integral estimates needed for Bayesian inference.
The BP phenotypes were derived in Chapter 4 came from a varying number of biological
replicates from the RI strains. Strain means of the phenotypes were used in this analysis
and the unequal number of replicates could influence the QTL mapping. To reduce the
effect of within strain variability on the mapping and increase the power, the strain means
were weighted based on the within strain variance. Genome-wide significance levels were
determined empirically from 1,000 phenotype permutations [Churchill and Doerge, 1994].
5.2.2 Gene expression
The genome-wide gene expression levels in adrenal gland (ADR), aorta (AORTA), adipose
(FAT), kidney (KID), liver (LIVER), left ventricle (LV) and skeletal muscle (SKM) described
in Chapter 2 were used for the eQTL and QTT analysis. As mentioned in Chapter 2, two
different Affymetrix expression arrays were used. ADR, FAT, and KID were run on the RAE
230 A array and AORTA, LIVER, LV and SKM were run on the RAE230 2 array. The
RAE 230 A array contains 15,923 probes and the RAE 2302 array contains 31,099 probes, of
which 15,923 are the same as the RAE230 A chip. The total, not proportional, differences
seen in the following analyses between tissues can be attributed to the differences in the
number of probes. For this genome-wide analysis, the probesets were filtered within each
tissue to remove expression levels from inadequate probes. Probes which mapped to multiple
locations, as determined by the Systematic Categorisation of Affymetrix Microarray Probeset
Annotations (SCAMPA) software developed in the Physiological Genomics and Medicine
group, were removed from the analysis. SCAMPA ranks the probes by aligning the probe
sequence to the genome sequence in Ensembl. There are four tiers:
1. Probes map to one location in the genome
2. Probes likely to map to a one location in the genome
3. Probes map to multiple locations in the genome
4. Probes do not map to locations in the genome
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and probes which fell under Tier 3 and Tier 4 were removed. For the RAE 230 2 array, the
tiers were broken down into: Tier 1 - 26,662; Tier 2 - 631; Tier 3 - 1,970; Tier 4 - 1,836.
The RAE 230 A array was broken down as: Tier 1 - 13,495; Tier 2 - 246; Tier 3 - 1,317;
Tier 4 - 865. In addition, the coefficient of variation was calculated for each transcript across
the tissues, and the bottom 10% of the transcripts were removed to eliminate non-varying
transcripts from this analysis.
5.2.3 eQTL analysis
eQTL analysis was carried out on the genome-wide gene expression from the seven tissues us-
ing a sparse Bayesian regression (SBR) method (see Chapter 3.2.2) [Petretto et al., 2010, Bot-
tolo et al., 2011a] and the SNP panel described in Chapter 2. The SBR method utilises an evo-
lutionary stochastic search (ESS) algorithm to effectively search the high dimensional model
space. The priors densities for the regression coefficients and error variance are Np(0, σ2, Hγ)
and σ2 ∼ InvGam(aσ, bσ). Hγ is the variance-covariance matrix between the predictors and
is modelled by a g-prior setup. The tuning parameter is specified from the data with a modi-
fied Jeffery’s prior. The exchange priors on the predictors are proportional to Binomial(p, ω).
The hyperparameters are calculated from two parameters, the expected model size and the
expected standard deviation. Here, the expected model size was two and the expected stan-
dard deviation is one. SBR was run with four parallel chains and 110,000 iterations with a
10,000 iteration burn-in.
Unlike the use of SBR in Chapter 3.2.2, a different multiple testing correction method
was used. While the SBR can detect polygenic control, here, only the SNP with the strongest
association with the expression trait was retrieved for the following analysis. Multiple testing
corrections were performed on the marginal posterior probably of inclusion (PPI) for the
strongest associated SNP of each transcript. The false discovery rate (FDR) was calculated
by the method proposed by Chen and Ghosh. They address controlling FDR in a Bayesian
regression context and show that the FDR is a by-product of Bayesian variable selection. For
a given FDR level, α, the threshold on the level is the minimum PPI, k, for which the average
of all the PPI > k, is greater than 1− α [Chen et al., 2008, Ghosh et al., 2006].
Among the selected SNPs, cis-acting eQTLs were the genetic control points that were
within 10 mega-bases (Mb) from the physical location of the associated probe. Trans-acting
eQTLs were those which mapped elsewhere in the genome. Trans clusters were identified
within the eQTL dataset, and were defined to be groups of ten or more genes whose transcripts
map in trans to the same location of the genome. Transcripts which did not significantly map
to the genome were referred to as non-eQTLs (NE). As these clusters of genes suggest co-
regulation from the effect of a ‘master genetic regulator’, potential ‘master regulators’ for the
clusters were identified by looking for the closest gene located within a 2 kilo-bases (Kb) and
a 20 Kb region around the trans cluster locus. Both the 2 kb and 20 kb regions were used to
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ensure that the results were not an artefact arising from the 2 kb region.
5.2.4 Quantitative trait transcript (QTT) analysis
To determine the association between physiological phenotypes and gene expression, genome-
wide gene expression levels in each of the seven tissues were correlated with each blood
pressure phenotype using pairwise Pearson correlation. Using the Westfall-Young proce-
dure [Westfall, 1993], empirical p-values of the pairwise Pearson correlation were calculated
based on 1,000 permutations, as previously described [Petretto et al., 2008]. Gene expression
abundances were separated into three groups, cis, trans and NE, based upon the eQTL map-
ping (see Chapter 5.2.3). Associations were deemed significant with an empirical p-value of
p < 0.05.
5.2.5 Functional annotation analysis
The pathway and gene ontology enrichment analysis was performed using the Database for
Annotation, Visualization and Integrated Discovery (DAVID) [Dennis Jr et al., 2003]. The
Kyoto Encyclopaedia of Genes and Genomics (KEGG) pathways are well defined molecular
pathways relating to biological function and diseases and Gene Ontology (GO) terms relate to
the molecular function, biological process and cellular component of a gene. The enrichment
was calculated by a Fisher’s exact test [Fisher, 1922] and the multiple testing correction was
calculated by the Benjamini FDR [Benjamini and Yekutieli, 2001].
5.2.6 Enrichment of BP associated rat genes in human GWAS genes
In order to compare genes associated with BP in the rat with genes associated with hyperten-
sion in humans, the enrichment of rat gene sets was calculated using the list of human GWAS
described in Chapter 2.3. The following subsets of genes identified in the rat were used:
1. cis and trans eQTLs;
2. non-eQTL (NE) transcripts;
3. trans clusters and genes underlying trans clusters;
4. ‘3C’ genes;
5. the subset of each of the above 1), 2) and 3) that were correlated by QTT with rat BP
phenotypes;
The human genes associated with the GWAS SNPs were determined using the Biomart
tool of the Ensemble genome browser (http://www.ensembl.org/index.html) and the dbSNP
database (http://www.ncbi.nlm.nih.gov/projects/SNP/). SNPs were linked with a gene if
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the SNP fell in the region between the 5’ and 3’ UTRs of that gene, providing a conservative
estimate of association with human hypertension. The enrichment in the human GWAS
results was assessed using an hypergeometric test [Fisher, 1935], while the empirical p-value
was based on 10,000+ permutations with the size of the sample drawn equal to that of the
set analysed [Fisher, 1935, Good, 2005].
5.3 Results
5.3.1 QTL mapping
Table 5.1 reports the results from the QTL mapping; seven out of the eleven phenotypes
mapped to at least one locus in genome. Most of these phenotypes map to previously known
QTL regions (SBP [St Lezin et al., 1997, Stoll et al., 2000, Pravenec et al., 1995], DBP
[Stoll et al., 2000], MBP [Kreutz et al., 1995, Pravenec et al., 1995], PP [Bilusic et al., 2004],
SPEC [Bilusic et al., 2004, Moreno et al., 2003, Stoll et al., 2000] and WAVE [Aneas et al.,
2009]) with HR mapping to a novel QTL on chromosome 14 (see Table 5.1 and Table 5.2).
The phenotypes were derived from time series analyses (see Chapter 4), where standard,
spectral and wavelet methods were used. SPEC and WAVE, spectral and wavelet phenotypes
respectively, map to QTLs on chromosomes 17 and 2 and the WAVE QTL on chromosome
2 was the strongest of any of the phenotypes (LOD = 4.70). These associations would not
have been found by the standard phenotypes and the potential genetic determinants effecting
BP regulation would have been missed. The QTL for WAVE on chromosome 2 is given here
in Figure 5.1 as an example. The genome-wide QTL scan is shown in Figure 5.1 (a) and the
posterior probability density plot of the QTL peak on chromosome 2 is shown in Figure 5.1
(b), where the dotted red line is the posterior probability and the green line is the 95%
Bayesian credible interval. Genome-wide QTL scans for each of the other phenotypes can be
found in Appendix B (Figure B.1).
The QTLs are reported at three significance levels, highly significant (5%), significant
(10%) and suggestive (25%). While the Bayesian credible intervals (CI) are large, they are
comparable to the previously published BP QTLs (see Table 5.2). The most of the previously
published results show that the individual QTLs exert a modest effect on BP variation (5% to
10%) [Rapp, 2000] which results in large (20 - 35 cM) confidence intervals [Rapp, 2000, Hyne
et al., 1995, Ooijen, 1992]. Three of the QTLs here are larger than the 20-35 cM range:
the SBP QTL on chromosome 1; the DBP QTL on chromosome 10 and the HR QTL on
chromosome 14. The SBP and HR QTLs are only suggestive QTLs, which is consistent with
the large CIs. The DBP QTL with a large CI is significant, but the QTL region overlaps with
SBP and MBP QTLs which are highly significant and have smaller CIs. Unlike the other two
suggestive QTLs, the MBP QTL on chromosome 19 has a much smaller CI. Similarly, though,
the MBP QTL overlaps with other highly significant QTLs, the PP QTL and the SBP QTL
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on chromosome 19. The MBP QTL on chromosome 19 and the DBP QTL on chromosome
10 likely show the same effects, albeit weaker, as the significant overlapping QTLs.
Phenotype CHR Position(Mbp) LOD score Emp. Sig CI (Mbp)
DBP 10 6.43 3.56 10% 5.58 - 84.03
HR 14 112.03 3.07 25% 7.94 - 112.03
MBP 10 6.43 3.91 5% 5.58 - 6.80
MBP 19 46.40 3.10 25% 45.85 - 52.18
PP 19 44.11 4.04 5% 39.99 - 46.40
SBP 1 125.73 2.77 25% 21.87 - 254.91
SBP 10 6.43 3.66 5% 5.58 - 22.74
SBP 19 46.40 4.12 5% 46.24 - 46.83
SPEC 17 9.80 3.28 10% 5.79 - 24.08
WAVE 2 49.17 4.70 5% 43.70 - 107.18
Table 5.1: Physiological QTL: The QTL(s) for each phenotype is listed above with the phenotype, chromo-
some and position (Mb) of the locus, the LOD score, the empirical significance and the 95% Bayesian credible
interval. QTLs were found using imputation and interval mapping while the significance was determined by
1,000 permutation tests.
Reference CHR CI (Mbp) LOD score or p-value Strain Combination
[St Lezin et al., 1997] 1 146.97-202.91 - SHR/Ola×BN/Crl
[Aneas et al., 2009] 2 36.43-112.33 P=0.01 SHR.BN×Jk
[Stoll et al., 2000] 10 21.61 - 91.47 LOD=2.94 BN×SHR
[Stoll et al., 2000] 10 21.61 - 91.47 LOD=4.82 BN×SHR
[Kreutz et al., 1995] 10 6.66-65.07 P=0.005 WKY.SHRSP×Bbb
[Bilusic et al., 2004] 17 1-81.04 LOD=4.5 LH/Mav×LN/Mav
[Moreno et al., 2003] 17 7.70-41.03 LOD=2.82 BN/SsNHsd×SS/JrHsdMcwi
[Stoll et al., 2000] 17 14.57-38.35 LOD=3.38 ACI/N×FHH
[Pravenec et al., 1995] 19 22.59-59.22 P=0.012 BXH/Ipcv×HXB/Ipcv
[Pravenec et al., 1995] 19 45.09-59.22 P=0.0008 BXH/Ipcv×HXB/Ipcv
Table 5.2: Previously Known QTL: Some of the previously published BP QTL are listed above with the
reference, location, statistic and strain. From the QTL calculated here (Table 5.1), all but the HR locus
on chromosome 14 overlapped to some extent with previously known QTLs. When available, the previously
published QTLs are from BN and SHR crosses. These QTLs were compiled from the Rat Genome Database
(RGD) [Twigger et al., 2007].
CHAPTER 5. INTEGRATIVE APPROACHES IN THE RAT 96
0
1
2
3
4
5
Wave
Chromosome
lod
1 2 3 4 5 6 7 8 9 10 11121314 15 16 17 18 1920
5%	  
10%	  
25%	  
LO
D
	  S
co
re
	  
Chr osome	  
(a) Genome-wide QTL scan: WAVE
0 50 100 150
0
1
2
3
4
Map position (cM)
lod
(a)Localization plot on Ch 2
0 50 100 150
0
1
2
3
4
Map position (cM)
lod
Localization plot on Ch 2
interval: 30.49 to 66.14 cM
0.
0
0.
1
0.
2
0.
3
0.
4
0.
5
0.
6
PP
D
LO
D
	  S
co
re
	  
Po
st
er
io
r	  
Pr
ob
ab
ili
ty
	  D
en
si
ty
	  
Map	  Loca5on	  (cM)	  
(b) PPD plot of chromosome 2: WAVE
Figure 5.1: QTL scan and posterior probability density plot for WAVE: The genome-wide QTL scan for
WAVE is given in (a) where the 5%, 10% and 25% empirical significance levels are indicated by the red, blue
and black lines, respectively. The posterior probability density for the significant QTL on chromosome 2 is
given in (b), where the posterior probability is outlined in red and the 95% Bayesian credible interval is given
in green (centi-Morgans(cM)).
5.3.2 eQTL mapping
Gene expression has previously been used as an intermediate phenotype between genetic
and phenotypic variation to identify candidate genes and elucidate their functional role in
cardiovascular traits [Hubner et al., 2005, Petretto et al., 2008, Pravenec et al., 2008a]. Here,
genome-wide eQTL mapping was performed in seven tissues using a SBR method, which has
been shown to have increased power to detect eQTLs with small effect sizes, see Chapter 3
[Petretto et al., 2010, Bottolo et al., 2011a]. As SBR relies on the evolutionary stochastic
search algorithm proposed by Bottolo and Richardson [Bottolo, 2010], it is possible that for
a given expression trait, the chains will not converge on a best model, leaving indeterminate
results.
ESS is based on ideas from the Evolutionary Monte Carlo algorithm [Bottolo, 2010, Liang
and Wong, 2001] and utilises multiple Markov chains set a different temperatures to efficiently
sample the model space. With this algorithm, it is possible that there will be inadequate
mixing between chains and that the chains will not converge on a best model. To identify non-
convergence, the estimated marginal probability of the best model for each trait was calculated
by dividing the number of visits to the model by the number of iterations performed. If the
chains converged, the estimated marginal probability should be approximately the same as the
calculated marginal probability. To visually inspect the convergence, the estimated marginal
probability was plotted against the calculated marginal probability, see Appendix B, Figure
B.2 (a-g). The twelve traits highlighted in the red boxes were deemed to be non-convergent
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and removed from further analyses.
5.3.2.1 Cis and trans eQTLs across tissues
26,990 eQTLs (FDR < 10%) were identified, both cis- and trans-regulated, across the seven
tissues (Appendix B, Table B.1). Figure 5.2 summarises the number of cis-, trans-regulated
transcripts and NE transcripts in each tissue. Overall, 4.0% to 7.0% of transcripts were
found to be cis-regulated and 9.8% to 15.1% were found to be trans-regulated. In keeping
with previous data [Petretto et al., 2006a, Petretto et al., 2010], stronger associations were
observed for the cis regulated transcripts (average marginal probability = 0.94) as compared
with the trans regulated transcripts (average marginal probability = 0.88), and there were
more (2.3 fold) trans regulated transcripts than cis identified (Figure 5.2). Figure 5.3 shows
the kernel density plots for marginal posterior probability of inclusion for cis (green) and trans
(red) regulated transcripts. Across the tissues, the PPI density of the cis regulated transcripts
show a discernible peak towards the higher values, while the PPI density of the trans regulated
transcripts plateaus over values of approximately 0.75-0.95. This is in agreement with trans
regulated transcripts having lower effects, whilst being greater in number than cis regulated
transcripts.
5.3.2.2 Trans-eQTL clusters
Multiple trans regulated genes can map to the same locus forming clusters, or ‘hot-spots’, of
eQTLs [Breitling et al., 2008]. These clusters can provide valuable insights into secondary
mechanisms underlying complex traits and disease phenotypes [Fehrmann et al., 2011, Heinig
et al., 2010]. Here, 160 trans clusters were identified across the seven tissues, where a trans
cluster was defined to be a group of ten or more genes whose expression maps to the same
locus (see Appendix B, Table B.2 for complete list of trans clusters). The distribution of the
number of genes present within a cluster is given by Figure 5.4, where the trans cluster sizes
range from 10 to 322 genes and 10% of all clusters contained more than 40 genes.
Figure 5.5 illustrates the proportion of trans regulated genes mapping across the genome
for the seven tissues. The named clusters are those which are present in two or more tissues.
Fourteen trans clusters were detected in multiple tissues, providing replication of the trans-
regulated signals and suggesting important co-regulation processes that are not restricted to a
single tissue. This observation is in keeping with a recent study, where a transcription factor
driven co-expression network found in multiple tissues was shown to be controlled by a single
locus on chromosome 15 in the rat [Heinig et al., 2010]. Here, a trans-eQTL cluster at the
same locus was identified in KID (kid15_106), LIVER (liver15_106) and LV (lv15_106), see
Appendix B, Table B.2. The identification of that same cluster in this analysis represents
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Figure 5.2: Number of transcripts significant by eQTL. The bars on the left represent the proportion of
cis- (black) and trans- (white) regulated transcripts at a 10% FDR level. ADR, FAT and KID were run using
Affymetrix 230 A and AORTA, LIVER, LV and SKM were run on Affymetrix 230 2, which accounts for the
differences in the total number of transcripts. The bars on the right show the distribution of PPI for the cis-
and trans-eQTLs in each tissue.
a positive control for the trans clustering as the clusters here were identified after deriving
the new set of eQTLs rather than being based on a co-expression network analysis as was
performed in Heinig et al. In addition, the authors showed that the co-regulation pattern was
due to a ‘master regulator’ gene (Ebi2 ) [Heinig et al., 2010], which resides at the trans cluster
locus. For this analysis, the proximal gene to each trans cluster locus (operatively defined as
genes within a 2 kb region around the SNP marker) was identified as the putative ‘master
regulator’ for the cluster. Out of the 138 unique trans cluster loci in the genome, 56 had a
gene within the 2 kb region and expanding the region to 20Kb resulted in an additional 20
putative ‘master regulators’.(Appendix B, Table B.3).
The enrichment for KEGG pathways and GO terms was calculated to determine the
functional relevance of all 160 trans clusters. Fifty-six clusters had significant functional en-
richment (FDR < 5%) for several KEGG pathways and GO terms, suggesting that sizeable
proportion of clusters (35%) can represent biologically relevant pathways and functional cat-
egories (Appendix B, Table B.4). Several of the clusters, in both tissues directly involved
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Figure 5.3: The graphs here represent the kernel density of the PPI for cis (green line) and trans (red line)
regulated transcripts which mapped to the genome at an FDR< 10%. Each panel represents a tissue with: (a)
ADR, (b) AORTA, (c) FAT, (d) KID, (e) LIVER, (f) LV, and (g) SKM.
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Figure 5.4: The distribution of trans cluster sizes. The number of genes in a trans cluster ranges from 10 to
322.
with BP regulation as well as secondary tissues, were of particular interest. The cluster
liver5_154_2 had the greatest functional enrichment, which was for ‘fatty acid metabolic
process’ (p = 1.38× 10−12) and ‘mitochondrion’ (p = 4.3× 10−08) well as several other fatty
acid metabolism terms (Appendix B, Table B.4). In addition, liver5_154_2 had a putative
‘master regulator’ residing at the locus. Lysophospholipase 2 (Lypla2 ) is involved in the
‘glycerophospholipid metabolism’ KEGG pathway in rat, mouse and human [Twigger et al.,
2007] and has been correlated with plasma HDL in humans [Ma et al., 2007]. Another cluster
of interest, aorta2_234, was enriched for terms and pathways important for cardiovascular
diseases such as the ‘actin filament-based process’ (p = 7.7×10−6) and ‘focal adhesion’ KEGG
pathways (p = 2.5×10−5), as well as for actual cardiovascular diseases pathways, such as ‘hy-
pertrophic cardiomyopathy’ (p = 1.7× 10−3) and ‘dilated cardiomyopathy’ (p = 2.2× 10−3).
The cluster also has a putative ‘master regulator’, Serine/threonine-protein phosphatase 2B
catalytic subunit alpha isoform (Ppp3ca). Ppp3ca is involved in cardiac and skeletal muscle
phenotypes including slow myosin heavy chain expression [He et al., 2010] and cardiac hyper-
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trophy [Bukowska et al., 2006] as well as modulating vascular endothelial growth factor [Wang
et al., 2008a]. Two proximal clusters in FAT, fat17_9 and fat17_16, were both enriched for
the KEGG pathway, ‘neuroactive ligand receptor interaction’ and are of particular interest
because they both co-localise with a physiological QTL for the spectral phenotype SPEC.
As an example, Figure 5.6 shows the ‘neuroactive ligand receptor interaction’ pathway from
KEGG and the genes which are in either fat17_9 or fat17_16 are highlighted with red stars.
The gene highlighted by the red box, histamine H2 receptor (Hrh2 ), is a cis regulated gene
which maps within the physiological QTL for SPEC and is also correlated with the SPEC
phenotype (i.e., a ‘3C’ gene).
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Figure 5.5: Trans clusters across tissues by chromosome (Mb). This gives the proportion of trans genes
across the genome for (a-g) ADR, FAT, KID, AORTA, LIVER LV and SKM. The trans clusters are indicated
by peaks in the graph and are distributed as: ADR - 12; AORTA - 32; FAT - 18; KID - 23; LIVER - 28; LV
- 19; SKM - 28. The clusters which replicate across tissues are named and those which have a human GWAS
gene at the locus are indicated with a star (Table 5.5 and Appendix B, Table B.2). The clusters indicated by
the red box is an example of one that replicates across tissues, and the cluster in the blue box has a putative
‘master regulator’.
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Figure 5.6: The KEGG pathway - ‘neuroactive ligand receptor interaction pathway’ where the genes high-
lighted with a star are those which are present in the two trans clusters in FAT and whose genetic mapping
co-localises with a physiological QTL for SPEC [Dennis Jr et al., 2003, Kanehisa, 2004]. The gene highlighted
in the red box is a cis regulated gene which co-localises with the QTL for SPEC and whose expression in FAT
is significantly correlated (FDR< 5%) with SPEC.
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5.3.3 QTT analysis
To further investigate the genes associated with the regulation of BP phenotypes in the rat,
a genome-wide correlation analysis was carried out between these traits and gene transcript
abundances in seven tissues (i.e., QTT analysis [Passador-Gurgel et al., 2007]). QTT analysis
is a powerful approach to prioritise complex traits genes (often cis-regulated) for transla-
tional studies, as previously shown [Morrissey et al., 2011, Petretto et al., 2008, Pravenec
et al., 2008a]. Figure 5.7 illustrates the number of transcripts associated with each phenotype
in each tissue. The percentage of transcripts within each tissue is given as well, for a better
comparison across the tissues assessed with two different arrays. Supplemental Table B.5
gives the distribution of genes (cis-regulated, trans-regulated and NE) that were significantly
associated by QTT analysis (FDR < 5%) with any BP phenotype across all tissues. Overall,
there were > 4 fold more NE transcripts associated with BP (ranging from 18.8 to 28.2%
of transcripts across tissues) than either cis (1.1-2.5%) or trans (2.2-6.5%) regulated tran-
scripts, suggesting that the transcripts which do not significantly map to the genome may
also contribute in regulating BP.
Figure 5.8 (a-g) illustrates the overlap in transcripts identified by QTT between the stan-
dard phenotypes and the spectral and wavelet phenotypes for each tissue. For each tissue,
there is a large proportion of the total number of transcripts measured (6.6% to 11.8%) which
were significantly associated with a wavelet or spectral phenotype and not a standard phe-
notype. This is a substantial subset of transcripts correlated with these spectral and wavelet
phenotypes which would have been missed if only the standard phenotypes has been used.
Figure 5.9 shows the proportion of transcripts associated with one or more of the physiological
phenotype clusters. Surprising, there is little overlap between the four physiological groups
(BP, HR, PP, W) across the tissues; at most, there are three transcripts which are shared
across the four phenotype groups. There is the occasional overlap, for example PP and HR
in LV and SKM with a ∼ 500 and ∼ 700 overlapping transcripts, but most of the transcripts
correlated with these phenotype groups were uniquely identified by the physiological group.
This suggests that the different features of BP variation have different genetic control points.
Finally, Figure 5.10 gives the proportions of cis regulated, trans regulated and NE tran-
scripts associated with the phenotype clusters (see Chapter 4.3) across the tissues. The
variations across the tissues for phenotypes and genetic regulation may inform on the rela-
tionship between BP and genetic determinants in tissues directly involved with BP regulation
as well as in secondary tissues. For cis regulated transcripts, there is an overall increase in the
number of transcripts correlated with the blood pressure cluster (BP) and WAVE phenotypes
as compared to the pulse pressure cluster (PP) and the heart rate cluster (HR). For trans and
NE transcripts, there is an increase in the number of transcripts correlated with PP in FAT
and for BP and WAVE in LIVER and, to some extent SKM. The increase for trans and NE
QTT transcripts in these secondary tissues suggests that there are downstream effects that
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Figure 5.7: The number of transcripts, separated by phenotype that were found significantly correlated,
FDR<5%, within each of the tissues. The percentage out of the total number of transcripts is given as well,
for a better comparison between the tissues run on the two different Affymetrix arrays.
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Figure 5.8: The Venn diagrams report the number of transcripts significantly correlated by the standard
phenotypes (DBP, HR, MBP, PDIST, PP, SBP) versus the spectral and wavelet phenotypes (FREQ, POWER,
SPEC, WAVE, WFREQ). Each panel represents a tissue with: (a) ADR, (b) AORTA, (c) FAT, (d) KID, (e)
LIVER, (f) LV, and (g) SKM. The percentages here are given with respect to the total number of transcripts
analysed to correct for the difference in the Affymetrix array sizes.
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Figure 5.9: The Venn diagrams here give the number of transcripts significantly correlated by the physio-
logical phenotype groups. BP = (DBP, MBP, SBP); HR=(FREQ, HR, PDIST, WFREQ); PP=(PP, SPEC,
POWER) and W = (WAVE). Each panel represents a tissue with: (a) ADR, (b) AORTA, (c) FAT, (d) KID,
(e) LIVER, (f) LV, and (g) SKM.
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would be missing by only considering cis regulated genes in tissues with primary regulation
for BP.
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(c) Phenotype groups NE
Figure 5.10: Represented here is the proportion of transcripts associated with a cluster of phenotypes by (a)
cis regulated transcripts (b) trans regulated transcripts (c) transcripts not under genetic control (NE). The
clusters of phenotypes were derived in Chapter 4.3 and correspond to physiological features: BP - (SBP, DBP,
MBP), PP - (PP, POWER, SPEC), HR - (HR, FREQ, WFREQ, PDIST), W - WAVE.
Amongst the QTT-associated genes (Appendix B, Tables B.6), there was a stronger func-
tional enrichment (FDR< 1%) and a higher number of KEGG pathways for the NE transcripts
as compared to cis- or trans regulated transcripts ( Appendix B, Table B.7 and Table B.8),
possibly indicating that NE transcripts can be involved with secondary pathways and bi-
ological processes for associated with BP. Some of highly enriched pathways found in NE
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transcripts include ‘ECM-receptor interaction’ (p = 3.3 × 10−06) and ‘Calcium signalling
pathway’ (p = 1.5× 10−05) which are relevant for cardiovascular function and disease.
5.3.4 Cis regulated, correlated and co-localised - ‘3C’ genes
By combining eQTLs, QTLs and QTT results, one can identify ‘3C’ genes which are cis reg-
ulated genes, correlated with a phenotype and have an eQTL co-localise with a QTL for that
same phenotype, see Figure 5.11. The relationship between the gene expression and the BP
phenotypes makes these genes strong functional candidates for their associated phenotypes.
Several functional variants have been identified in the rat from this approach, including Cd36
as determinant of BP regulation [Pravenec et al., 2008a] and Ogn as a determinant of left
ventricular mass [Petretto et al., 2008].
SNPs
Gene
Expression
eQTL
BP
QTL
QTT
Figure 5.11: ‘3C’ genes are those with expression traits that are cis regulated, co-localised with a physiological
QTL and are significantly correlated with the physiological trait. The expression traits are mapped to the
genome via eQTL analysis and correlated with the physiological traits via QTT analysis. The physiological
trait is mapped to the genome via QTL analysis.
Across the phenotypes and tissues here, there were 138 genes which were ‘3C’ genes ,see
Appendix B, Table B.9. Across the tissues, there breakdown of ‘3C’ genes is as follows: ADR
- 21; AORTA - 33; FAT - 19; KID - 21; LIVER - 51; LV - 35; SKM - 57. Each of the
seven BP and HR phenotypes with QTLs had a ‘3C’ gene associated with it. Several of these
genes identified here, including angiotensin II receptor, type 1b (Agtr1b) and adducin-gamma
(Add3 ) are known hypertension genes in both humans and rats [Lanzani et al., 2005, Obata
et al., 2000, Bonnardeaux et al., 1994, Wang et al., 2008b]. The identification of these known
hypertension genes acts as a positive control for the approaches and suggests that the BP
associated genes identified in the rat may be conserved with human hypertension. In addition,
46 out of the 138 ‘3C’ genes contained non-synonymous SNPs between the spontaneously
hypertensive rat (SHR) and the Brown Norway (BN) in the coding regions of the genes with
Add3 amongst those 46 genes (SNP data provided by Santosh Atanur, MRC Clinical Science
Centre, Imperial College London). The presence of a SNP within the coding region of a ‘3C’
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gene provides evidence that the gene harbours a functional variant affecting gene expression
and phenotypic levels. While cis eQTLs suggest that the gene expression levels are under the
regulation of the gene itself, there are instances where the gene may be under trans regulation
by a variant located within the defined cis region. The variant could reside in a long range
promoter or enhancer for the particular gene, rather than the gene itself. The presence of the
SNP within each of these 46 genes indicates that it is not a variant in a promoter or enhancer,
but a variant in the gene itself that is causing the differences in expression levels.
5.3.5 Enrichment of BP associated rat genes in human GWAS genes
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Figure 5.12: Human genes associated with hypertension (4,145) were collected from fifteen publicly available
GWAS which resulted in a subset (2,292) of rat orthologs. The enrichment for several subsets of rat genes
associated BP within these genes associated with human hypertension was calculated, providing information
on the genetic regulation of BP and hypertension across species.
Several studies have successfully translated single QTT-associated genes identified in the
rat to humans [Petretto et al., 2008, Pravenec et al., 2008a]; here, an unbiased and systematic
analysis has been carried out on all transcripts analysed in the context of human GWAS of
BP and hypertension (Appendix B, Table B.10). Rat cis and trans regulated genes as well
as NE genes were compared with human GWAS results to identify subsets of rat genes which
were enriched for human GWAS results. Adopting the relaxed statistical threshold (genome-
wide P < 0.001) utilised by Johnson and O’Donnell [Johnson and O’Donnell, 2009], a large
set of human genes (n=4,145) associated with hypertension was identified along with the rat
orthologs (n=2,292) (Appendix B, Tables B.10 and B.11). While these variants may not reach
genome-wide significance in a GWAS study, they may inform on the secondary regulation of
hypertension and represent networks which contain genes with small effect sizes.
The relationship between these 2,292 genes and human disease was explored by looking
for an enrichment in OMIM disease terms. The enrichment analysis shows that, as expected,
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the list is enriched for the ‘Framingham Heart Study 100K Project’ (p = 5.9 × 10−11). This
also indicates that, even though these genes were identified with a relaxed threshold, they
are still relevant for heart disease. Interestingly, though, the other enriched OMIM disease
term was ‘Meta-analysis of genome-wide association data and large-scale replication identifies
additional susceptibility loci for type 2 diabetes’ (p = 6.3 × 10−5). This highlights the close
relationship between hypertension and other metabolic syndrome traits.
Out of the 2,292 rat genes that were orthologous to human GWAS genes (Appendix B,
Table B.11), 795 (35%) were associated with one or more BP phenotypes in the rat by QTT
analysis (FDR < 5%) (Appendix B, Table B.12). Comparing the 795 genes with the 34 human
GWAS genes which reached genome-wide significance (see Table 1.1) reveals that 16 of them
have a rat ortholog that shows association with at least one BP phenotype. This equates to
approximately 47% of the GWAS results which reached genome wide significance were also
identified in the rat. Table 5.3 shows the 16 human and rat genes.
Rat Gene Symbol Human Gene Symbol Rat Ensembl Gene ID Human Ensembl Gene ID
RGD1306739 C10orf107 ENSRNOG00000000634 ENSG00000183346
F1LXI6_RAT ATXN2 ENSRNOG00000001256 ENSG00000204842
Plcd3 PLCD3 ENSRNOG00000003033 ENSG00000161714
Acbd4 ACBD4 ENSRNOG00000003108 ENSG00000181513
D3ZNJ3_RAT ADAMTS8 ENSRNOG00000005574 ENSG00000134917
Clcn6 CLCN6 ENSRNOG00000008345 ENSG00000011021
Slc39a8 SLC39A8 ENSRNOG00000012508 ENSG00000138821
Mecom MECOM ENSRNOG00000012645 ENSG00000085276
Mov10 MOV10 ENSRNOG00000012946 ENSG00000155363
Plce1 PLCE1 ENSRNOG00000014276 ENSG00000138193
Hfe HFE ENSRNOG00000016967 ENSG00000010704
Znf652 ZNF652 ENSRNOG00000017001 ENSG00000198740
Cacnb2 CACNB2 ENSRNOG00000018378 ENSG00000165995
Cyp17a1 CYP17A1 ENSRNOG00000020035 ENSG00000148795
Map4 MAP4 ENSRNOG00000020748 ENSG00000047849
D4ABY6_RAT SH2B3 ENSRNOG00000028198 ENSG00000111252
Table 5.3: The 16 genes which reached genome-wide significance in a human GWAS study and were correlated
with one or more BP phenotypes in the rat.
A fraction of these QTT-associated genes may represent primary candidates for hyper-
tension that are conserved across species and are cis regulated in the rat, while others may
be informative of trans-effects of susceptibility variants on downstream genes (i.e., trans-
eQTLs and NE transcripts). In contrast with NE transcripts, rat cis and trans genes were
significantly over-represented in human GWAS results, irrespective of whether they were sig-
nificantly associated with BP traits in the rat by QTT analysis (Table 5.4). Trans regulated
genes alone were significantly over-represented (13.6%, p = 0.021) in the human GWAS results
as well as cis regulated genes (14.4%, p = 0.018), suggesting that both primary cis-regulation
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and trans-regulation of rat genes’ expression are relevant to significant association signals in
humans. Surprisingly, given that the eQTLs were significantly enriched, the ‘3C’ genes were
not; ‘3C’ genes are considered to be strong functional candidates. Although all trans clusters
were not significantly over-represented in human GWAS (Table 5.4), twenty-two individual
clusters showed significant over-representation (Appendix B, Table B.2) and four of those
contained more than 50% genes associated with BP by QTT.
Category All QTT
NE 405 (10.8%; p = 1) 289 (10.7%; p = 1)
eQTLs 1314 (13.4%; p = 0.016) 506 (14.2%; p = 0.017)
genes regulated in cis 354 (14.4%; p = 0.018) 129 (14.4%; p = 0.12)
genes regulated in trans 1128 (13.6%; p = 0.021) 406 (14.2%; p=0.017)
clusters of genes regulated in trans 419 (13.2%; p = 0.37) 176 (13.4%; p = 0.36)
3C genes - 12 ( 8.7%; p = 0.93)
genes underlying trans-eQTL clusters 16 (28.6%; p = 5× 10−4) –
Table 5.4: Enrichment of rat genes in human GWAS results: Each group of rat genes tested is listed with the
number of genes found in common, the percentage of the common genes out of those tested in the group and
the p-value. Each group was tested with all genes and then a subset of those which were found significantly
correlated with a physiological phenotype by QTT. Empirical p-values calculated by > 10, 000 permutation
tests
The most significant over-representation was observed for genes underlying the trans clus-
ter loci (∼ 29%, p = 5 × 10−4), within a 2 Kb range. These 16 genes might represent the
putative ‘master regulators’ for the trans clusters in the rat and were previously associated
with BP or hypertension in humans by GWAS (Table 5.5). The expanded list of putative
‘master regulators’ (i.e., those present within a 20 Kb region) were also significantly enriched
for human GWAS genes with 19 genes ( 25% ; p = 0.0014). This suggests that the enrichment
for these ‘master regulators’ is not an artefact of the conservative 2Kb region size. Several
of these putative ’master regulators’ and their associated clusters have previously identified
associations with cardiovascular traits or diseases. Ppp3ca, is one of these ‘master regula-
tors’ and is involved in calcium signalling and Wnt signalling as well being associated with
hypertrophy in both mice, rats and humans [Twigger et al., 2007, Blake et al., 2011]. It
resides at the locus for the aorta2_234 cluster where the trans cluster itself is enriched for
cardiovascular pathways and diseases.
Rat genes Bcat1 and D3ZCG8_RAT underlie trans clusters (skm4_182 and skm7_90,
respectively) which in turn exhibited over-representation for human GWAS signals (p <
0.05), suggesting that both trans clusters and their putative ‘master regulator’ play a role
in human hypertension, either as primary or secondary genetic determinants. Table 5.6 lists
the two clusters, skm4_182 and skm7_90 which have master regulators and were enriched
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for human GWAS themselves. Bcat1 is also a cis regulated gene that is involved in resting
heart rate [Eijgelsheim et al., 2010] and salt sensitivity [Rhee et al., 2011] in humans, further
strengthening its position as a putative ‘master regulator’.
Rat Gene Human Gene Cluster
Bcat1 BCAT1 skm4_182
Svs5, Sec31a, Aldh3a2, Fstl1∗, Ninj1, Gdi2
Keg1∗, Cmbl, Trim41, D4A301_RAT, RGD1559896
Mlf1∗, Faim3, A2bp1, Fn3k, Med13, Ctps2
Tyr∗, Ahnak2, Anxa5∗, PHLB1_RAT, Loxl1
D3ZCG8_RAT SAMD12 skm7_90
Stk10, Mrpl36, Kcnip3, F1MAG5_RAT, Rnf138∗
D3ZIM0_RAT, D4A914_RAT∗, Lrrc8c, Fgd2∗, Zc3h3
Table 5.6: Clusters with putative ‘master regulators’ which are also themselves enriched for human GWAS
genes. The genes indicated with a ∗ are those which have human orthologs associated with hypertension.
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5.4 Discussion
To disentangle the complex genetic determinants underlying BP variation and hypertension,
an ‘integrative genomics’ approach was taken to address some of the limitations in current
genetic and genomic studies of hypertension. Novel BP indices were integrated with genome-
wide gene expression to inform on cis and trans regulatory mechanisms affecting hypertension
and BP regulation. Utilising gene expression from seven tissues in the BXH/HXB rat RI
panel, a new set of ∼ 27,000 of eQTLs was derived using a sparse Bayesian regression method.
This set included transcripts located in tissues which directly regulated BP at either a local
or global level, as well as tissues secondary to BP regulation. Hypertension is classified as a
metabolic syndrome trait along with obesity and lipid disorders [Grundy et al., 2004], and,
while the secondary tissues do not directly regulate BP, they are primary tissues for other
metabolic syndrome traits [Jornayvaz et al., 2010, Watanabe et al., 2008, Després et al.,
2008] and may be responsive to changes in BP. The BP phenotypes derived from time series
blood pressure measurements were correlated with the eQTLs (both cis and trans), as well as
the transcripts which were not under genetic control, to inform on the relationship between
gene expression and physiological phenotypes. BP phenotypes were mapped to the genome,
resulting in six loci associated with BP, including a novel locus on chromosome 14. There
were two out of the six distinct loci (chromosome 2 and chromosome 17) which were found
uniquely by spectral and wavelet methods, and the wavelet and spectral phenotypes were
significantly correlated with a large proportion of transcripts which were not correlated to
any of the standard phenotypes. These novel phenotypes capture different aspects of BP
variation which is then reflected in the additional QTLs and large proportion of transcripts
uniquely identified by these phenotypes. Results from QTL mapping, eQTL mapping and
QTT analysis were combined to create several subsets of genes associated with BP variation
in the rat. These subsets were then tested for an enrichment in human GWAS results to
examine the extent to which BP associated genes in the rat were conserved in humans. The
enrichment in human GWAS genes can identify specific genes associated with hypertension
in both rats and humans, as well as inform on the general regulatory mechanisms relating to
disease which are conserved across species.
Cis regulated genes, especially the ‘3C’ genes, can be considered as primary genetic de-
terminants [Morrissey et al., 2011], while trans regulated genes may inform on the functional
downstream effects of disease [Gilad et al., 2008]. Cis regulated genes have previously been
identified as genetic determinants for disease traits in both rats and humans [Morrissey et al.,
2011, Petretto et al., 2008, Pravenec et al., 2008a]. By integrating the eQTL and QTL re-
sults, ‘3C’ genes were identified as those whose gene expression was cis regulated, correlated
with a BP phenotype and whose location co-localised with that of the same BP phenotype
(Appendix , Table B.9). Out of the BP phenotypes, the strongest QTL was for the wavelet
phenotype, WAVE, on chromosome 2. WAVE was correlated with as well as co-localised with
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the expression from a cis regulated gene, angiotensin II receptor, type 1b (Agtr1b). Agtr1b is a
known hypertension gene in both rats and humans as it plays a role in the renin-angiotensin
system [Twigger et al., 2007, Obata et al., 2000, Bonnardeaux et al., 1994, Wang et al.,
2008b]. Adducin-gamma (Add3 ) is another previously known hypertension gene identified in
this analysis as a ‘3C’ gene [Lanzani et al., 2005]. Its expression in LV correlates with SBP
and co-localised with the SBP QTL on chromosome 1, making it a strong candidate gene for
the regulation of SBP. Both Agtr1b and Add3 contain non-synonymous SNPs within their
coding regions, which indicates that they could be functional variants. Surprisingly, despite
the previous studies which focused on cis regulated candidate genes in rats and humans, both
the ‘3C’ genes as well as cis regulated genes as a whole, did not show the same levels of
enrichment for human GWAS genes as did the trans genes (see Table 5.4). The enrichment
for the ‘3C’ genes was not even suggestive (p = 0.93) and only 12 ‘3C’ genes had human
orthologs associated with hypertension GWAS results. As known hypertension genes have
been identified by this analysis (for example, both Agtr1b and Add3 ), it does not appear that
this lack of enrichment for human hypertension genes is a failure of the method, but suggests
that cis regulated genes may not be the genetic regulatory mechanism which is conserved
across species.
While the effects of trans regulated genes and trans clusters are not as well understood
due to their weaker genetic signal [Gilad et al., 2008], there have been studies in several
organisms [Yvert et al., 2003, Ruden et al., 2009, Wu et al., 2008], including rat and humans
[Hubner et al., 2005, Petretto et al., 2006a, Morley et al., 2004, Dixon et al., 2007], which
have identified trans clusters and their putative ‘master regulators’. Due to the strength of
the SBR method, there is a large number (2,589) of trans regulated transcripts which are
associated with the BP phenotypes across the tissues. Here, 160 trans clusters were identified
across the seven tissues, where a cluster was defined to be a group of ten or more genes whose
expression maps to the same locus. These trans regulated genes may represent underlying
and secondary pathways related to hypertension and the functional enrichment showed that
several trans clusters were enriched for pathways and terms relevant to cardiovascular diseases
and metabolic syndrome (see Appendix B, Table B.4).
Intriguingly, the trans regulated genes were significantly enriched for human hypertension
genes as both a whole (p = 0.021) and as the subset associated with BP in the rat (p = 0.017).
This suggests that these trans regulatory mechanisms may be conserved across species and
is surprising given that the cis regulated genes had minimal significant enrichment in human
hypertension genes. While the trans cluster genes together were not significantly enriched
for human hypertension genes, individual clusters, both in tissues directly involved with BP
regulation and secondary tissues, showed significant enrichment.
The defined regions designating cis and trans may have an effect on the individual enrich-
ment of cis and trans eQTL genes. In line with previous work, cis eQTLs were defined to be
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those which mapped to within 10 Mb either side of the probe location. The 10Mb region was
originally chosen to be inclusive for cis eQTLs. The average identical-by-descent region in the
RI panel is ∼ 5− 6 Mb, so the 10 Mb region slightly biases the analysis towards detecting cis
eQTL [Hubner et al., 2005]. In other genetic models, however, different distances have been
used, from 10 Kb [Cookson et al., 2009] to 20 Mb [Derry et al., 2010]. Expanding or reducing
the defined cis region would not change the total number of eQTLs, but would change the
proportion of cis and trans eQTLs. The eQTLs which map to different chromosomes would
remain trans, but the eQTLs that map to the same chromosome could be either cis or trans
depending on the defined region. The shift in the number of cis and trans eQTLs could cause
the enrichment for human GWAS to shift as well. However, the subset of genes showing
the strongest enrichment (p = 5× 10−4) was the putative ‘master regulators’ underlying the
trans clusters. These putative ‘master regulators’ would not be affected by the shift in cis
and trans eQTLs; the number of genes within a trans cluster may change, but the clusters
would still remain. The strong enrichment for these ‘master regulators’ indicates the impor-
tance of potential upstream regulators of trans clusters with respect to hypertension and BP
regulation.
Perhaps the most interesting of the putative ‘master regulators’ is serine/threonine-protein
phosphatase 2B catalytic subunit alpha isoform (Ppp3ca) which underlies the aorta2_234
trans cluster in AORTA. Ppp3ca is protein coding gene which expresses a Ca2+/CaM-
dependent protein phosphotase and is the catalytic subunit of calcineurin [Twigger et al.,
2007]. Calcineurin is a calcium dependent phosphotase which mediates several transcription
factors, including NFAT and regulates ion channels as well as T-cell activation [Rinne et al.,
2009, Twigger et al., 2007]. As mentioned previously Ppp3ca is involved in several pathways
relevant for cardiovascular disease and associated with myosin heavy chain expression [He
et al., 2010] and cardiac hypertrophy [Bukowska et al., 2006]. The trans cluster aorta2_234
was enriched for KEGG and GO terms relating to the cytoskeleton and extracellular matrix
as well as dilated and hypertrophic cardiomyopathy (see Appendix B, Table B.4).
To further support the implications of Ppp3ca on hypertrophy and cardiomyopathy, there
is a transgenic mouse (Tg(Myh6-Ppp3ca)37Eno/J) for which the expression for Ppp3ca is
controlled by the cardiomyocyte-specific alpha myosin heavy chain (alpha MHC) promoter
[Blake et al., 2011, Molkentin et al., 1998]. An insertion in the myosin heavy chain promoter
causes a disruption in the expression of Ppp3ca in cardiomyocites. These transgenic mice
develop cardiac hypertrophy which then progresses to dilated cardiomyopathy. This disease
progression in the transgenic mice follows the potential genetic regulation in the rat where
Ppp3ca is associated with hypertrophy and aorta2_234 is enriched for the ‘dilated cardiomy-
opathy’ KEGG pathway. The strongest functional enrichment of aorta2_234, though, was
for GO term ‘actin filament-based process’ (p = 7.68× 10−06) and several others relating to
structural elements such as the extracellular matrix and cytoskeleton. Until recently, Ppp3ca
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and calcineurin were thought only to regulated an immune response through T-cell activation,
but recent work suggests that there is a second mechanism by which Ppp3ca and calcineurin
regulate actin binding and cytoskeletal proteins [Descazeaud et al., 2012]. The cellular re-
modelling seen in cardiac hypertrophy and cardiomyopathy could be caused by the effects of
Ppp3ca and calcineurin on this trans cluster, aorta2_234.
The presence of PPP3CA in the human GWAS results also suggests that the gene plays
a role in human hypertension. Calcineurin has been shown to affect hypertension as well
as hyperkalemia, hypercalciuria and acidosis [Hoorn et al., 2011, Descazeaud et al., 2012].
Calcineurin inhibitors have frequently been used to suppress the immune response of organ
transplant patients, especially those who have undergone kidney transplants, and those pa-
tients commonly develop hypertension as a results of the inhibitors [Descazeaud et al., 2012].
Hoorn et al. have recently shown that the increase in hypertension in post-transplant patients
taking calcineurin inhibitors can be attributed to an activation of the renal sodium chloride
cotransporter in both mice and humans [Hoorn et al., 2011]. The effects of Ppp3ca and cal-
cineurin on cardiovascular diseases is complex and tissue specific with the under expression in
cardiomyocites and AORTA causing hypertrophy leading to dilated cardiomyopathy and the
inhibition in kidney causing hypertension. The presence of the transgenic mouse, the results
presented here in the rat and the identification of PPP3CA as a human hypertension gene
indicates that the conservation between species of this disease pathway may not be limited to
mice and rats, but may extend to humans as well. Further work in humans would be needed
to determine if a trans cluster co-localised with PPP3CA and to validate the influence of
PPP3CA and a potential trans cluster on hypertrophy and cardiomyopathy.
Four other of the putative ‘master regulators’ were associated with cardiovascular disease
or metabolic syndrome traits. As stated previously (Chapter 5.3.5), branched chain amino-
acid transaminase 1, cytosolic, (Bcat1 ) has been shown to be associated with cardiovascular
traits, including resting heart rate [Eijgelsheim et al., 2010] and salt sensitivity [Rhee et al.,
2011] in humans. Here, Bcat1 underlies a cluster which also has significant over-representation
(p = 0.02) in human GWAS. Five out of twenty-five genes in the skm4_182 cluster (Fstl1,
Mlf1, A2bp1, Tyr and Anxa5 ), have also been associated with human hypertension. In the
rat, Bcat1 was under cis regulation in SKM and its gene expression was correlated with MBP
and SBP. Dihydropyrimidinase-like 5 (Dpysl5 ) was another cis regulated putative ‘master’
regulator. DPYSL5 has been associated with fasting glucose levels in a human GWAS [Man-
ning et al., 2012] and is in the axon guidance KEGG pathway in both the rat and human.
The trans-cluster that Dpysl5 underlies, aorta6_25, has an over-representation (p = 0.03)
for human GWAS genes. Platelet derived growth factor C (Pdgfc) has been linked to car-
diovascular disease as well as cancer. PDGFC activates matrix metalloproteinase 2 (MMP2)
and 9 (MMP9) which are important factors in the development of atherosclerosis . Elevated
levels of PDGFC were also detected in relation to chronic myocarditis and fibrosis, which
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can progress on to dilated cardiomyopathy [Grün et al., 2005]. Cytochrome P450, family 24,
subfamily A, polypeptide 1 (Cyp24A1 ) is a vitamin D gene which has been associated with
the calcification of coronary arteries in humans [Shen et al., 2010]. Vitamin D deficiency has
been linked to hypertension [Pilz et al., 2009] and it has been suggested that vitamin D may
play a protective role on the vasculature, reducing arterial calcification and arterial stiffness .
Vitamin D has also been associated with insulin resistance and type II diabetes [Sung et al.,
2012, Yilmaz et al., 2012]. In addition, Cyp24A1 is involved in skeletal muscle development
in both humans and rats, according to GO terms, and vitamin D deficiency is a causal factor
in several skeletal disorders, including rickets [Holick, 2007].
Two other putative ‘master regulators’ show an association with skeletal disorders, Trps1
and Large. Mutations in Tricho-rhino-phalangeal syndrome type I (TRPS1 ) are known to
cause trichorhinophalangeal syndrome type II, an autosomal dominant genetic disorder in
humans which includes skeletal malformations [Michikami et al., 2012]. Here, Trps1 underlies
a trans cluster in SKM and its gene expression was correlated with MBP and DBP. Likewise,
mutations in LARGE are known to cause a form of congenital muscular dystrophy which is
accompanied by mental retardation [Longman et al., 2003]. In addition, in the rat, Large, is
linked to the GO term ‘muscle maintenance’.
Interestingly, several of the putative ‘master regulators’ have been shown to be asso-
ciated with mental disorders. Membrane associated guanylate kinase, WW and PDZ do-
main containing 2 (MAGI2 ), has an associated risk, in humans, for cognitive impairment in
schizophrenic patients [Koide et al., 2012]. Here, in both rats and humans Magi2 is linked to
GO terms related to ‘intracellular signalling cascade’ and ‘tight junction’. Magi2 underlies a
trans cluster which is enriched for the GO term ‘immune response’ (p = 4.4× 10−5). A locus
containing Odz, odd Oz/ten-m homolog 4 (Drosophila) (ODZ4 ) has recently been associ-
ated with bipolar disorder in a human GWAS study [Psychiatric GWAS Consortium Bipolar
Disorder Working Group, 2011]. Opioid binding protein/cell adhesion molecule-like OPCML
is resides in a schizophrenia risk locus in humans [Panichareon et al., 2012]. Additionally,
OPCML is a known tumour suppressor gene linked to epithelial ovarian cancer [McKie et al.,
2012].
Two other of these ‘master regulators’ show an association to disease traits and three
are relatively uncharacterised. Disks large homolog 2 DLG2, in humans, has been linked to
Parkinson’s disease [Fung et al., 2006] and, in the rat, the cluster it underlies is enriched
for mitochondrial proteins. Mitochondrial disfunction has been implicated in pathogenesis
of Parkinson’s disease [Exner et al., 2012] and the combination of Dgl2 with the enrichment
of the trans cluster may indicate a functional role of DLG2 in mitochondria disfunction
associated with Parkinson’s disease. Mutations in myosin IIIA (MYO3A) are know to cause
an autosomal recessive form of deafness [Walsh et al., 2002]. The disorder results from a
disruption in the neural receptors in the ear and brain. D3ZCG8_RAT/Samd12, Fam190A
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and Vit are the three genes with little information about potential disease pathogenesis.
The genes linked to cardiovascular and metabolic traits, Bcat1, Dypsl5, Cyp24A1 and
Ppp3ca suggest that these putative ‘master regulators’ and the trans clusters they were as-
sociated with do play a role in the pathogenesis of cardiovascular disease and hypertension.
Whether or not they are causal or reactive is indeterminable here, but these putative ‘master
regulators’ and their corresponding trans clusters could be used as initial starting points for
further functional studies . The relationship between the other putative ‘master regulators’
and hypertension is unclear. It may be that these genes, while associated with human hy-
pertension GWAS hits, play a role in shared disease pathways. These results may be false
positives due to the relaxed GWAS threshold, but, the high percentage (81%) of the puta-
tive master regulators with disease associations indicates that these regulators and associated
trans clusters are functionally important.
In accordance with recently published work in humans [Nicolae et al., 2010], significant
over-representation was detected for the cis and trans regulated transcripts together versus
NE transcripts in both groups despite the fact there was a > 4 fold more NE transcripts
associated with BP phenotypes. However, while the NE are not significantly enriched for
human hypertension genes, there are ∼ 300 NE genes which are significantly (FDR< 5%)
correlated with a BP phenotype and have a human ortholog associated with hypertension.
Combining the ∼ 300 NE genes with the cis and trans regulated genes results in a list of 795
genes which show an association with BP regulation in the rat and hypertension in humans.
Many of these genes (trans regulated and NE) have small genetic effect sizes and thus, would
not be identified by an association or linkage study. These genes missed by GWAS and
linkage studies may contribute to the ‘missing heritability’ of hypertension and even metabolic
syndrome traits in general. Several of these genes reached genome-wide significance. Out of
the 34 genes listed in Table 1.1 in Chapter 1, 16 had rat orthologs which were correlated with
BP. Only four of the 16 genes were cis-eQTLs in any tissue whereas the other 11 were either
trans-eQTLs or NE transcripts, indicating, at least in the rat, that these hypertension genes
are of smaller effect sizes.
In addition to informing on the genetic regulation of hypertension and BP variation in
rats and humans, much of the work presented here can be used to inform on other complex
diseases and traits, especially metabolic syndrome. The large dataset of human hypertension
GWAS genes (2,292) which are conserved in rat are informative not only on hypertension,
but other metabolic diseases traits as well. A functional enrichment of those human genes
within diseases shows that, as expected, the strongest enrichment is for the Framingham Heart
study(p = 5.9 × 10−11), but the other significant enrichment for this set of genes is for type
2 diabetes mellitus (p = 6.3 × 10−5). This further highlights the interconnectedness of the
metabolic syndrome traits in humans. Within the rat, there are two clusters in FAT, fat17_9
and fat17_16, which were significantly enriched for ‘neuroactive ligand receptor interaction’
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(p = 2.39 × 10−03 and p = 3.93 × 10−05) and contain a high percentage of genes associated
with BP phenotypes (75.9% and 65.5%, respectively). These two clusters also co-localised
with the QTL for SPEC and are enriched for ‘neuroactive ligand receptor interaction’ in FAT.
While there was also a significant enrichment in NE transcripts associated with BP, the NE
transcripts actually may be under trans regulation, but do not have strong enough signals
to genome-wide significance. Finally, there is a cis regulated gene, histamine receptor H2
(Hrh2 ) which lies at the locus for both the trans clusters and the QTL. Hrh2 can be consid-
ered as a putative ‘master regulator’ for the trans clusters and could be underlying the SPEC
QTL; this is further strengthened by Hrh2 ’s presence in the ‘neuroactive ligand receptor in-
teraction’ pathway in the rat, mouse and human [Twigger et al., 2007] (see Figure 5.6 for
the ‘neuroactive ligand receptor interaction pathway in the rat, with the trans cluster genes
highlighted). Hrh2 encodes for a protein which exhibits g-protein coupled histamine receptor
activity and is also present in the ‘calcium signalling’ KEGG pathway. While the direct func-
tional implications of the ‘neuroactive ligand receptor interaction’ pathway on hypertension
and metabolic syndrome may not be clearly understood, the pathway has been associated
with metabolic syndrome traits in several studies [Das and Rao, 2007, Wang et al., 2009, El-
bers et al., 2009]. The high percentage of genes within these two trans clusters which are
associated with BP phenotypes in the rat suggest that these metabolic syndrome traits in sec-
ondary tissues may play a role in hypertension and that incorporating these secondary tissues
into further hypertension studies may aid in identifying regulatory mechanisms associated
with BP regulation.
These results highlight the complexities dictating the genetic regulation hypertension,
where multiple genes and pathways affecting blood pressure regulation. These networks and
pathways consisting of small effect genes may account for the missing heritability and genetic
control in candidate gene and GWAS studies. The enrichment for functional pathways and
trans clusters in tissues not directly involved in the regulation of BP suggests the influence
of other metabolic syndrome traits in these tissues may have an effect on BP regulation
and hypertension. As shown above, these effects found in the rat genetic system can be
translated to conserved variants within humans and may inform on the regulation of human
hypertension. This integrated approach has identified a large number of genes associated
with BP in the rat and a subset of those which have an association with hypertension in
humans. Several trans clusters and their putative ‘master regulators’, in particular Ppp3ca
and its associated trans cluster, are of interest for further studies. In addition, this study has
provided a resource for eQTLs in the rat as well as a set of QTT genes associated with BP
and hypertension.
Chapter 6
Discussion
The overall aim of the work presented here was to dissect the underlying genetic complexities
of hypertension using a rat model and to relate the findings in the rat back to humans. This
was achieved by addressing some of the limitations in current hypertension studies by way
of new genetic mapping techniques, novel blood pressure (BP) phenotypes and an integrated
analysis using primary and secondary tissues related to blood pressure regulation in rat. By
using a rat model of hypertension, I was able to take advantage of a data set composed
of gene expression from multiple tissues as well as high density time series blood pressure
measurements, that would not be available in humans. I have used human genome-wide
association studies (GWAS) data to then investigate the extent to which the genes associated
with accurate and informative BP in the rat correspond to those associated with BP and
hypertension in humans.
To identify expression quantitative trait loci (eQTL) and employ optimal approaches to
this aim, I performed a comparative analysis of eQTL mapping methods in Chapter 3, using
a subset of gene expression from the BXH/HXB recombinant inbred panel. I compared
both single and multiple response eQTL mapping methods to determine the best approach
for further multi-tissue, genome-wide analyses of eQTLs. In terms of both identifying trans
eQTLs and polygenic control of gene expression, the sparse Bayesian regression methods
(SBR and SBMR) outperformed the other methods. The comparison was published in part
in Petretto et al. and further work was done to optimise a C++ implementation in Bottolo
et al. [Petretto et al., 2010, Bottolo et al., 2011a].
In Chapter 4, I discussed the need for accurate BP phenotyping. Current genetic studies,
in both humans and rat models, use either a case/control classification or quantitative single
BP measurements [Pickering et al., 2005, Kurtz et al., 2005]. To improve upon these methods,
I employed spectral and wavelet techniques to extract phenotypes which capture features of
the dynamic aspects of BP from time series BP data in the BXH/HXB RI panel, and derived
seven standard phenotypes, three spectral phenotypes and two wavelet phenotypes. Each of
the phenotypes shows continuous variation throughout the BXH/HXB strains and exhibits
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differences between the parental strains, the spontaneously hypertensive rat (SHR) and Brown
Norway (BN). I clustered the phenotypes using a Gaussian graphical model (GGM) and found
that the phenotypes grouped by physiological means, with a cluster relating to blood pressure,
one relating to pulse pressure, one relating to heart rate and a wavelet phenotype on its own.
Chapter 5 presents an integrated systems-wide analysis where I combined the phenotypes
derived in Chapter 4 with a new set of genome-wide eQTLs mapped in seven tissues. By
utilising the increased power of the SBR methodology to detect smaller genetic effects, I
identified a set of approximately 27,000 cis and trans eQTLs across the seven tissues. Using
this large eQTL dataset I correlated each category of eQTL (cis, trans and non-eQTLs (NE))
in all of the tissues with each of the BP phenotypes. This resulted in a set of genes associated
with BP variation across tissues. In addition, I mapped the BP phenotypes to the genome
and investigated the co-localisation of cis regulated transcripts and clusters of trans regulated
transcripts with the BP quantitative trait loci. I performed functional enrichment analysis
on eQTL and NE genes as well as for each individual trans cluster to look for significant
enrichment in KEGG pathways and GO terms relevant to BP and hypertension. To translate
these findings from the BXH/HXB RI panel to human studies, I focused on the relationship
between the genes associated with BP in the rat and the genes associated with BP and
hypertension in humans. To examine this relationship, I looked for an enrichment of the rat
BP associated genes within a set of genes taken from publicly available GWAS results. I used
and expanded upon a database of human GWAS results published by Johnson and O’Donnell
[Johnson and O’Donnell, 2009] resulting in a list of genes from fifteen studies [Wellcome
Trust Case Control Consortium, 2007, Kato et al., 2008, Diabetes Genetics Initiative of
Broad Institute of Harvard and MIT et al., 2007, Newton-Cheh et al., 2009, Levy et al.,
2009, Adeyemo et al., 2009, Fox et al., 2011, Org et al., 2009, Cho et al., 2009, Lettre
et al., 2011, Padmanabhan et al., 2010, Sabatti et al., 2009, Hong et al., 2010, International
Consortium for Blood Pressure Genome-Wide Association Studies et al., 2011, Wain et al.,
2011]. I used a hypergeometric test to determine where a subset of rat genes associated
with hypertension was more likely to be found in common with human GWAS genes than
by chance. There was a higher extent of enrichment for genes under genetic control (cis
regulated and trans regulated) than NE genes. The greatest enrichment, though, comes from
the putative ‘master regulators’ which underlie the trans clusters where 29% of the genes
identified in the rat were also associated with hypertension in humans.
By taking an integrated, systems-wide approach, I identified candidate genes and pathways
associated with hypertension in the rat. The large set of eQTLs identified across the tissues
allowed for both cis and trans regulatory mechanisms associated with hypertension to be
elucidated. While the relationship between cis regulated genes and disease pathologies has
been extensively studied [Morrissey et al., 2011], the relationship between the trans regulated
genes and disease states is not as well characterised. Several cis regulated genes which affect
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cardiovascular traits have previously been shown to be conserved in humans [Pravenec et al.,
2008a, Petretto et al., 2008, McDermott-Roe et al., 2011], but the trans regulatory effects
conserved across species have been harder to elucidate due to their small effect sizes. In this
study, by taking advantage of new genetic mapping techniques and novel BP phenotypes,
I identified several trans regulated genes associated with BP variation in the rat which are
conserved in humans. I looked for enrichment of several subsets of BP associated genes in
the rat within human GWAS results and, surprisingly, found that it was the putative ‘master
regulators’ underlying trans clusters which showed the greatest enrichment (p = 5 × 10−4,
Table 5.4). As expected, genes which were not under genetic control in the rat (NE) did not
show significant enrichment for human GWAS genes (p = 1, Table 5.4), but intriguingly trans
regulated genes showed a greater enrichment (p = 0.017, Table 5.4) than cis regulated genes
(p = 0.12, Table 5.4).
Several of the trans clusters identified showed significant enrichment in functional path-
ways relevant for cardiovascular traits and diseases. I performed a KEGG and a gene ontology
(GO) term enrichment analysis [Dennis Jr et al., 2003] on each of the trans clusters and found
significant enrichment for trans clusters present in tissues directly involved with BP regulation
and those tissues secondary to BP regulation. The trans cluster aorta2_234 is of particu-
lar interest due to its functional enrichment coupled with the a putative ‘master regulator’
(Ppp3ca) conserved in humans. Ppp3ca is encoded for the catalytic subunit of calcineurin
and is associated with cardiac hypertrophy [Twigger et al., 2007], while the cluster is enriched
for actin binding and cytoskeletal proteins as well as dilated and hypertrophic cardiomyopa-
thy (see Table B.4). The transgenic mouse with the same disease pathology (hypertrophy
to dilated cardiomyopathy) well as the known hypertensive effects of calcineurin inhibitors
in humans further strengthens the role Ppp3ca and calcineurin play in cardiovascular dis-
ease and suggests a conservation of the effects across mouse, rat and human [Blake et al.,
2011, Molkentin et al., 1998, Bukowska et al., 2006, Hoorn et al., 2011].
The cluster with the highest functional enrichment was the cluster liver5_154_2 in LIVER.
The cluster liver5_154_2 was highly enriched for several fatty acid metabolism traits (fatty
acid metabolic process, p = 1.38 × 10−12, Table B.4) and the cluster has a putative ‘master
regulator’, Lypla2 which is also involved with fatty acid metabolism. While the liver is not
a primary tissue for BP regulation, and fatty acid metabolism is not a direct cardiovascu-
lar mechanism, the effects of fatty acids on cardiovascular disease and metabolic syndrome
have been well documented [Wakil, 2009, Kusunoki et al., 2006, Poudyal et al., 2011]. The
identification of this cluster highlights the advantage of using a rat model with a cumulative
resource of expression and phenotypic data as the cluster is present in a tissue secondary to
BP regulation.
While cis regulated mechanisms as a subset were not enriched for human GWAS, there
were several cis regulated genes of interest. Out of the 16 ‘master regulatory’ genes conserved
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across species, three of them (Bcat1, Dpysl5, D3ZCG8_RAT ) were under cis regulation, and
two of those genes (Bcat1, D3ZCG8_RAT ) co-localised with clusters which were enriched for
human GWAS results. The branched chain amino-acid transaminase 1, cytosolic gene (Bcat1 )
has been previously linked to cardiovascular traits in humans [Eijgelsheim et al., 2010, Rhee
et al., 2011]. As a positive control for this analysis, several known hypertension genes, in
both humans and rats, were identified as candidate, ‘3C’ genes. Angiotensin II receptor,
type 1b (Agtr1b) and adducin-gamma (Add3 ) are known hypertension genes [Lanzani et al.,
2005, Obata et al., 2000, Bonnardeaux et al., 1994, Wang et al., 2008b]. T
Overall, there were 795 genes associated with BP variation in the rat (both NE and eQTLs)
that had human orthologs associated with hypertension. The results here reaffirm the effect
cis regulated genes have on BP variation and hypertension, but more importantly, the results
show the effect that trans regulated genes have on the pathogenesis of hypertension and
highlight the conservation of BP associated trans genes in the rat to those in humans. Trans
regulated genes, and especially those which cluster and are suggestive of co-regulation, can
suggest pathogenic mechanisms and pathways for disease. Because these trans regulated genes
have smaller effect sizes, they do not reach genome-wide significance and are often missed in
human GWAS. The multiple testing corrections applied to human GWAS are stringent to
avoid false positives, but, in return, may miss true positives of smaller effect sizes. By using a
relaxed GWAS significance threshold, I incorporated associations with genes (including trans
regulated genes) with weaker signals, albeit at the cost of a high false positive rate. These
795 genes show an association with hypertension and BP regulation in humans and in rats,
which increases the evidence for a biological role in the disease.
These associations with small to moderate effect sizes could explain a proportion of the so
called ‘missing heritability’ associated with complex traits and inform on secondary genetic
pathways for hypertension. The conservation between rat and human of these trans clusters
and their upstream regulators suggest that they play an important functional role in the
regulation of BP and hypertension and that genetic regulation of hypertension is highly
complex, with effects from both cis regulatory and wide-reaching trans regulatory mechanisms
as well as the interaction between the two.
Further work would be necessary to biologically validate the results presented here. In
the rat, either knock-down or knock-out studies could be performed on the ‘master regula-
tors’ which underlie the trans clusters. BP phenotyping and quantitative gene expression
measurements would used to assess the effects of the knock-down or knock-out gene. Ideally,
if a ‘master regulator’ was knocked-down or out, the effects would be seen through out the
gene expression of the genes in the trans cluster and the BP phenotypes would be altered. To
further investigate the results in humans, fine mapping of the syntenic regions surrounding
the putative ‘master regulators’ could be performed. The fine mapping would reduce some of
the limitations of multiple testing corrections and perhaps, allows these trans mechanisms to
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reach genome-wide significance.
6.1 Final Remarks
The work presented here highlights the advantages of taking a systems-wide approach to
complex diseases as well as further illustrates the high genetic complexity which underlies
hypertension in both the rat model system and humans. I identified both cis and trans
regulatory elements which were associated with BP in the rat and compared those with results
from human GWAS. Intriguingly, it was the trans regulatory elements, in particular the trans
clusters and their putative ‘master regulators’, which showed the greatest enrichment for
human GWAS results as well as enrichment for functionally relevant pathways. I identified
several of these clusters in tissues secondary to BP regulation, suggesting that these may be
downstream effects caused by BP variations. However, it may also be that hypertension is
influenced by the overall effects of metabolic syndrome and these mechanisms in secondary
tissues represent that effect. Although the hormonal regulation of BP and hypertension was
not the focus of this study, I identified several hormonal genes, including Agtbr1 and ADD3
in the rat which were associated with hypertension [Wang et al., 2008b, Lanzani et al., 2005].
These genes, however, were not identified in the set of human GWAS genes, suggesting that
it is the GWAS data which is not identifying these effects.
This work also illustrates some of the advantages in using model systems for the study of
human diseases. Multi-tissue, genome-wide integrative analyses, like the one presented here in
the rat, are nearly impossible to perform in humans. By investigating the genetic determinants
in the rat first, one is able to have greater experimental control and utilise data which are
not readily available for humans. It is likely that the trans regulatory elements identified
here have weak effect sizes individually, and would not reach genome-wide significance in a
large GWAS. By utilising a rat model, I was able to identify these trans regulatory elements
and then look for conservation with human data. While what is found in the rat is not
always transferable to humans, the mechanisms which are, give insight into the functional
conservation across species.
This work has also left the rat genetics community with a list of genes associated with
BP in the rat and the subset which are also associated with BP and hypertension in humans.
While I derived the new eQTLs in the seven tissues for the purpose of studying hypertension,
the eQTLs are not BP or hypertension specific. This set of eQTLs can be used for further
genetic studies in the BXH/HXB system and will be made publicly available.
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Appendix A
Supplementary materials for
Chapter 4
The materials for Appendix A can be found in the attached CD.
Figure A.1: The range of phenotypes across the strains: (a) DBP, (b) HR, (c) MBP, (d) PDIST,
(e) PP, (f) SBP, (g) FREQ, (h) POWER, (i) SPEC, (j) WAVE, and (k) WFREQ. The boxes stretch
from the first to the third quartile and the black lines represent the median. The whiskers of the plots
extend to the farthest data point within 1.5 times the interquartile range. The strains are ordered
from lowest to highest by mean and the strain means for BN and SHR are highlighted by the red
boxes.
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Appendix B
Supplementary materials for
Chapter 5
The materials for Appendix B can be found in the attached CD.
Figure B.1: The genome-wide QTL scans for all eleven phenotypes (a) DBP, (b) HR, (c) MBP, (d)
PDIST, (e) PP, (f) SBP, (g) FREQ, (h) POWER, (i) SPEC, (j) WAVE, and (k) WFREQ. The 5%,
10% and 25% empirical significance levels are indicated by the red, blue and black lines, respectively.
Figure B.2: To identify transcripts which do not have MCMC convergence, the estimated marginal
probability was plotted against the calculated marginal probability in each of the tissues: (a) ADR,
(b) AORTA, (c) FAT, (d) KID, (e) LIVER, (f) LV, and (g) SKM. The transcripts within the red boxes
did not converge and were removed from further analysis.
Table B.1: List of all eQTLs across the seven tissues at a FDR < 10%. The tissue, Affymetrix probe
ID, the posterior probability of inclusion, The SNP name, the chromosome and base pair position
of the SNP, the chromosome and base pair position of the probe, the Affymetrix gene ID and the
cis/trans designation. The transcripts which mapped to within 10 Mb of the probe location were
deemed to be cis acting and those which map else where were deemed to be trans acting. The FDR
was calculated within each tissue.
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Table B.2: List of all trans clusters across all seven tissues. The cluster name, the Affymetrix
probe ID, the chromosome and base pair position of the cluster, and the genes in the cluster and
their chromosome and base pair positions are give here. The clusters denoted by ** were significantly
enriched for human hypertension GWAS genes and the genes denoted with a * were also human GWAS
genes. The genes highlighted in grey are those which were significantly correlated with a BP phenotype
(FDR< 5%).
Table B.3: Putative ‘master regulators’ underlying the trans clusters within both a 2 kilo base and
a 20 Kb region. The gene along with the chromosome and base pair position, the cluster the gene
underlies, and whether or not the gene is an eQTL or a human hypertension GWAS gene. The first 56
genes (those up to the black line) are located within 1 Kb either side of the trans cluster locus. The
twenty genes after the line are those within 10 Kb either side of the locus.
Table B.4: Functional enrichment for trans clusters across all seven tissues. The functional enrichment
was calculated using DAVID [Dennis Jr et al., 2003]. The trans clusters are listed along with the KEGG
or GO term, the p-value and the FDR. The results are listed at a 5% FDR level.
Table B.5: The number of transcripts, separated into cis, trans and NE, that were found significantly
correlated, FDR<5%, with each of the eleven phenotypes is given here. The total number is the total number
of unique transcripts.
Table B.6: QTT results for all tissues at FDR< 5%. The tissue, Affymetrix probe ID, gene symbol
and cis/trans/NE designation are give for each transcript along with the correlation value for the
eleven phenotypes. The correlation values highlighted in grey represent those which are significant
(FDR<5%). The FDR was calculated within tissues and by cis/trans/NE designation.
Table B.7: KEGG Enrichment of both cis and trans genes found to be significantly correlated with
physiological phenotypes by QTT: The tissue and phenotype of the QTT analysis is give as well as
the KEGG pathway the genes are enriched for and the p-values and FDR % for each pathway. Results
are given at a FDR < 1%.
Table B.8: KEGG Enrichment of NE genes found to be significantly correlated with physiological
phenotypes by QTT: The tissue and phenotype of the QTT analysis is give as well as the KEGG
pathway the genes are enriched for and the p-values and FDR % for each pathway. Results are given
at a FDR < 1%.
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Table B.9: Cis regulated, correlated, co-localised genes. The tissue, Affymetrix probe ID, Ensembl
gene ID and chromosome and base pair position of each of the ‘3C’ genes is listed along with the
correlated phenotype. Genes identified in more than one tissues are listed with each tissue. The genes
with human orthologs and those with non-synonymous SNPs are indicated as well.
Table B.10: Human GWAS genes with corresponding publications. The list of all human GWAS genes
is listed along with the PubMed ID for the publication the gene came from. A relaxed significance
threshold of (P < 0.001) was used to compile the list of genes (n = 4, 145). If an SNP from a
human GWAS fell within the 3‘ to 5‘ region of a gene, that gene was deemed to be associated with
hypertension.
Table B.11: Listed here are the 2,292 rat orthologs of the human hypertension genes. The rat and
human gene symbols, the rat and human Ensembl IDs, the rat and human gene names, and the GWAS
p-value. For the rat genes, the list indicates if the gene is an eQTL, correlated to a BP phenotype or
underlying a trans cluster. As several of the SNPs were found in more than one human GWAS, the
reported p-value is the highest of them.
Table B.12: The list of genes associated with BP in the rat and human orthologs GWAS are given
here with the rat Ensembl ID and name, the Affymetrix probe ID, the correlated phenotype, the
cis/trans/NE designation, the tissue and the QTT FDR . The human Ensembl ID with the associated
GWAS SNP and GWAS p-value are also given. Many of the genes (740) are correlated with more
than one phenotype/tissue, so each are listed.
